<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000026.pub2" GROUP_ID="GYNAECA" ID="464999092216203948" MERGED_FROM="" MODIFIED="2017-03-08 11:40:13 +0000" MODIFIED_BY="Joanne Platt" NOTES="&lt;p&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;Exported from Review Manager 4.2.5&lt;br&gt;Short title (no longer in use): Antifungal therapy in cancer patients&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2017-03-08 11:38:34 +0000" NOTES_MODIFIED_BY="Joanne Platt" REVIEW_NO="B024" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="16.0">
<COVER_SHEET MODIFIED="2017-03-08 11:40:11 +0000" MODIFIED_BY="Joanne Platt">
<TITLE>Routine versus selective antifungal administration for control of fungal infections in patients with cancer</TITLE>
<CONTACT MODIFIED="2017-03-08 11:40:11 +0000" MODIFIED_BY="Joanne Platt"><PERSON ID="6571" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Peter</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>Gøtzsche</LAST_NAME><POSITION>Director</POSITION><EMAIL_1>pcg@cochrane.dk</EMAIL_1><URL>http://nordic.cochrane.org</URL><ADDRESS><DEPARTMENT>Nordic Cochrane Centre</DEPARTMENT><ORGANISATION>Rigshospitalet</ORGANISATION><ADDRESS_1>Blegdamsvej 9, 7811</ADDRESS_1><CITY>Copenhagen</CITY><ZIP>DK-2100</ZIP><COUNTRY CODE="DK">Denmark</COUNTRY><PHONE_1>+45 3545 7112</PHONE_1><FAX_1>+45 3545 7007</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2017-03-08 11:40:11 +0000" MODIFIED_BY="Joanne Platt"><PERSON ID="6571" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Peter</FIRST_NAME><MIDDLE_INITIALS>C</MIDDLE_INITIALS><LAST_NAME>Gøtzsche</LAST_NAME><POSITION>Director</POSITION><EMAIL_1>pcg@cochrane.dk</EMAIL_1><URL>http://nordic.cochrane.org</URL><ADDRESS><DEPARTMENT>Nordic Cochrane Centre</DEPARTMENT><ORGANISATION>Rigshospitalet</ORGANISATION><ADDRESS_1>Blegdamsvej 9, 7811</ADDRESS_1><CITY>Copenhagen</CITY><ZIP>DK-2100</ZIP><COUNTRY CODE="DK">Denmark</COUNTRY><PHONE_1>+45 3545 7112</PHONE_1><FAX_1>+45 3545 7007</FAX_1></ADDRESS></PERSON><PERSON ID="12436" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Helle Krogh</FIRST_NAME><LAST_NAME>Johansen</LAST_NAME><POSITION>Senior Researcher</POSITION><EMAIL_1>hkj@cochrane.dk</EMAIL_1><EMAIL_2>hkj@biosustain.dtu.dk</EMAIL_2><ADDRESS><DEPARTMENT>The Nordic Cochrane Centre</DEPARTMENT><ORGANISATION>Rigshospitalet</ORGANISATION><ADDRESS_1>Blegdamsvej 9, 3343</ADDRESS_1><CITY>Copenhagen</CITY><ZIP>DK 2100</ZIP><COUNTRY CODE="DK">Denmark</COUNTRY><PHONE_1>+45 35 45 7112</PHONE_1><FAX_1>+45 35 45 70 07</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2017-03-08 11:38:01 +0000" MODIFIED_BY="Joanne Platt">
<UP_TO_DATE>
<DATE DAY="7" MONTH="7" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="7" MONTH="7" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="7" MONTH="7" YEAR="2017"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="1996"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="1997"/>
<LAST_CITATION_ISSUE ISSUE="9" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2017-03-08 11:38:34 +0000" MODIFIED_BY="Joanne Platt">
<WHATS_NEW_ENTRY EVENT="STABLE" MODIFIED="2017-03-08 11:38:34 +0000" MODIFIED_BY="Joanne Platt">
<DATE DAY="8" MONTH="3" YEAR="2017"/>
<DESCRIPTION>
<P>Intervention no longer in general use.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2016-09-21 14:27:21 +0100" MODIFIED_BY="Tracey Harrison">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-09-21 14:27:21 +0100" MODIFIED_BY="Tracey Harrison">
<DATE DAY="7" MONTH="7" YEAR="2014"/>
<DESCRIPTION>
<P>Literature searches updated</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2016-09-21 14:27:21 +0100" MODIFIED_BY="Tracey Harrison">
<DATE DAY="7" MONTH="7" YEAR="2014"/>
<DESCRIPTION>
<P>No new trials identified for inclusion, one study excluded</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-03-27 12:04:38 +0000" MODIFIED_BY="Tracey Bishop">
<DATE DAY="14" MONTH="9" YEAR="2011"/>
<DESCRIPTION>
<P>Review updated with new search details. No new studies were identified for inclusion.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2014-03-27 12:04:38 +0000" MODIFIED_BY="Tracey Bishop">
<DATE DAY="18" MONTH="7" YEAR="2011"/>
<DESCRIPTION>
<P>Searches re-run July 2011</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-07-15 11:40:22 +0100" MODIFIED_BY="Clare Jess">
<DATE DAY="5" MONTH="2" YEAR="2008"/>
<DESCRIPTION>
<P>Minor update. One new drug added (voriconazole); one new trial added (Penack); two new excluded trials added (Schiel, Vehreschild); two new outcomes added (death ascribed to fungal infection and harms).</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-07-11 09:34:28 +0100" MODIFIED_BY="Clare Jess">
<DATE DAY="5" MONTH="11" YEAR="2007"/>
<DESCRIPTION>
<P>New studies found and included or excluded</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-07-15 11:40:27 +0100" MODIFIED_BY="Clare Jess">
<DATE DAY="9" MONTH="1" YEAR="2002"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-07-11 09:34:32 +0100" MODIFIED_BY="Clare Jess">
<DATE DAY="8" MONTH="1" YEAR="2002"/>
<DESCRIPTION>
<P>Conclusions changed</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Rigshospitalet, Copenhagen</NAME>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-09-03 12:27:02 +0100" MODIFIED_BY="Clare Jess">
<SUMMARY MODIFIED="2014-09-03 12:19:05 +0100" MODIFIED_BY="Clare Jess">
<TITLE>Prevention of fungal infections in patients with cancer with antifungal drugs</TITLE>
<SUMMARY_BODY MODIFIED="2014-09-03 12:19:05 +0100" MODIFIED_BY="Clare Jess">
<P>Cancer patients receiving chemotherapy or a bone marrow transplant are at risk of fungal infections. These can be life-threatening, especially when they spread throughout the body. Those patients with low white cell counts (neutropenia) are particularly at risk. Antifungal drugs are often given as a routine preventive measure, or when people who are at risk have a fever. The review found that intravenous amphotericin B could reduce the number of deaths. Three of the drugs, amphotericin B, fluconazole and itraconazole, reduced fungal infections.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-09-03 12:18:58 +0100" MODIFIED_BY="Clare Jess">
<ABS_BACKGROUND MODIFIED="2014-09-03 12:18:25 +0100" MODIFIED_BY="Clare Jess">
<P>Systemic fungal infection is considered to be an important cause of morbidity and mortality in cancer patients, particularly those with neutropenia. Antifungal drugs are often given prophylactically, or empirically to patients with persistent fever.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2014-09-03 12:18:28 +0100" MODIFIED_BY="Clare Jess">
<P>To assess whether commonly used antifungal drugs decrease mortality in cancer patients with neutropenia.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-09-03 12:18:28 +0100" MODIFIED_BY="Clare Jess">
<P>We searched PubMed from 1966 to 7 July 2014 and the reference lists of identified articles.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised clinical trials of amphotericin B, fluconazole, ketoconazole, miconazole, itraconazole or voriconazole compared with placebo or no treatment in cancer patients with neutropenia.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-09-03 12:18:30 +0100" MODIFIED_BY="Clare Jess">
<P>The two review authors independently assessed trial eligibility and risk of bias, and abstracted data.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-09-03 12:18:56 +0100" MODIFIED_BY="Clare Jess">
<P>Thirty-two trials involving 4287 patients were included. Prophylactic or empirical treatment with amphotericin B significantly decreased total mortality (relative risk (RR) 0.69, 95% confidence interval (CI) 0.50 to 0.96), whereas the estimated RRs for fluconazole, ketoconazole, miconazole, and itraconazole were close to 1.00. No eligible trials were found with voriconazole. Amphotericin B and fluconazole decreased mortality ascribed to fungal infection (RR 0.45, 95% CI 0.26 to 0.76 and RR 0.42, 95% CI 0.24 to 0.73, respectively). The incidence of invasive fungal infection decreased significantly with administration of amphotericin B (RR 0.41, 95% CI 0.24 to 0.73), fluconazole (RR 0.39, 95% CI 0.27 to 0.57) and itraconazole (RR 0.53, 95% CI 0.29 to 0.97), but not with ketoconazole or miconazole. Effect estimates were similar for those 13 trials that had adequate allocation concealment and were blinded. The reporting of harms was far too variable from trial to trial to allow a meaningful overview. For the 2011 and 2014 updates no additional trials were identified for inclusion.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-09-03 12:18:58 +0100" MODIFIED_BY="Clare Jess">
<P>Intravenous amphotericin B was the only antifungal agent that reduced total mortality. It should therefore be preferred when prophylactic or empirical antifungal therapy is introduced in cancer patients with neutropenia.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-09-03 12:27:02 +0100" MODIFIED_BY="Clare Jess">
<BACKGROUND MODIFIED="2014-09-03 12:19:12 +0100" MODIFIED_BY="Clare Jess">
<P>Bacterial infections are an important cause of death in cancer patients (<LINK REF="REF-Inagaki-1974" TYPE="REFERENCE">Inagaki 1974</LINK>), and patients with low white blood cell counts are particularly at risk (<LINK REF="REF-Estey-1982" TYPE="REFERENCE">Estey 1982</LINK>). Systemic fungal infection, with wide dissemination of infection throughout the body, is also considered to be an important cause of morbidity and mortality (<LINK REF="REF-Meyers-1990" TYPE="REFERENCE">Meyers 1990</LINK>; <LINK REF="REF-Verfaillie-1991" TYPE="REFERENCE">Verfaillie 1991</LINK>). This type of infection is mainly caused by Candida or Aspergillus species (<LINK REF="REF-Walsh-1991" TYPE="REFERENCE">Walsh 1991</LINK>). The mortality rate in patients with Candida sepsis or deep tissue involvement is around 75% (<LINK REF="REF-Meyers-1990" TYPE="REFERENCE">Meyers 1990</LINK>; <LINK REF="REF-Verfaillie-1991" TYPE="REFERENCE">Verfaillie 1991</LINK>), and a positive blood culture or histologic signs of invasion were found before death in 37% of the patients in one series of patients (<LINK REF="REF-Estey-1982" TYPE="REFERENCE">Estey 1982</LINK>).</P>
<P>Antifungal agents are often given prophylactically in conjunction with chemotherapy or bone marrow transplantation, or empirically to patients without documented fungal infection but with persisting fever despite antibiotic treatment. The rationale for these approaches is to start therapy before it is too late, since it is difficult to diagnose an invasive fungal infection with certainty (<LINK REF="REF-Verfaillie-1991" TYPE="REFERENCE">Verfaillie 1991</LINK>; <LINK REF="REF-Walsh-1990" TYPE="REFERENCE">Walsh 1990</LINK>).</P>
<P>Studies with historical controls have shown a positive effect of antifungal agents on mortality (<LINK REF="REF-Stein-1986" TYPE="REFERENCE">Stein 1986</LINK>; <LINK REF="REF-Walsh-1991" TYPE="REFERENCE">Walsh 1991</LINK>) but such non-randomised comparisons have been shown to overestimate the effect of cancer treatments considerably (<LINK REF="REF-Berlin-1989" TYPE="REFERENCE">Berlin 1989</LINK>). We performed a meta-analysis of trials in which commonly used antifungal agents were compared with an untreated control group.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2014-09-03 12:19:16 +0100" MODIFIED_BY="Clare Jess">
<P>The primary aim was to assess whether commonly used antifungal agents decrease mortality in cancer patients with neutropenia.</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-09-03 12:26:36 +0100" MODIFIED_BY="Clare Jess">
<SELECTION_CRITERIA MODIFIED="2014-09-03 12:19:20 +0100" MODIFIED_BY="Clare Jess">
<CRIT_STUDIES MODIFIED="2014-09-03 12:19:18 +0100" MODIFIED_BY="Clare Jess">
<P>Only randomised trials were included. We accepted reports in any language. Studies concerned with the treatment or prevention of oral candidiasis were excluded.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2014-09-03 12:19:19 +0100" MODIFIED_BY="Clare Jess">
<P>Cancer patients with neutropenia caused by chemotherapy or bone marrow transplantation, as defined by the researchers within each study.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2014-09-03 12:19:20 +0100" MODIFIED_BY="Clare Jess">
<P>Experimental: amphotericin B (including lipid soluble formulations), fluconazole, ketoconazole, miconazole, itraconazole or voriconazole given orally or intravenously. Control: placebo or no treatment.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<UL>
<LI>Mortality</LI>
<LI>Mortality ascribed to fungal infection</LI>
<LI>Invasive fungal infection (defined as positive blood culture, oesophageal candidiasis, lung infection or microscopically confirmed deep tissue involvement)</LI>
<LI>Colonisation</LI>
<LI>Use of additional (escape) antifungal therapy</LI>
<LI>Harms</LI>
</UL>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-09-03 12:19:23 +0100" MODIFIED_BY="Clare Jess">
<ELECTRONIC_SEARCHES MODIFIED="2014-09-03 12:19:22 +0100" MODIFIED_BY="Clare Jess">
<P>We searched PubMed from 1966 to 7 July 2014 and the reference lists of identified articles.</P>
<P>The search strategy used is in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>. </P>
<P>The search strategies have been developed and executed by the authors.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2014-09-03 12:19:23 +0100" MODIFIED_BY="Clare Jess">
<P>This has not been carried out since 2007 as we have not found it worthwhile.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-09-03 12:26:36 +0100" MODIFIED_BY="Clare Jess">
<DATA_EXTRACTION MODIFIED="2014-09-03 12:19:35 +0100" MODIFIED_BY="Clare Jess">
<P>Decisions on which trials to include, and also which variables to use when a number of options were available for the same outcome, were based on the methods sections of the trials. Details on diagnosis, drug, dose, rules for use of additional (rescue) antifungal therapy, average length of treatment with placebo, length of follow-up, randomisation (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>) and blinding methods, number of randomised patients, number of patients excluded from analysis, deaths, invasive fungal infections, colonisation and use of rescue drug were independently extracted by both review authors; differences in the data extracted were resolved by consensus.</P>
<P>We defined invasive fungal infection as a positive blood culture, oesophageal candidiasis, lung infection or microscopically confirmed deep tissue infection. We excluded cases of oropharyngeal and vulvovaginal candidiasis, skin infections, Candida in the urine and vaguely described infections.</P>
<P>We asked the trial authors to confirm the extracted information and to answer additional questions; numbers in the tables may therefore be different from those given in the published articles. To increase the response rate, the authors' most recent addresses were located in PubMed. In an attempt to increase the power of the meta-analyses and avoid reporting bias, the trial authors were specifically asked for the three months mortality data for all randomised patients, also secondarily excluded patients. We asked the trial authors for details on the randomisation process, especially whether it was concealed and irreversible so that an allocation could not be known beforehand or changed later.</P>
</DATA_EXTRACTION>
<DATA_SYNTHESIS MODIFIED="2014-09-03 12:26:36 +0100" MODIFIED_BY="Clare Jess">
<P>The outcomes were weighted by the inverse variance. Since heterogeneity of the studies was expected because of various designs; diagnoses; drugs; doses and routes of administration; and criteria for fungal invasion, colonisation and use of rescue drug a random-effects model was used. A fixed-effect analysis was preferred, however, if the P value was greater than 0.10 for the test of heterogeneity. Ninety-five per cent confidence intervals (CI) were presented.</P>
</DATA_SYNTHESIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-09-03 12:20:43 +0100" MODIFIED_BY="Clare Jess">
<STUDY_DESCRIPTION MODIFIED="2014-09-03 12:19:48 +0100" MODIFIED_BY="Clare Jess">
<P>We identified 44 potentially eligible trials of which 12 were excluded: two were not randomised (<LINK REF="STD-Hiddemann-1991" TYPE="STUDY">Hiddemann 1991</LINK>; <LINK REF="STD-Schaison-1990" TYPE="STUDY">Schaison 1990</LINK>); one concerned oropharyngeal candidiasis only (<LINK REF="STD-Samonis-1990" TYPE="STUDY">Samonis 1990</LINK>); one had a control group receiving active drugs (<LINK REF="STD-Wang-2003" TYPE="STUDY">Wang 2003</LINK>); in one only 14 of 146 patients had neutropenia and only data on oropharyngeal candidiasis were provided (<LINK REF="STD-Bodey-1990" TYPE="STUDY">Bodey 1990</LINK>); one only reported a subgroup of 72 of 298 randomised patients who underwent autopsy (<LINK REF="STD-Ezdinli-1979" TYPE="STUDY">Ezdinli 1979</LINK>); one used a surrogate outcome (resolution of fever) and only one patient developed candidaemia (<LINK REF="STD-Schiel-2006" TYPE="STUDY">Schiel 2006</LINK>); one was published as an abstract without useful data and where no fungal diseases were found (<LINK REF="STD-Reed-1993" TYPE="STUDY">Reed 1993</LINK>); and four were excluded since they were unpublished and we could not obtain any data from them (<LINK REF="STD-Benhamou-1991b" TYPE="STUDY">Benhamou 1991b</LINK>; <LINK REF="STD-Brincker-1990" TYPE="STUDY">Brincker 1990</LINK>; <LINK REF="STD-Prentice-1989" TYPE="STUDY">Prentice 1989</LINK>; <LINK REF="STD-Siegel-1982b" TYPE="STUDY">Siegel 1982b</LINK>).</P>
<P>Two of the included 32 trials were published only as abstracts (<LINK REF="STD-Acuna-1981" TYPE="STUDY">Acuna 1981</LINK>; <LINK REF="STD-Siegel-1982a" TYPE="STUDY">Siegel 1982a</LINK>); one was an interim analysis (<LINK REF="STD-Goldstone-1994" TYPE="STUDY">Goldstone 1994</LINK>); and two were published in Japanese (<LINK REF="STD-Fukuda-1994" TYPE="STUDY">Fukuda 1994</LINK>; <LINK REF="STD-Suda-1980" TYPE="STUDY">Suda 1980</LINK>).</P>
<P>Finally, we found a conference abstract describing a small placebo-controlled trial of voriconazole (25 patients) (<LINK REF="STD-Cornely-2006" TYPE="STUDY">Cornely 2006</LINK>). This trial awaits assessment and may not be eligible as the primary outcome was lung infiltrates, which have other causes than fungal infection.</P>
<P>For the 2011 and 2014 updates no additional trials were identified for inclusion.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-09-03 12:19:57 +0100" MODIFIED_BY="Clare Jess">
<P>We adopted broad quality assessment criteria and considered the risk of bias as low if the randomisation method was concealed, if central randomisation, use of sealed envelopes, a code provided by a pharmacy or a company was described; generation of the allocation sequence was adequate (for example random numbers); and the trial was placebo controlled and blinded. On one occasion what seemed to be a sound randomisation, provided by a pharmacy, on further questioning proved to result in medicine packages labelled A or B (<LINK REF="STD-Vreugdenhil-1993" TYPE="STUDY">Vreugdenhil 1993</LINK>), which one would not have expected for a trial published in 1993. Such a procedure is risky as code breaking for just one patient would make it possible to predict all future allocations. Thirteen trials had adequate allocation concealment and were blinded (<LINK REF="STD-Brincker-1978" TYPE="STUDY">Brincker 1978</LINK>; <LINK REF="STD-Brincker-1983" TYPE="STUDY">Brincker 1983</LINK>; <LINK REF="STD-Goodman-1992" TYPE="STUDY">Goodman 1992</LINK>; <LINK REF="STD-Kelsey-1999" TYPE="STUDY">Kelsey 1999</LINK>; <LINK REF="STD-Nucci-2000" TYPE="STUDY">Nucci 2000</LINK>; <LINK REF="STD-Perfect-1992" TYPE="STUDY">Perfect 1992</LINK>; <LINK REF="STD-Riley-1994" TYPE="STUDY">Riley 1994</LINK>; <LINK REF="STD-Rotstein-1999" TYPE="STUDY">Rotstein 1999</LINK>; <LINK REF="STD-Schaffner-1995" TYPE="STUDY">Schaffner 1995</LINK>; <LINK REF="STD-Tollemar-1993" TYPE="STUDY">Tollemar 1993</LINK>; <LINK REF="STD-Vreugdenhil-1993" TYPE="STUDY">Vreugdenhil 1993</LINK>; <LINK REF="STD-Wingard-1987" TYPE="STUDY">Wingard 1987</LINK>; <LINK REF="STD-Winston-1993" TYPE="STUDY">Winston 1993</LINK>). One trial maintained the blinding during data analysis (<LINK REF="STD-Schaffner-1995" TYPE="STUDY">Schaffner 1995</LINK>).</P>
<P>The antifungal agent was given prophylactically in 29 trials and empirically in three. Acute leukaemia was the most common indication in 21 trials, bone marrow transplantation in 11. The length of the follow-up period was often not reported; it probably varied for different patients even within the same study since many trial authors stated that the trial drugs had been given till the neutropenia had resolved.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-09-03 12:20:43 +0100" MODIFIED_BY="Clare Jess">
<P>Thirty-two trials involving 4287 patients were included. Prophylactic or empirical treatment with amphotericin B significantly decreased total mortality (relative risk (RR) 0.69, 95% confidence interval (CI) 0.50 to 0.96). The point estimate was the same for those four trials that had adequate allocation concealment and were blinded (RR 0.69, 95% CI 0.41 to 1.19). Intravenous administration of amphotericin B was used in the trials apart from one in which the drug was given orally (<LINK REF="STD-Suda-1980" TYPE="STUDY">Suda 1980</LINK>). RRs for the other drugs were close to 1.00: fluconazole, RR of 1.04 (95% CI 0.84 to 1.30); ketoconazole, RR of 0.97 (95% CI 0.63 to 1.49); miconazole, RR of 1.16 (95% CI 0.71 to 1.87); and itraconazole, RR of 0.94 (95% CI 0.63 to 1.40).</P>
<P>Amphotericin B and fluconazole decreased mortality ascribed to fungal infection (RR 0.45, 95% CI 0.26 to 0.76 and RR 0.42, 95% CI 0.24 to 0.73, respectively).</P>
<P>The incidence of invasive fungal infection decreased significantly with administration of amphotericin B (RR 0.41, 95% CI 0.24 to 0.73), fluconazole (RR 0.39, 95% CI 0.27 to 0.57) and itraconazole (RR 0.53, 95% CI 0.29 to 0.97); but not with ketoconazole (RR 1.32, 95% CI 0.68 to 2.54) or miconazole (RR 0.52, 95% CI 0.20 to 1.31). Effect estimates were similar for those 13 trials that had adequate allocation concealment and were blinded. We did not find any eligible trials with voriconazole.</P>
<P>The trial authors' definitions of fungal colonisation and their methods varied widely and there was considerable heterogeneity between the trials for the effects of the drugs. The overall reduction in fungal colonisation was statistically significant for prophylactic amphotericin B, fluconazole and ketoconazole.</P>
<P>Use of rescue antifungal agents tended to be more common in the untreated groups. There was considerable heterogeneity for those drugs that were used in most of the studies.</P>
<P>The reporting of harms was far too variable from trial to trial to allow a meaningful overview. Usually no treatment discontinuations because of harms were reported in the fluconazole trials, whereas 16% discontinued in one trial with itraconazole (<LINK REF="STD-Menichetti-1999" TYPE="STUDY">Menichetti 1999</LINK>) and only 3% in another trial with this drug (<LINK REF="STD-Nucci-2000" TYPE="STUDY">Nucci 2000</LINK>). We have listed the most important harms that were reported in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-09-03 12:27:02 +0100" MODIFIED_BY="Clare Jess">
<P>Amphotericin B was the only antifungal agent among those we studied that significantly decreased total mortality. The trials were relatively small but this finding is supported by another review in which we reported on three trials that compared intravenous lipid soluble amphotericin B (AmBisome) with smaller doses of standard intravenous amphotericin B (<LINK REF="REF-Johansen-2001" TYPE="REFERENCE">Johansen 2001</LINK>). The relative risk (RR) for total mortality in these trials was 0.74 (95% CI 0.52 to 1.07).</P>
<P>The advantage of using total mortality as an outcome measure is not only that it is unbiased but it may also be the most relevant outcome since the drugs could have important harms leading to drug-related mortality. Ketoconazole, for example, is immunosuppressive and in all three trials in which bacterial infections were reported they were more common with ketoconazole than with placebo; 37 versus 21 patients (<LINK REF="STD-Palmblad-1992" TYPE="STUDY">Palmblad 1992</LINK>), 33 versus 24 patients (<LINK REF="STD-Estey-1984" TYPE="STUDY">Estey 1984</LINK>), and 20% of neutropenic courses versus 15% (<LINK REF="STD-Hansen-1987" TYPE="STUDY">Hansen 1987</LINK>). Interestingly this adverse effect could be a class effect related to azoles as an increased incidence of bacteraemias has also been reported with fluconazole, 27 versus 16 patients (<LINK REF="STD-Schaffner-1995" TYPE="STUDY">Schaffner 1995</LINK>) and 15 versus 7 patients (<LINK REF="STD-Kern-1998" TYPE="STUDY">Kern 1998</LINK>); and with itraconazole, 47 versus 31 patients (<LINK REF="STD-Menichetti-1999" TYPE="STUDY">Menichetti 1999</LINK>). Fluconazole has been associated with an excess of graft-versus-host disease or organ failure in the two large studies of bone marrow transplant recipients; 29 versus 16 deaths (<LINK REF="STD-Goodman-1992" TYPE="STUDY">Goodman 1992</LINK>), or 44 versus 24 according to later correspondence (<LINK REF="STD-Goodman-1992" TYPE="STUDY">Goodman 1992</LINK>), and 102 versus 85 cases of graft-versus-host disease (<LINK REF="STD-Slavin-1995" TYPE="STUDY">Slavin 1995</LINK>). It is noteworthy that the largest trial of fluconazole found no difference in total mortality, 55 versus 46 deaths (RR 1.18, 95% CI 0.85 to 1.65), whereas fewer deaths were ascribed to acute systemic fungal infections in the group receiving fluconazole compared to the group receiving placebo (1 of 179 versus 10 of 177 patients, P value 0.01) (<LINK REF="STD-Goodman-1992" TYPE="STUDY">Goodman 1992</LINK>). This indicates that fluconazole increases mortality from other causes (54 versus 36 deaths, P value 0.04). Itraconazole has been associated with congestive heart failure, which does not seem to be a class effect (<LINK REF="REF-Ahmad-2001" TYPE="REFERENCE">Ahmad 2001</LINK>).</P>
<P>In an eight year follow-up of the only study that has reported a significant but possibly flawed effect of fluconazole on total mortality (<LINK REF="STD-Slavin-1995" TYPE="STUDY">Slavin 1995</LINK>) the trial authors ascribe this finding to the fact that most of their patients (88%) had received allogeneic grafts. They write that the other large trial (<LINK REF="STD-Goodman-1992" TYPE="STUDY">Goodman 1992</LINK>) primarily included autologous graft recipients, but in fact 48% of the patients in that trial had also received allogeneic grafts and the trial had three times as many deaths as the trial authors' own trial. Commentators (<LINK REF="STD-Slavin-1995" TYPE="STUDY">Slavin 1995</LINK>) have suggested that the trial authors' positive result on mortality might represent a statistical aberration. We agree that this seems more likely than the tentative explanation based on type of graft offered by the trial authors. Furthermore, we suspect that a biased decision on length of follow-up may have been made in this trial. A conference abstract notes a follow-up period of 75 days (maximum length of treatment) plus an additional two weeks, that is 89 days (<LINK REF="STD-Slavin-1995" TYPE="STUDY">Slavin 1995</LINK>). The final article gives no explanation why the follow-up period had been extended to 110 days. We used the data after 89 days (21 versus 28 deaths), which came closest to the three months follow-up we aimed for in the meta-analysis and which we assume was also the time frame stipulated in the trial protocol for the study.</P>
<P>Another bias that involves reporting at favourable time points relates to informal interim analyses. Concern about bias in cancer trials that is caused by lax stopping rules has previously been raised (<LINK REF="REF-Pocock-1978" TYPE="REFERENCE">Pocock 1978</LINK>) and a survey showed that the majority of cancer cooperative groups perform annual interim analyses of their trials without formal stopping rules (<LINK REF="REF-Buyse-1993" TYPE="REFERENCE">Buyse 1993</LINK>). A trial author informed us that one of his studies was stopped prematurely after 30 patients when an interim analysis showed a significant effect, but the trial report did not describe that this had occurred or that the study was planned to include more patients (<LINK REF="STD-Brincker-1978" TYPE="STUDY">Brincker 1978</LINK>). A third study report did not mention any interim analysis, although an earlier conference abstract reported an interim analysis (<LINK REF="STD-Riley-1994" TYPE="STUDY">Riley 1994</LINK>); a fourth study described interim analyses but gave no rules (<LINK REF="STD-Estey-1984" TYPE="STUDY">Estey 1984</LINK>); and a fifth study has only been published as an interim analysis (<LINK REF="STD-Goldstone-1994" TYPE="STUDY">Goldstone 1994</LINK>).</P>
<P>Publication bias (<LINK REF="REF-Stern-1997" TYPE="REFERENCE">Stern 1997</LINK>), which is a well documented phenomenon in cancer trials (<LINK REF="REF-Berlin-1989" TYPE="REFERENCE">Berlin 1989</LINK>; <LINK REF="REF-Simes-1986" TYPE="REFERENCE">Simes 1986</LINK>), is also of concern. A study on fluconazole was stopped by the company in 1990 when 32 patients had been entered; the investigator never learned about the results (<LINK REF="STD-Brincker-1990" TYPE="STUDY">Brincker 1990</LINK>, personal communication). Our efforts to make contact with the medical companies were disappointing; Pfizer and Janssen-Cilag did not wish to share their unpublished reports with us, or even to give us a list of the trials so that we could approach the investigators. This secrecy, which we have previously reported for Pfizer's trials that compared fluconazole with amphotericin B (<LINK REF="REF-Johansen-1999" TYPE="REFERENCE">Johansen 1999</LINK>), and which other meta-analysts have reported when they approached Janssen (<LINK REF="REF-Huston-1996" TYPE="REFERENCE">Huston 1996</LINK>), is unethical and must be changed (<LINK REF="REF-Chalmers-1990" TYPE="REFERENCE">Chalmers 1990</LINK>). Clinical trial data can only be assembled through the patients' willingness to contribute to science for the benefit of future patients; the data should therefore be regarded as public property to be used for the common good. It has been amply documented that the withholding of data that are not favourable for the drug in question may be harmful to patients.</P>
<P>It should be noted that a possible effect on total mortality may be overlooked if rescue antifungal therapy is instituted too quickly in the control group. The positive effect of amphotericin B was seen despite the fact that rescue antifungal therapy was introduced rather quickly in the control group, for example after an average of 10, 10 and 15 days in three of the most positive trials (<LINK REF="STD-Perfect-1992" TYPE="STUDY">Perfect 1992</LINK>; <LINK REF="STD-Pizzo-1982" TYPE="STUDY">Pizzo 1982</LINK>; <LINK REF="STD-Riley-1994" TYPE="STUDY">Riley 1994</LINK>); there were no data on this in the trial by <LINK REF="STD-Penack-2006" TYPE="STUDY">Penack 2006</LINK>. This problem was hardly the reason for the lack of effect of fluconazole as the three largest studies with fluconazole 400 mg daily reported the use of rescue antifungal therapy after an average of 14 days (<LINK REF="STD-Winston-1993" TYPE="STUDY">Winston 1993</LINK>), 20 days (<LINK REF="STD-Goodman-1992" TYPE="STUDY">Goodman 1992</LINK>) and 55 days (<LINK REF="STD-Slavin-1995" TYPE="STUDY">Slavin 1995</LINK>).</P>
<P>In previous versions of this review we did not include death attributed to fungal infection as an outcome measure. It is difficult to determine the cause of death in these severely ill patients and we therefore suspected that disease-specific mortality would be unreliable. As we could not confirm this suspicion in a study of disease-specific mortality (<LINK REF="REF-Due-2006" TYPE="REFERENCE">Due 2006</LINK>), we have now included this outcome.</P>
<P>The harms we have listed in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> should be interpreted cautiously. Biased reporting of harms is very common (<LINK REF="REF-Chan-2004" TYPE="REFERENCE">Chan 2004</LINK>; <LINK REF="REF-G_x00f8_tzsche-1989" TYPE="REFERENCE">Gøtzsche 1989</LINK>), and we suspected that biased reporting had occurred in several of the trials we reviewed. For example, arbitrary cut-offs delineating what constitutes a clinically relevant increase in creatinine and liver enzymes can have a major impact on what is found. We have described this type of biased reporting in a pivotal trial that compared voriconazole with liposomal amphotericin B (<LINK REF="REF-J_x00f8_rgensen-2006" TYPE="REFERENCE">Jørgensen 2006</LINK>). The investigators found that 29 versus 32 patients had a two-fold increase in S-creatinine. They also found that 43 versus 80 patients experienced a 1.5-fold increase (P value &lt; 0.001), which is the result they reported in the abstract. This case was unusual as the bias was so obvious. We have never seen a 1.5-fold increase in S-creatinine reported in other trials, and the lack of clinical relevance of the trivial difference in S-creatinine was underlined by the fact that two patients in the voriconazole group and one in the amphotericin B group died from renal failure.</P>
<P>Amphotericin B, fluconazole and itraconazole all had an effect on invasive fungal infection. The data on mortality that we have presented in this review suggest that amphotericin B is a better drug than fluconazole. The comparisons are indirect, however. Unfortunately it is not possible to make a direct judgement on whether fluconazole is of similar effectiveness as amphotericin B on mortality or invasive infection despite the fact that more than a dozen comparative trials have been published (<LINK REF="REF-Johansen-1999" TYPE="REFERENCE">Johansen 1999</LINK>; <LINK REF="REF-Johansen-2002a" TYPE="REFERENCE">Johansen 2002a</LINK>). First, most of the trials have used oral amphotericin B, which is not absorbed from the gastrointestinal tract and which is poorly documented. Second, the results for amphotericin B were combined with those for nystatin in large three-armed trials despite the fact that nystatin is no better than placebo when given to patients with severe immunodeficiency, such as those with cancer complicated by neutropenia (<LINK REF="REF-Johansen-1999" TYPE="REFERENCE">Johansen 1999</LINK>; <LINK REF="REF-Johansen-2002b" TYPE="REFERENCE">Johansen 2002b</LINK>). It is also of concern that widespread use of fluconazole could lead to the development of resistance or to infection with inherently resistant species of fungi, for example <I>Candida krusei</I> and <I>Candida (Torulopsis) glabrata</I> (<LINK REF="REF-Working-Party-1995" TYPE="REFERENCE">Working Party 1995</LINK>). For itraconazole, little data is available at present to judge its efficacy compared with amphotericin B.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-09-03 12:23:58 +0100" MODIFIED_BY="Clare Jess">
<IMPLICATIONS_PRACTICE MODIFIED="2014-09-03 12:23:55 +0100" MODIFIED_BY="Clare Jess">
<P>Intravenous amphotericin B was the only antifungal agent that reduced total mortality. It should therefore be preferred when prophylactic or empirical antifungal therapy is instituted in cancer patients with neutropenia.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-09-03 12:23:58 +0100" MODIFIED_BY="Clare Jess">
<P>It may be difficult to justify further placebo-controlled trials whereas there is a need for unbiased trials comparing intravenous amphotericin B with other antifungal drugs. Such trials should comprise at least 1000 patients and they should include data on length of hospital stay and similar measures, allowing cost-benefit analyses to be performed. Data on the incidence of bacterial infections should be collected since azole compounds might increase the risk of such infections.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-07-31 10:19:08 +0100" MODIFIED_BY="Clare Jess">
<P>We are grateful to the following investigators for having provided additional information on their trials: Dr Ellen Benhamou, Dr Hans Brincker, Dr Masataka Fukuda, Dr Jesse L Goodman, Dr Richard M Hansen, Dr Wolfgang Kern, Dr Marcio Nucci, Dr Jan Palmblad, Dr Andrew T Pavia, Dr John R Perfect, Professor Philip A Pizzo, Dr Ben E de Pauw, Dr Andreas Schaffner, Professor Gérard Schaison, Dr Jan Tollemar, Professor John R Wingard, and Dr Drew J Winston. We are grateful for the translation of the Japanese articles provided by Dr Hiroto Takada. We thank Bristol-Myers Squibb and Janssen-Cilag for supplementary literature searches. Finally, we thank Dr Hans Brincker for a useful discussion and Professor Peter Skinhøj for comments on the first published version of this meta-analysis.</P>
<P>The National Institute for Health Research (NIHR) is the largest single funder of the Cochrane Gynaecological, Neuro-oncology, Orphan Cancer Group<I>. </I>The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the NIHR, NHS or the Department of Health.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2014-09-03 12:23:59 +0100" MODIFIED_BY="Clare Jess">
<P>Peter C Gøtzsche - nothing to declare<BR/>Helle Krogh Johansennothing - nothing to declare</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>PCG wrote the protocol and the draft manuscript, did the searches and performed the statistical analyses. Both authors read the papers and extracted the data independently. HKJ commented on the various versions of the draft.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2014-09-03 12:24:01 +0100" MODIFIED_BY="Clare Jess">
<P>We have not recorded dropouts due to toxicity as they were reported rarely and inconsistently. We have added harms and also death ascribed to fungal infection as our research has shown that this outcome is reliable (<LINK REF="REF-Due-2006" TYPE="REFERENCE">Due 2006</LINK>), contrary to our expectations.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2017-03-08 11:40:13 +0000" MODIFIED_BY="Joanne Platt">
<STUDIES MODIFIED="2014-09-03 12:40:46 +0100" MODIFIED_BY="Clare Jess">
<INCLUDED_STUDIES MODIFIED="2014-09-03 12:25:53 +0100" MODIFIED_BY="Clare Jess">
<STUDY DATA_SOURCE="PUB" ID="STD-Acuna-1981" MODIFIED="2014-07-31 15:27:27 +0100" MODIFIED_BY="Clare Jess" NAME="Acuna 1981" YEAR="1981">
<REFERENCE MODIFIED="2014-07-31 15:27:27 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Acuna G, Winston DJ, Young LS</AU>
<TI>Ketoconazole prophylaxis of fungal infections in the granulocytopenic patient: a double-blind, randomized controlled trial</TI>
<SO>Program and Abstracts of 22nd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology</SO>
<YR>1981</YR>
<PG>abstract 852</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405716"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405715"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Benhamou-1991a" MODIFIED="2014-07-31 15:27:33 +0100" MODIFIED_BY="Clare Jess" NAME="Benhamou 1991a" YEAR="1991">
<REFERENCE MODIFIED="2014-07-31 15:27:33 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Benhamou E, Hartmann O, Nogues C, Maraninchi D, Valteau D, Lemerle J</AU>
<TI>Does ketoconazole prevent fungal infection in children treated with high dose chemotherapy and bone marrow transplantation? Results of a randomized placebo-controlled trial</TI>
<SO>Bone Marrow Transplant</SO>
<YR>1991</YR>
<VL>7</VL>
<NO>2</NO>
<PG>127-31</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405718"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-09-29 11:17:35 +0100" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Hartmann O, Benhamou E, Maraninchi D et al. Results of a randomized double-blind placebo controlled trial with ketoconazole in the prevention of fungal infection in children treated with high dose chemotherapy and BMT [abstract]. Bone-Marrow-Transplant 1990; 5 Suppl 2:19.&lt;/p&gt;" NOTES_MODIFIED="2011-09-29 11:17:35 +0100" NOTES_MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hartmann O, Benhamou E, Maraninchi D, Valteau D, Brugières L, Kalifa C, et al</AU>
<TI>Results of a randomized double-blind placebo controlled trial with ketoconazole in the prevention of fungal infection in children treated with high dose chemotherapy and BMT [abstract]</TI>
<SO>Bone Marrow Transplant</SO>
<YR>1990</YR>
<VL>5 Suppl 2</VL>
<PG>19</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405719"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405717"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Brincker-1978" MODIFIED="2014-07-31 15:27:37 +0100" MODIFIED_BY="Clare Jess" NAME="Brincker 1978" YEAR="1978">
<REFERENCE MODIFIED="2014-07-31 15:27:37 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Brincker H</AU>
<TI>Prophylactic treatment with miconazole in patients highly predisposed to fungal infection. A placebo-controlled double-blind study</TI>
<SO>Acta Medica Scandinavica</SO>
<YR>1978</YR>
<VL>204</VL>
<NO>1-2</NO>
<PG>123-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405721"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405720"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Brincker-1983" MODIFIED="2014-07-31 15:27:41 +0100" MODIFIED_BY="Clare Jess" NAME="Brincker 1983" YEAR="1983">
<REFERENCE MODIFIED="2014-07-31 15:27:41 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Brincker H</AU>
<TI>Prevention of mycosis in granulocytopenic patients with prophylactic ketoconazole treatment</TI>
<SO>Mykosen</SO>
<YR>1983</YR>
<VL>26</VL>
<NO>5</NO>
<PG>242-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405723"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405722"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caselli-1990" MODIFIED="2014-07-31 15:27:45 +0100" MODIFIED_BY="Clare Jess" NAME="Caselli 1990" YEAR="1990">
<REFERENCE MODIFIED="2014-07-31 15:27:45 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Caselli D, Arico M, Michelone G, Cavanna C, Nespoli L, Burgio GR</AU>
<TI>Antifungal chemoprophylaxis in cancer children: a prospective randomized controlled study</TI>
<SO>Microbiologica</SO>
<YR>1990</YR>
<VL>13</VL>
<PG>347-51</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405725"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405724"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-EORTC-1989" MODIFIED="2014-07-31 15:27:50 +0100" MODIFIED_BY="Clare Jess" NAME="EORTC 1989" YEAR="1989">
<REFERENCE MODIFIED="2014-07-31 15:27:50 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>EORTC International Antimicrobial Therapy Cooperative Group</AU>
<TI>Empiric antifungal therapy in febrile granulocytopenic patients</TI>
<SO>The American Journal of Medicine</SO>
<YR>1989</YR>
<VL>86</VL>
<PG>668-72</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405727"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405726"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Estey-1984" MODIFIED="2014-07-31 15:27:54 +0100" MODIFIED_BY="Clare Jess" NAME="Estey 1984" YEAR="1984">
<REFERENCE MODIFIED="2014-07-31 15:27:54 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Estey E, Maksymiuk A, Smith T, Fainstein V, Keating M, McCredie KB</AU>
<TI>Infection prophylaxis in acute leukemia. Comparative effectiveness of sulfamethoxazole and trimethoprim, ketoconazole, and a combination of the two</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1984</YR>
<VL>144</VL>
<NO>8</NO>
<PG>1562-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405729"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405728"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Fukuda-1994" MODIFIED="2014-07-31 15:27:59 +0100" MODIFIED_BY="Clare Jess" NAME="Fukuda 1994" YEAR="1994">
<REFERENCE MODIFIED="2014-07-31 15:27:59 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fukuda M, Hirashima K, Kurane R, Abe T, Sampi K, Tominaga K</AU>
<TI>[Empiric therapy with fluconazole in granulocytopenic patients with carcinoma or leukemia][Japanese]</TI>
<SO>The Japanese Journal of Antibiotics</SO>
<YR>1994</YR>
<VL>47</VL>
<NO>8</NO>
<PG>1065-70</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405731"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405730"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goldstone-1994" MODIFIED="2014-07-31 15:28:03 +0100" MODIFIED_BY="Clare Jess" NAME="Goldstone 1994" YEAR="1994">
<REFERENCE MODIFIED="2014-07-31 15:28:03 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Goldstone AH, O'Driscoll A</AU>
<TI>Early AmBisome in febrile neutropenia in patients with haematological disorders</TI>
<SO>Bone Marrow Transplant</SO>
<YR>1994</YR>
<VL>14 Suppl 5</VL>
<PG>S15-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405733"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405732"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goodman-1992" MODIFIED="2014-07-31 15:28:27 +0100" MODIFIED_BY="Clare Jess" NAME="Goodman 1992" YEAR="">
<REFERENCE NOTES="&lt;p&gt;Chandrasekar PH, Gatny CM. Effect of fluconazole prophylaxis on fever and use of amphotericin in neutropenic cancer patients. Bone Marrow Transplantation Team. Chemotherapy 1994; 40(2):136-43.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chandrasekar PH, Gatny CM</AU>
<TI>Effect of fluconazole prophylaxis on fever and use of amphotericin in neutropenic cancer patients. Bone Marrow Transplantation Team</TI>
<SO>Chemotherapy</SO>
<YR>1994</YR>
<VL>40</VL>
<NO>2</NO>
<PG>136-43</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405735"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Chandrasekar PH, Gatny CM. The effect of fluconazole prophylaxis on fungal colonization in neutropenic cancer patients. Bone Marrow Transplantation Team. J Antimicrob Chemother 1994; 33(2):309-18.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chandrasekar PH, Gatny CM</AU>
<TI>The effect of fluconazole prophylaxis on fungal colonization in neutropenic cancer patients. Bone Marrow Transplantation Team</TI>
<SO>The Journal of Antimicrobial Chemotherapy</SO>
<YR>1994</YR>
<VL>33</VL>
<NO>2</NO>
<PG>309-18</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405736"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goodman JL, Greenfield R, Buell D</AU>
<TI>Prophylactic fluconazole and marrow transplantation [correspondence]</TI>
<SO>The New England Journal of Medicine</SO>
<YR>1992</YR>
<VL>327</VL>
<PG>645</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405737"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-07-31 15:28:27 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H</AU>
<TI>A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation</TI>
<SO>The New England Journal of Medicine</SO>
<YR>1992</YR>
<VL>326</VL>
<NO>13</NO>
<PG>845-51</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405738"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405734"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hansen-1987" MODIFIED="2014-07-31 15:28:31 +0100" MODIFIED_BY="Clare Jess" NAME="Hansen 1987" YEAR="1987">
<REFERENCE MODIFIED="2014-07-31 15:28:31 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hansen RM, Reinerio N, Sohnle PG, Abrams RA, Ritch PS, Libnoch JA</AU>
<TI>Ketoconazole in the prevention of candidiasis in patients with cancer. A prospective, randomized, controlled, double-blind study</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1987</YR>
<VL>147</VL>
<NO>4</NO>
<PG>710-2</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405740"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405739"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hughes-1983" MODIFIED="2014-07-31 15:28:35 +0100" MODIFIED_BY="Clare Jess" NAME="Hughes 1983" YEAR="1983">
<REFERENCE MODIFIED="2014-07-31 15:28:35 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Hughes WT, Bartley DL, Patterson GG, Tufenkeji H</AU>
<TI>Ketoconazole and candidiasis: a controlled study</TI>
<SO>The Journal of Infectious Diseases</SO>
<YR>1983</YR>
<VL>147</VL>
<NO>6</NO>
<PG>1060-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405742"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405741"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaptan-2003" MODIFIED="2014-07-31 15:28:40 +0100" MODIFIED_BY="Clare Jess" NAME="Kaptan 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-07-31 15:28:40 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kaptan K, Ural AU, Cetin T, Avcu F, Beyan C, Yalcin A</AU>
<TI>Itraconazole is not effective for the prophylaxis of fungal infections in patients with neutropenia</TI>
<SO>Journal of Infection and Chemotherapy</SO>
<YR>2003</YR>
<VL>9</VL>
<PG>40-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405744"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405743"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kelsey-1999" MODIFIED="2014-07-31 15:28:43 +0100" MODIFIED_BY="Clare Jess" NAME="Kelsey 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-07-31 15:28:43 +0100" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Kelsey SM, Goldman JM, McCann S et al. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study. Bone Marrow Transplant 1999; 23(2):163-8.&lt;/p&gt;" NOTES_MODIFIED="2014-07-31 15:28:43 +0100" NOTES_MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kelsey SM, Goldman JM, McCann S</AU>
<TI>Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study</TI>
<SO>Bone Marrow Transplant</SO>
<YR>1999</YR>
<VL>23</VL>
<NO>2</NO>
<PG>163-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405746"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405745"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Kern-1998" MODIFIED="2014-09-03 12:25:53 +0100" MODIFIED_BY="Clare Jess" NAME="Kern 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-09-03 12:25:53 +0100" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Kern W, Behre G, Buchner Th, and Hiddemann W. Failure of fluconazole prophylaxis to reduce mortality during treatment for refractory acute myeloid leukemia: a phase III multicenter study. Annals of Hematology 1996; 73 suppl 2:A10.&lt;/p&gt;" NOTES_MODIFIED="2014-09-03 12:25:53 +0100" NOTES_MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kern W, Behre G, Büchner T, Hiddemann W</AU>
<TI>Failure of fluconazole prophylaxis to reduce mortality during treatment for refractory acute myeloid leukemia: a phase III multicenter study [abstract]</TI>
<SO>Annals of Hematology</SO>
<YR>1996</YR>
<VL>73 Suppl 2</VL>
<PG>A10</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405748"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Kern W, Behre G, Kerkhoff A, Grote-Metke A, Eimermacher H, Kubica U et al. Failure of fluconazole prophylaxis to reduce mortality during treatment for refractory acute myleoid leukemia: results of a phase III multicenter study. Ann Hematol 1997; 74 Suppl 1:A52, abstract 207.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kern W, Behre G, Kerkhoff A, Grote-Metke A, Eimermacher H, Kubica U</AU>
<TI>Failure of fluconazole prophylaxis to reduce mortality during treatment for refractory acute myleoid leukemia: results of a phase III multicenter study</TI>
<SO>Annals of Hematology</SO>
<YR>1997</YR>
<VL>74 Suppl 1</VL>
<PG>A52, abstract 207</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405749"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-07-31 15:29:01 +0100" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Kern-W, Behre-G, Rudolf-T et al. Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: results of a prospective randomized phase III study. German AML Cooperative Group. Cancer 1998; 83:291-301.&lt;/p&gt;" NOTES_MODIFIED="2014-07-31 15:29:01 +0100" NOTES_MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kern W, Behre G, Rudolf T</AU>
<TI>Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: results of a prospective randomized phase III study. German AML Cooperative Group</TI>
<SO>Cancer</SO>
<YR>1998</YR>
<VL>83</VL>
<PG>291-301</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405750"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405747"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Menichetti-1999" MODIFIED="2014-09-03 12:25:53 +0100" MODIFIED_BY="Clare Jess" NAME="Menichetti 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-09-03 12:25:53 +0100" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Menichetti F, Del Favero A, Martino P et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto. Clin Infect Dis 1999; 28(2):250-5.&lt;/p&gt;" NOTES_MODIFIED="2014-09-03 12:25:53 +0100" NOTES_MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Menichetti F, Del Favero A, Martino P</AU>
<TI>Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>1999</YR>
<VL>28</VL>
<NO>2</NO>
<PG>250-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405752"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>del Favero A, Menichetti F, Micozzi A, Bucaneve G, de Beule K, Martino P</AU>
<TI>Antifungal prophylaxis in neutropenic pts (&lt;1000/mmc) with haematological malignancy: a double-blind trial to compare itraconazole oral solution (IOS) with placebo (PLA)</TI>
<SO>37th Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC); 28 Sept-1 Oct 1997; Toronto</SO>
<YR>1997</YR>
<VL>abstract</VL>
<PG>LM-84</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405753"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405751"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Nucci-2000" MODIFIED="2014-09-03 12:25:53 +0100" MODIFIED_BY="Clare Jess" NAME="Nucci 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Nucci M, Biasoli I, Akiti T, Silveira F, Solza C, Barreiros G, et al</AU>
<TI>A double-blind, randomized placebo-controlled trial of itraconazole capsules for antifungal prophylaxis in neutropenic patients</TI>
<SO>The Tenth International Symposium on Infections in the Immunocompromised Host. Davos, Switzerland, 21-24 June 1998</SO>
<YR>1998</YR>
<PG>Abstract 104</PG>
<PB>International Immunocompromised Host Society</PB>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405755"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-09-03 12:25:53 +0100" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Nucci M, Biasoli I, Akiti T, Silveira F, Solza C, Barreiros G et al. A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients. Clin Infect Dis 2000; 30(2):300-5.&lt;/p&gt;" NOTES_MODIFIED="2014-09-03 12:25:53 +0100" NOTES_MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nucci M, Biasoli I, Akiti T, Silveira F, Solza C, Barreiros G</AU>
<TI>A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2000</YR>
<VL>30</VL>
<NO>2</NO>
<PG>300-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405756"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-09-03 12:25:53 +0100" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Nucci M, Biasoli I, Solza C, Silveira F, Akiti T, Derossi A et al. Itraconazole capsules versus placebo in the prophylaxis of fungal infections in neutropenic cancer patients: a double-blind, randomized study. Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), 38th Meeting, San Diego, Sept 24-27 1998; abstract J-102 (p. 480).&lt;/p&gt;" NOTES_MODIFIED="2014-09-03 12:25:53 +0100" NOTES_MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Nucci M, Biasoli I, Solza C, Silveira F, Akiti T, Derossi A</AU>
<TI>Itraconazole capsules versus placebo in the prophylaxis of fungal infections in neutropenic cancer patients: a double-blind, randomized study</TI>
<SO>Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), 38th Meeting, San Diego, Sept 24-27 1998</SO>
<YR>1998</YR>
<PG>480 (Abstract J-102)</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405757"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405754"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Palmblad-1992" MODIFIED="2014-07-31 15:32:00 +0100" MODIFIED_BY="Clare Jess" NAME="Palmblad 1992" YEAR="1992">
<REFERENCE MODIFIED="2014-07-31 15:32:00 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Palmblad J, Lönnqvist B, Carlsson B, Grimfors G, Järnmark M, Lerner R</AU>
<TI>Oral ketoconazole prophylaxis for Candida infections during induction therapy for acute leukaemia in adults: more bacteraemias</TI>
<SO>Journal of Internal Medicine</SO>
<YR>1992</YR>
<VL>231</VL>
<NO>4</NO>
<PG>363-70</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405759"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405758"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Penack-2006" MODIFIED="2014-09-03 12:25:53 +0100" MODIFIED_BY="Clare Jess" NAME="Penack 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-09-03 12:25:53 +0100" MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Penack O, Schwartz S, Martus P, Reinwald M, Schmidt-Hieber M, Thiel E, et al</AU>
<TI>A randomized phase III trial of low dose liposomal amphotericin B (L-AmB) as prophylaxis of invasive fungal infections (IFI) in neutropenic patients (pts)</TI>
<SO>Blood</SO>
<YR>2005</YR>
<VL>106</VL>
<NO>11</NO>
<PG>Abstract No. 82</PG>
<PB>Proceedings of the 47th Annual Meeting of the American Society of Hematology; 10-13 December, 2005; Atlanta, Georgia</PB>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405761"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-09-03 12:25:53 +0100" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Penack O, Schwartz S, Martus P et al. Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. Ann Oncol 2006; 17(8):1306-12.&lt;/p&gt;" NOTES_MODIFIED="2014-09-03 12:25:53 +0100" NOTES_MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Penack O, Schwartz S, Martus P, Reinwald M, Schmidt-Hieber M, Thiel E, et al</AU>
<TI>Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial</TI>
<SO>Annals of Oncology</SO>
<YR>2006</YR>
<VL>17</VL>
<NO>8</NO>
<PG>1306-12</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405762"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Penack OP, Reinwald M, Schmidt-Hieber M et al. Low dose liposomal amphotericin B (L-AMB) as prophylaxis of invasive fungal infections in patients with prolonged neutropenia: preliminary results of a randomized phase III trial. 10th Congress of the European Hematology Association 2005.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Penack OP, Reinwald M, Schmidt-Hieber M, Schwartz S, Thiel E, Blau IW</AU>
<TI>Low dose liposomal amphotericin B (L-AMB) as prophylaxis of invasive fungal infections in patients (pts) with prolonged neutropenia: preliminary results of a randomized phase III trial</TI>
<SO>10th Congress of the European Hematology Association</SO>
<YR>2005</YR>
<VL>abstract</VL>
<PG>0376</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405763"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405760"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Perfect-1992" MODIFIED="2014-07-31 15:32:24 +0100" MODIFIED_BY="Clare Jess" NAME="Perfect 1992" YEAR="1992">
<REFERENCE MODIFIED="2014-07-31 15:32:24 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Perfect JR, Klotman ME, Gilbert CC</AU>
<TI>Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients</TI>
<SO>The Journal of Infectious Diseases</SO>
<YR>1992</YR>
<VL>165</VL>
<NO>5</NO>
<PG>891-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405765"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405764"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pizzo-1982" MODIFIED="2014-09-03 12:25:53 +0100" MODIFIED_BY="Clare Jess" NAME="Pizzo 1982" YEAR="1982">
<REFERENCE MODIFIED="2014-09-03 12:25:53 +0100" MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Pizzo PA, Robichau KJ, Simon R</AU>
<TI>Empiric antifungal therapy for cancer patients with prolonged fever and granulocytopenia</TI>
<SO>Proceedings of the American Association of Cancer Research</SO>
<YR>1980</YR>
<PG>348 (Abstract C-115)</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405767"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-07-31 15:32:47 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG</AU>
<TI>Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia</TI>
<SO>The American Journal of Medicine</SO>
<YR>1982</YR>
<VL>72</VL>
<NO>1</NO>
<PG>101-11</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405768"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405766"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Riley-1994" MODIFIED="2014-07-31 15:33:00 +0100" MODIFIED_BY="Clare Jess" NAME="Riley 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Riley D, Beatty P, Pavia A, Evans TG</AU>
<TI>Prophylactic use of low-dose amphotericin B (AMB) in bone marrow transplant (BMT) patients</TI>
<SO>32nd Interscience Conference of Antimicrobial Agents and Chemotherapy. American Society for Microbiology, 1992</SO>
<YR>1992</YR>
<PG>abstract 620</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405770"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-07-31 15:33:00 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Riley DK, Pavia AT, Beatty PG</AU>
<TI>The prophylactic use of low-dose amphotericin B in bone marrow transplant patients</TI>
<SO>The American Journal of Medicine</SO>
<YR>1994</YR>
<VL>97</VL>
<NO>6</NO>
<PG>509-14</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405771"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405769"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rotstein-1999" MODIFIED="2014-09-03 12:25:53 +0100" MODIFIED_BY="Clare Jess" NAME="Rotstein 1999" YEAR="1999">
<REFERENCE MODIFIED="2014-09-03 12:25:53 +0100" MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laverdiere M, Rotstein C, Bow EJ, Carr D, Moghaddam N, Ioannou S; Canadian Fluconazole Study Group</AU>
<TI>The impact of fluconazole (F) prophylaxis on fungal colonization and subsequent infection in cancer neutropenic patients</TI>
<SO>37th Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC); 28 Sept-1 Oct 1997; Toronto</SO>
<YR>1997</YR>
<VL>abstract</VL>
<PG>LM-85</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405773"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-09-03 12:25:53 +0100" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Laverdiere M, Rotstein C, Bow EJ, Carr D, Moghaddam N, Ioannou S. The impact of fluconazole (F) prophylaxis on fungal colonization and subsequent infection in cancer neutropenic patients. The Canadian Fluconazole Study Group. Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Sept 28-Oct 1, 1997 1997; Abstract LM-85 (p. 380).&lt;/p&gt;" NOTES_MODIFIED="2014-09-03 12:25:53 +0100" NOTES_MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laverdiere M, Rotstein C, Bow EJ, Roberts RS, Ioannou S, Carr D, et al; Canadian Fluconazole Study Group</AU>
<TI>Impact of fluconazole prophylaxis on fungal colonization and infection rates in neutropenic patients</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>2000</YR>
<VL>46</VL>
<PG>1001-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405774"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-09-03 12:25:53 +0100" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Rotstein C, Bow EJ, Laverdiere M, Ioannou S, Carr D, Moghaddam N. Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group. Clin Infect Dis 1999; 28(2):331-40.&lt;/p&gt;" NOTES_MODIFIED="2014-09-03 12:25:53 +0100" NOTES_MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Rotstein C, Bow EJ, Laverdiere M, Ioannou S, Carr D, Moghaddam N</AU>
<TI>Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>1999</YR>
<VL>28</VL>
<NO>2</NO>
<PG>331-40</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405775"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405772"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Schaffner-1995" MODIFIED="2014-07-31 15:33:19 +0100" MODIFIED_BY="Clare Jess" NAME="Schaffner 1995" YEAR="1995">
<REFERENCE MODIFIED="2014-07-31 15:33:19 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schaffner A, Schaffner M</AU>
<TI>Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias</TI>
<SO>The Journal of Infectious Diseases</SO>
<YR>1995</YR>
<VL>172</VL>
<NO>4</NO>
<PG>1035-41</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405777"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405776"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Siegel-1982a" MODIFIED="2014-07-31 15:33:26 +0100" MODIFIED_BY="Clare Jess" NAME="Siegel 1982a" YEAR="1982">
<REFERENCE MODIFIED="2014-07-31 15:33:26 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Siegel M, Murphy M, Counts GW, Meyers JD</AU>
<TI>Prophylactic ketoconazole for the prevention of fungal infection in bone marrow transplant patients</TI>
<SO>23rd Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC). American Society for Microbiology</SO>
<YR>1982</YR>
<PG>abstract 166</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405779"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405778"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Slavin-1995" MODIFIED="2014-09-03 12:25:53 +0100" MODIFIED_BY="Clare Jess" NAME="Slavin 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Marr KA, . = Seidel K, Slavin MA, Bowden RA, Schoch HG, Flowers ME et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000; 96:2055-61.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marr KA, Seidel K, Slavin MA, Bowden RA, Schoch HG, Flowers MED</AU>
<TI>Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial</TI>
<SO>Blood</SO>
<YR>2000</YR>
<VL>96</VL>
<PG>2055-61</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405781"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-07-29 14:25:10 +0100" MODIFIED_BY="Tracey Bishop" NOTES="&lt;p&gt;Slavin M, Bowden R, Osborne B, Adams R, Levenstein M, Feldman A, et al. Fluconazole prophylaxis in marrow transplant recipients: a&lt;/p&gt;" NOTES_MODIFIED="2014-07-29 14:25:10 +0100" NOTES_MODIFIED_BY="Tracey Bishop" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Slavin M, Bowden R, Osborne B, Adams R, Levenstein M, Feldman A</AU>
<TI>Fluconazole prophylaxis in marrow transplant recipients: a randomized placebo controlled double blind study</TI>
<SO>32nd Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC). American Society for Microbiology</SO>
<YR>1992</YR>
<PG>abstract 623</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405782"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-07-31 15:33:53 +0100" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Slavin MA, Osborne B, Adams R, Levenstein M, Schoch HG, Feldman AR, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 1995; 171(6):15 45-52.&lt;/p&gt;" NOTES_MODIFIED="2014-07-31 15:33:53 +0100" NOTES_MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Slavin MA, Osborne B, Adams R, Levenstein M, Schoch HG, Feldman AR</AU>
<TI>Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study</TI>
<SO>The Journal of Infectious Diseases</SO>
<YR>1995</YR>
<VL>171</VL>
<NO>6</NO>
<PG>1545-52</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405783"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-09-03 12:25:53 +0100" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Upton A, McCune JS, Kirby KA et al. Fluconazole coadministration concurrent with cyclophosphamide conditioning may reduce regimen-related toxicity postmyeloablative hematopoietic cell transplantation. Biol Blood Marrow Transplant 2007; 13(7):760-4.&lt;/p&gt;" NOTES_MODIFIED="2014-09-03 12:25:53 +0100" NOTES_MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Upton A, McCune JS, Kirby KA, Leisenring W, McDonald G, Batchelder A, et al</AU>
<TI>Fluconazole coadministration concurrent with cyclophosphamide conditioning may reduce regimen-related toxicity postmyeloablative hematopoietic cell transplantation</TI>
<SO>Biology of Blood and Marrow Transplantation</SO>
<YR>2007</YR>
<VL>13</VL>
<NO>7</NO>
<PG>760-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405784"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405780"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Suda-1980" MODIFIED="2014-07-31 15:33:58 +0100" MODIFIED_BY="Clare Jess" NAME="Suda 1980" YEAR="1980">
<REFERENCE MODIFIED="2014-07-31 15:33:58 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Suda T, Omine M, Tsuchiya J, Maekawa T, Muto Y, Mizoguchi H</AU>
<TI>[A co-operative study on prophylaxis of fungal infection in patients with hematological diseases: prophylactic effect of oral administration of amphotericin B][Japanese]</TI>
<SO>[Rinsho Ketsueki] The Japanese Journal of Clinical Hematology</SO>
<YR>1980</YR>
<VL>21</VL>
<NO>2</NO>
<PG>195-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405786"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405785"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tollemar-1993" MODIFIED="2014-09-03 12:25:53 +0100" MODIFIED_BY="Clare Jess" NAME="Tollemar 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Tollemar J, Hockerstedt K, Ericzon BG, Sundberg B, Ringden O. Fungal prophylaxis with AmBisome in liver and bone marrow transplant recipients: results of two randomized double-blind studies. Transplant Proc 1994; 26(3):1833.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tollemar J, Hockerstedt K, Ericzon BG, Sundberg B, Ringden O</AU>
<TI>Fungal prophylaxis with AmBisome in liver and bone marrow transplant recipients: results of two randomized double-blind studies</TI>
<SO>Transplantation Proceedings</SO>
<YR>1994</YR>
<VL>26</VL>
<NO>3</NO>
<PG>1833</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405788"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-09-03 12:25:53 +0100" MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tollemar J, Ringdén O</AU>
<TI>Double-blind randomized trials with AmBisome (TM) as prophylaxis in bone marrow and liver transplant patients</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>1993</YR>
<VL>12 Suppl 4</VL>
<PG>S151-2</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405789"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Tollemar J, Ringden O, Andersson S, Sundberg B, Ljungman P, Sparrelid E, et al. Prophylactic use of liposomal amphotericin B (AmBisome) against fungal infections: a randomized trial in bone marrow transplant recipients. Transplant Proc 1993; 25(1 Pt 2):1495-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tollemar J, Ringden O, Andersson S, Sundberg B, Ljungman P, Sparrelid E</AU>
<TI>Prophylactic use of liposomal amphotericin B (AmBisome) against fungal infections: a randomized trial in bone marrow transplant recipients</TI>
<SO>Transplantation Proceedings</SO>
<YR>1993</YR>
<VL>25</VL>
<NO>1 Pt 2</NO>
<PG>1495-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405790"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2011-09-29 11:17:35 +0100" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Tollemar J, Ringden O, Andersson S, Sundberg B, Ljungman P, Tyden G. Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant 1993; 12 (6):577-82.&lt;/p&gt;" NOTES_MODIFIED="2011-09-29 11:17:35 +0100" NOTES_MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tollemar J, Ringden O, Andersson S, Sundberg B, Ljungman P, Tyden G</AU>
<TI>Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>1993</YR>
<VL>12</VL>
<NO>6</NO>
<PG>577-82</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405791"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405787"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Vreugdenhil-1993" MODIFIED="2014-07-31 15:35:50 +0100" MODIFIED_BY="Clare Jess" NAME="Vreugdenhil 1993" YEAR="1993">
<REFERENCE MODIFIED="2014-07-31 15:35:50 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Vreugdenhil G, Van Dijke BJ, Donnelly JP, Novakova IRO, Raemaekers JMM, Hoogkamp-Korstanje MAA</AU>
<TI>Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy. A double blind, placebo controlled study</TI>
<SO>Leukemia &amp; Lymphoma</SO>
<YR>1993</YR>
<VL>11</VL>
<NO>5-6</NO>
<PG>353-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405793"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405792"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wingard-1987" MODIFIED="2014-07-31 15:36:00 +0100" MODIFIED_BY="Clare Jess" NAME="Wingard 1987" YEAR="1987">
<REFERENCE MODIFIED="2014-07-31 15:36:00 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wingard JR, Vaughan WP, Braine HG, Merz WG, Saral R</AU>
<TI>Prevention of fungal sepsis in patients with prolonged neutropenia: a randomized, double-blind, placebo-controlled trial of intravenous miconazole</TI>
<SO>The American Journal of Medicine</SO>
<YR>1987</YR>
<VL>83</VL>
<NO>6</NO>
<PG>1103-10</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405795"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405794"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Winston-1993" MODIFIED="2014-07-31 15:36:06 +0100" MODIFIED_BY="Clare Jess" NAME="Winston 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Kelsey SM, Goldman JM, McCann S et al. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study. Bone Marrow Transplant 1999; 23(2):163-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kelsey SM, Goldman JM, McCann S</AU>
<TI>Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>1999</YR>
<VL>23</VL>
<NO>2</NO>
<PG>163-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405797"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-07-31 15:36:06 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Winston DJ, Chandrasekar PH, Lazarus HM, Goodman JL, Silber JL, Horowitz H</AU>
<TI>Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1993</YR>
<VL>118</VL>
<NO>7</NO>
<PG>495-503</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405798"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405796"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yamac-1995" MODIFIED="2014-07-31 15:36:13 +0100" MODIFIED_BY="Clare Jess" NAME="Yamac 1995" YEAR="1995">
<REFERENCE MODIFIED="2014-07-31 15:36:13 +0100" MODIFIED_BY="Clare Jess" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Yamac K, Senol E, Haznedar R</AU>
<TI>Prophylactic use of fluconazole in neutropenic cancer patients</TI>
<SO>Postgraduate Medical Journal</SO>
<YR>1995</YR>
<VL>71</VL>
<NO>835</NO>
<PG>284-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405800"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405799"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-09-03 12:25:53 +0100" MODIFIED_BY="Clare Jess">
<STUDY DATA_SOURCE="UNPUB" ID="STD-Benhamou-1991b" NAME="Benhamou 1991b" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Benhamou E, Hartmann O, Nogues C, Maraninchi D, Valteau D, Lemerle J</AU>
<TI>Does ketoconazole prevent fungal infection in children treated with high dose chemotherapy and bone marrow transplantation? Results of a randomized placebo-controlled trial</TI>
<SO>Bone Marrow Transplantation</SO>
<YR>1991</YR>
<VL>7</VL>
<NO>2</NO>
<PG>127-31</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405802"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405801"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bodey-1990" MODIFIED="2014-09-03 12:25:53 +0100" MODIFIED_BY="Clare Jess" NAME="Bodey 1990" YEAR="1990">
<REFERENCE MODIFIED="2014-09-03 12:25:53 +0100" MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bodey GP, Samonis G, Rolston K</AU>
<TI>Prophylaxis of candidiasis in cancer patients</TI>
<SO>Seminars in Oncology</SO>
<YR>1990</YR>
<VL>7 Suppl 6</VL>
<PG>24-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405804"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405803"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Brincker-1990" NAME="Brincker 1990" YEAR="1990">
<REFERENCE PRIMARY="YES" TYPE="CORRESPONDENCE">
<AU>Brincker H</AU>
<SO>Personal communication; unpublished study on fluconazole</SO>
<YR>1990</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405806"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405805"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caselli-2012" MODIFIED="2014-09-03 12:25:53 +0100" MODIFIED_BY="Clare Jess" NAME="Caselli 2012" YEAR="2012">
<REFERENCE MODIFIED="2014-09-03 12:25:53 +0100" MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Caselli D, Cesaro S, Ziino O, et al</AU>
<TI>A prospective, randomized study of empirical antifungal therapy for the treatment of chemotherapy-induced febrile neutropenia in children</TI>
<SO>British Journal of Haematology</SO>
<YR>2012</YR>
<VL>158</VL>
<PG>249-55</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405808"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405807"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ezdinli-1979" NAME="Ezdinli 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ezdinli EZ, O'Sullivan DD, Wasser LP, Kim U, Stutzman L</AU>
<TI>Oral amphotericin for candidiasis in patients with hematologic neoplasms. An autopsy study</TI>
<SO>JAMA</SO>
<YR>1979</YR>
<VL>242</VL>
<NO>3</NO>
<PG>258-60</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405810"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405809"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hiddemann-1991" MODIFIED="2011-09-29 11:17:35 +0100" MODIFIED_BY="Clare Jess" NAME="Hiddemann 1991" YEAR="1991">
<REFERENCE MODIFIED="2011-09-29 11:17:35 +0100" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Hiddemann W, Essink ME, Fegeler W, Zuhlsdorf M, Sauerland C, Buchner T. Antifungal treatment by amphotericin B and 5-fluorocytosine delays the recovery of normal hematopoietic cells after intensive cytostatic therapy for acute myeloid leukemia. Cancer 1991; 68(1):9-14.&lt;/p&gt;" NOTES_MODIFIED="2011-09-29 11:17:35 +0100" NOTES_MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hiddemann W, Essink ME, Fegeler W, Zuhlsdorf M, Sauerland C, Buchner T</AU>
<TI>Antifungal treatment by amphotericin B and 5-fluorocytosine delays the recovery of normal hematopoietic cells after intensive cytostatic therapy for acute myeloid leukemia</TI>
<SO>Cancer</SO>
<YR>1991</YR>
<VL>68</VL>
<NO>1</NO>
<PG>9-14</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405812"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405811"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Prentice-1989" NAME="Prentice 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Prentice AG, Bradford GR</AU>
<TI>Prophylaxis of fungal infections with itraconazole during remission-induction therapy</TI>
<SO>Mycoses</SO>
<YR>1989</YR>
<VL>32 Suppl 1</VL>
<PG>96-102 (describes an unpublished study)</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405814"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405813"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reed-1993" NAME="Reed 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reed E, Rasmussen J, Robertson P, Armitage J, Bierman P, Vose J</AU>
<TI>Interim analysis of fluconazole (flu), intermittent amphotericin (ampho) and no treatment (ntx) for prophylaxis of fungal disease in bone marrow transplant (bmt) and acute leukemia (al) patients (pts)</TI>
<SO>Proceedings of the Annual Meeting of the American Society of Clinical Oncology</SO>
<YR>1993</YR>
<VL>12</VL>
<PG>465, abstract 1622</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405816"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405815"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Samonis-1990" MODIFIED="2014-09-03 12:25:53 +0100" MODIFIED_BY="Clare Jess" NAME="Samonis 1990" YEAR="1990">
<REFERENCE MODIFIED="2014-09-03 12:25:53 +0100" MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Samonis G, Rolston K, Karl C, Miller P, Bodey G</AU>
<TI>Prophylaxis of oropharyngeal candidiasis with fluconazole</TI>
<SO>Reviews of Infectious Diseases</SO>
<YR>1990</YR>
<VL>12 Suppl 3</VL>
<PG>S369-73</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405818"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405817"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schaison-1990" NAME="Schaison 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schaison G, Baruchel A, Arlet G</AU>
<TI>Prevention of gram-positive and Candida albicans infections using teicoplanin and fluconazole: a randomized study in neutropenic children</TI>
<SO>British Journal of Haematology</SO>
<YR>1990</YR>
<VL>76 Suppl 2</VL>
<PG>24-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405820"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405819"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schiel-2006" MODIFIED="2014-09-03 12:25:53 +0100" MODIFIED_BY="Clare Jess" NAME="Schiel 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-09-03 12:25:53 +0100" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Schiel X, Link H, Maschmeyer G et al. A prospective, randomized multicenter trial of the empirical addition of antifungal therapy for febrile neutropenic cancer patients: results of the Paul Ehrlich Society for Chemotherapy (PEG) Multicenter Trial II. Infection 2006; 34(3):118-26.&lt;/p&gt;" NOTES_MODIFIED="2014-09-03 12:25:53 +0100" NOTES_MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schiel X, Link H, Maschmeyer G, Cornely OA, Buchheidt D, Wilhelm M, et al</AU>
<TI>A prospective, randomized multicenter trial of the empirical addition of antifungal therapy for febrile neutropenic cancer patients: results of the Paul Ehrlich Society for Chemotherapy (PEG) Multicenter Trial II</TI>
<SO>Infection</SO>
<YR>2006</YR>
<VL>34</VL>
<NO>3</NO>
<PG>118-26</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405822"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405821"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Siegel-1982b" NAME="Siegel 1982b" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Siegel M, Murphy M, Counts GW, Meyers JD</AU>
<TI>Prophylactic ketoconazole for the prevention of fungal infection in bone marrow transplant patients</TI>
<SO>23rd Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC). American Society for Microbiology, 1982</SO>
<YR>1982</YR>
<PG>abstract 166</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405824"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405823"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vehreschild" MODIFIED="2014-09-03 12:25:53 +0100" MODIFIED_BY="Clare Jess" NAME="Vehreschild" YEAR="2007">
<REFERENCE MODIFIED="2014-09-03 12:25:53 +0100" MODIFIED_BY="Clare Jess" NOTES="&lt;p&gt;Vehreschild JJ, Bohme A, Buchheidt D et al. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). J Infect 2007; 55(5):445-9.&lt;/p&gt;" NOTES_MODIFIED="2014-09-03 12:25:53 +0100" NOTES_MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vehreschild JJ, Bohme A, Buchheidt D, Arenz D, Harnischmacher U, Heussel CP, et al</AU>
<TI>A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML)</TI>
<SO>Journal of Infection</SO>
<YR>2007</YR>
<VL>55</VL>
<NO>5</NO>
<PG>445-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405826"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405825"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-2003" NAME="Wang 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Wang CY, Wu BY, Guo KY. A controlled clinical trial of itraconazole for prevention of fungal infections secondary to chemotherapy. Di Yi Jun Yi Da Xue Xue Bao 2003; 23(4):389-90.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang CY, Wu BY, Guo KY</AU>
<TI>A controlled clinical trial of itraconazole for prevention of fungal infections secondary to chemotherapy</TI>
<SO>Di Yi Jun Yi Da Xue Xue Bao [Academic Journal of the First Medical College of PLA]</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>4</NO>
<PG>389-90</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405828"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405827"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2014-09-03 12:40:46 +0100" MODIFIED_BY="Clare Jess">
<STUDY DATA_SOURCE="PUB" ID="STD-Cornely-2006" MODIFIED="2014-09-03 12:40:46 +0100" MODIFIED_BY="Clare Jess" NAME="Cornely 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-09-03 12:40:46 +0100" MODIFIED_BY="Clare Jess" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Cornely OA, Böhme A, Vehreschild JJ, Buchheidt D, Arenz D, Harnischmacher U, et al</AU>
<TI>Evaluating voriconazole (VCZ) as primary antifungal prophylaxis during induction chemotherapy for acute myelogenous leukemia (AML)</TI>
<SO>46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sept 27-30; San Francisco</SO>
<YR>2006: abstract M-884</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="3405830"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="3405829"/></IDENTIFIERS>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-09-03 12:48:15 +0100" MODIFIED_BY="Clare Jess">
<ADDITIONAL_REFERENCES MODIFIED="2011-09-29 11:21:26 +0100" MODIFIED_BY="Clare Jess">
<REFERENCE ID="REF-Ahmad-2001" NAME="Ahmad 2001" NOTES="&lt;p&gt;Ahmad SR, Singer SJ, Leissa BG. Congestive heart failure associated with itraconazole. Lancet 2001; 357(9270):1766-7.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Ahmad SR, Singer SJ, Leissa BG</AU>
<TI>Congestive heart failure associated with itraconazole</TI>
<SO>Lancet</SO>
<YR>2001</YR>
<VL>357</VL>
<NO>9270</NO>
<PG>1766-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Berlin-1989" NAME="Berlin 1989" TYPE="JOURNAL_ARTICLE">
<AU>Berlin JA, Begg CB, Louis TA</AU>
<TI>An assessment of publication bias using a sample of published clinical trials</TI>
<SO>Journal of the American Statistical Association</SO>
<YR>1989</YR>
<VL>84</VL>
<PG>381-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Buyse-1993" NAME="Buyse 1993" TYPE="JOURNAL_ARTICLE">
<AU>Buyse M</AU>
<TI>Interim analyses, stopping rules and data monitoring in clinical trials in Europe</TI>
<SO>Statistics in Medicine</SO>
<YR>1993</YR>
<VL>2</VL>
<PG>509-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chalmers-1990" NAME="Chalmers 1990" TYPE="JOURNAL_ARTICLE">
<AU>Chalmers I</AU>
<TI>Underreporting research is scientific misconduct</TI>
<SO>JAMA</SO>
<YR>1990</YR>
<VL>263</VL>
<PG>1405-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chan-2004" NAME="Chan 2004" NOTES="&lt;p&gt;Chan AW, Hrobjartsson A, Haahr MT et al. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004; 291(20):2457-65.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Chan AW, Hrobjartsson A, Haahr MT, Gøtzsche PC, Altman DG</AU>
<TI>Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles</TI>
<SO>JAMA</SO>
<YR>2004</YR>
<VL>291</VL>
<NO>20</NO>
<PG>2457-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Due-2006" NAME="Due 2006" TYPE="JOURNAL_ARTICLE">
<AU>Due AK, Johansen HK, Gøtzsche PC</AU>
<TI>Fungal infection-related mortality versus total mortality as an outcome in trials of antifungal agents</TI>
<SO>BioMed Central Medical Research Methodology</SO>
<YR>2006</YR>
<VL>6</VL>
<PG>40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Estey-1982" NAME="Estey 1982" TYPE="JOURNAL_ARTICLE">
<AU>Estey EH, Keating MJ, McCredie KB, Bodey GP, Freireich EJ</AU>
<TI>Causes of initial remission induction failure in acute myelogenous leukemia</TI>
<SO>Blood</SO>
<YR>1982</YR>
<VL>60</VL>
<PG>309-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-G_x00f8_tzsche-1989" NAME="Gøtzsche 1989" NOTES="&lt;p&gt;Gotzsche PC. Multiple publication of reports of drug trials. Eur J Clin Pharmacol 1989; 36(5):429-32.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Gøtzsche PC</AU>
<TI>Multiple publication of reports of drug trials</TI>
<SO>European Journal of Clinical Pharmacology</SO>
<YR>1989</YR>
<VL>36</VL>
<NO>5</NO>
<PG>429-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Huston-1996" NAME="Huston 1996" TYPE="JOURNAL_ARTICLE">
<AU>Huston P, Moher D</AU>
<TI>Pharmaceutical company trials and the integrity of medical research (letter)</TI>
<SO>Lancet</SO>
<YR>1996</YR>
<VL>347</VL>
<PG>1628</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Inagaki-1974" NAME="Inagaki 1974" NOTES="&lt;p&gt;I&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Inagaki J, Rodriguez V, Bodey G</AU>
<TI>Causes of death in cancer patients</TI>
<SO>Cancer</SO>
<YR>1974</YR>
<VL>33</VL>
<PG>568-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Johansen-1999" NAME="Johansen 1999" TYPE="JOURNAL_ARTICLE">
<AU>Johansen HK, Gøtzsche PC</AU>
<TI>Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis</TI>
<SO>JAMA</SO>
<YR>1999</YR>
<VL>282</VL>
<PG>1752-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Johansen-2001" MODIFIED="2011-09-29 11:19:24 +0100" MODIFIED_BY="Clare Jess" NAME="Johansen 2001" TYPE="COCHRANE_REVIEW">
<AU>Johansen HK, Gøtzsche PC</AU>
<TI>Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2011-09-29 11:19:19 +0100" MODIFIED_BY="Clare Jess"><IDENTIFIER MODIFIED="2011-09-29 11:19:19 +0100" MODIFIED_BY="Clare Jess" TYPE="DOI" VALUE="10.1002/14651858.CD000969"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Johansen-2002a" MODIFIED="2011-09-29 11:19:56 +0100" MODIFIED_BY="Clare Jess" NAME="Johansen 2002a" TYPE="COCHRANE_REVIEW">
<AU>Johansen HK, Gøtzsche PC</AU>
<TI>Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2011-09-29 11:19:48 +0100" MODIFIED_BY="Clare Jess"><IDENTIFIER MODIFIED="2011-09-29 11:19:48 +0100" MODIFIED_BY="Clare Jess" TYPE="DOI" VALUE="10.1002/14651858.CD000239"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Johansen-2002b" MODIFIED="2011-09-29 11:21:26 +0100" MODIFIED_BY="Clare Jess" NAME="Johansen 2002b" TYPE="COCHRANE_REVIEW">
<AU>Johansen HK, Gøtzsche PC</AU>
<TI>Nystatin prophylaxis and treatment in severely immunodepressed patients</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2011-09-29 11:21:26 +0100" MODIFIED_BY="Clare Jess"><IDENTIFIER MODIFIED="2011-09-29 11:21:26 +0100" MODIFIED_BY="Clare Jess" TYPE="DOI" VALUE="10.1002/14651858.CD002033"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-J_x00f8_rgensen-2006" MODIFIED="2011-09-29 11:18:51 +0100" MODIFIED_BY="Clare Jess" NAME="Jørgensen 2006" NOTES="&lt;p&gt;Jorgensen KJ, Gotzsche PC, Johansen HK. Voriconazole versus amphotericin B in cancer patients with neutropenia. Cochrane Database Syst Rev 2006; (1):CD004707.&lt;/p&gt;" NOTES_MODIFIED="2011-09-29 11:18:51 +0100" NOTES_MODIFIED_BY="Clare Jess" TYPE="COCHRANE_REVIEW">
<AU>Jørgensen KJ, Gøtzsche PC, Johansen HK</AU>
<TI>Voriconazole versus amphotericin B in cancer patients with neutropenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2011-09-29 11:18:49 +0100" MODIFIED_BY="Clare Jess"><IDENTIFIER MODIFIED="2011-09-29 11:18:49 +0100" MODIFIED_BY="Clare Jess" TYPE="DOI" VALUE="10.1002/14651858.CD004707"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Meyers-1990" NAME="Meyers 1990" TYPE="JOURNAL_ARTICLE">
<AU>Meyers JD</AU>
<TI>Fungal infections in bone marrow transplant patients</TI>
<SO>Seminars in Oncology</SO>
<YR>1990</YR>
<VL>17</VL>
<PG>10-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pocock-1978" NAME="Pocock 1978" TYPE="JOURNAL_ARTICLE">
<AU>Pocock SJ</AU>
<TI>Size of cancer clinical trials and stopping rules</TI>
<SO>British Journal of Cancer</SO>
<YR>1978</YR>
<VL>38</VL>
<PG>757-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias, dimension of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simes-1986" NAME="Simes 1986" TYPE="JOURNAL_ARTICLE">
<AU>Simes RJ</AU>
<TI>Publication bias: the case for an international registry of clinical trials</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1986</YR>
<VL>4</VL>
<PG>529-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stein-1986" NAME="Stein 1986" TYPE="JOURNAL_ARTICLE">
<AU>Stein RS, Greer JP, Ferrin W, Lenox R, Baer MR, Flexner JM</AU>
<TI>Clinical experience with amphotericin B in acute myelogenous leukemia</TI>
<SO>Southern Medical Journal</SO>
<YR>1986</YR>
<VL>79</VL>
<NO>7</NO>
<PG>863-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stern-1997" NAME="Stern 1997" TYPE="JOURNAL_ARTICLE">
<AU>Stern JM, Simes RJ</AU>
<TI>Publication bias: evidence of delayed publication in a cohort study of clinical research projects</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>640-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Verfaillie-1991" NAME="Verfaillie 1991" TYPE="JOURNAL_ARTICLE">
<AU>Verfaillie C, Weisdorf D, Haake R, Hostetter M, Ramsay N, McGlave P</AU>
<TI>Candida infections in bone marrow transplant recipients</TI>
<SO>Bone Marrow Transplant</SO>
<YR>1991</YR>
<VL>8</VL>
<PG>177-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walsh-1990" NAME="Walsh 1990" TYPE="JOURNAL_ARTICLE">
<AU>Walsh TJ</AU>
<TI>Role of surveillance cultures in prevention and treatment of fungal infections</TI>
<SO>Journal of National Cancer Institute Monographs</SO>
<YR>1990</YR>
<VL>9</VL>
<PG>43-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walsh-1991" NAME="Walsh 1991" TYPE="JOURNAL_ARTICLE">
<AU>Walsh TJ, Lee J, Lecciones J, Rubin M, Butler K, Francis P</AU>
<TI>Empiric therapy with amphotericin B in febrile granulocytopenic patients</TI>
<SO>Reviews of Infectious Diseases</SO>
<YR>1991</YR>
<VL>13</VL>
<NO>3</NO>
<PG>496-503</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Working-Party-1995" NAME="Working Party 1995" TYPE="JOURNAL_ARTICLE">
<AU>Working Party of the British Society for Antimicrobial Chemotherapy</AU>
<TI>Antifungal drug susceptibility testing</TI>
<SO>The Journal of Antimicrobial Chemotherapy</SO>
<YR>1995</YR>
<VL>36</VL>
<PG>899-909</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2014-09-03 12:48:15 +0100" MODIFIED_BY="Clare Jess">
<REFERENCE ID="REF-G_x00f8_tzsche-1997" NAME="Gøtzsche 1997" TYPE="JOURNAL_ARTICLE">
<AU>Gøtzsche PC, Johansen HK</AU>
<TI>Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>314</VL>
<PG>1238-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-G_x00f8_tzsche-2000" MODIFIED="2011-09-29 11:22:40 +0100" MODIFIED_BY="Clare Jess" NAME="Gøtzsche 2000" TYPE="COCHRANE_REVIEW">
<AU>Gøtzsche PC, Johansen HK</AU>
<TI>Routine versus selective antifungal administration for control of fungal infections in patients with cancer (Cochrane Review)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>2.</NO>
<IDENTIFIERS MODIFIED="2011-09-29 11:22:34 +0100" MODIFIED_BY="Clare Jess"><IDENTIFIER MODIFIED="2011-09-29 11:22:34 +0100" MODIFIED_BY="Clare Jess" TYPE="DOI" VALUE="10.1002/14651858.CD000026"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-G_x00f8_tzsche-2002" MODIFIED="2011-09-29 11:23:03 +0100" MODIFIED_BY="Clare Jess" NAME="Gøtzsche 2002" TYPE="COCHRANE_REVIEW">
<AU>Gøtzsche PC, Johansen HK</AU>
<TI>Routine versus selective antifungal administration for control of fungal infections in patients with cancer</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2011-09-29 11:23:00 +0100" MODIFIED_BY="Clare Jess"><IDENTIFIER MODIFIED="2011-09-29 11:23:00 +0100" MODIFIED_BY="Clare Jess" TYPE="DOI" VALUE="10.1002/14651858.CD000026"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-09-03 12:46:32 +0100" MODIFIED_BY="Clare Jess">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-09-03 12:25:21 +0100" MODIFIED_BY="Clare Jess" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2014-07-29 14:15:11 +0100" MODIFIED_BY="Tracey Bishop" STUDY_ID="STD-Acuna-1981">
<CHAR_METHODS MODIFIED="2014-07-29 14:15:03 +0100" MODIFIED_BY="Tracey Bishop">
<P>Allocation concealment: NA<BR/>Blinding of study: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-29 14:15:05 +0100" MODIFIED_BY="Tracey Bishop">
<P>52 participants total, excluded: NA<BR/>BMT</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-29 14:15:07 +0100" MODIFIED_BY="Tracey Bishop">
<P>Ketoconazole 200 mg/d oral<BR/>Prophylactic</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Infections<BR/>Colonisation<BR/>Use of escape drug</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-29 14:15:11 +0100" MODIFIED_BY="Tracey Bishop">
<P>Follow-up period (days): NA<BR/>Days on placebo: NA</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:24:02 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Benhamou-1991a">
<CHAR_METHODS MODIFIED="2014-09-03 12:24:02 +0100" MODIFIED_BY="Clare Jess">
<P>Allocation concealment: not described<BR/>Blinding of study: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-29 14:15:24 +0100" MODIFIED_BY="Tracey Bishop">
<P>125 participants total, excluded: none<BR/>BMT</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-29 14:15:25 +0100" MODIFIED_BY="Tracey Bishop">
<P>Ketoconazole 600 mg/d oral<BR/>Prophylactic</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death<BR/>Infections<BR/>Colonisation<BR/>Use of escape drug</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-29 14:15:30 +0100" MODIFIED_BY="Tracey Bishop">
<P>Follow-up period (days): 36<BR/>Days on placebo: 30<BR/>3 viral infections included in 25 bacterial infections as they could not be separated</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-29 14:15:50 +0100" MODIFIED_BY="Tracey Bishop" STUDY_ID="STD-Brincker-1978">
<CHAR_METHODS MODIFIED="2014-07-29 14:15:36 +0100" MODIFIED_BY="Tracey Bishop">
<P>Allocation concealment: computer generated numbers<BR/>Blinding of study: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-29 14:15:43 +0100" MODIFIED_BY="Tracey Bishop">
<P>30 participants total, excluded: none<BR/>AL</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-29 14:15:45 +0100" MODIFIED_BY="Tracey Bishop">
<P>Miconazole 2 g/d oral<BR/>Prophylactic</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death<BR/>Infections<BR/>Colonisation<BR/>Use of escape drug</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-29 14:15:50 +0100" MODIFIED_BY="Tracey Bishop">
<P>Follow-up period (days): 90<BR/>Days on placebo: 23</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-29 14:15:59 +0100" MODIFIED_BY="Tracey Bishop" STUDY_ID="STD-Brincker-1983">
<CHAR_METHODS MODIFIED="2014-07-29 14:15:52 +0100" MODIFIED_BY="Tracey Bishop">
<P>Allocation concealment: computer<BR/>Blinding of study: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-29 14:15:54 +0100" MODIFIED_BY="Tracey Bishop">
<P>38 participants total, excluded: none<BR/>AL</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-29 14:15:57 +0100" MODIFIED_BY="Tracey Bishop">
<P>Ketoconazole 400 mg/d oral<BR/>Prophylactic</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death<BR/>Infections<BR/>Colonisation<BR/>Use of escape drug</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-29 14:15:59 +0100" MODIFIED_BY="Tracey Bishop">
<P>Follow-up period (days): 28<BR/>Days on placebo: 28</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:24:03 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Caselli-1990">
<CHAR_METHODS MODIFIED="2014-09-03 12:24:03 +0100" MODIFIED_BY="Clare Jess">
<P>Allocation concealment: not described<BR/>Blinding of study: NA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-29 14:16:03 +0100" MODIFIED_BY="Tracey Bishop">
<P>40 participants total, excluded: none<BR/>AL</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-29 14:16:06 +0100" MODIFIED_BY="Tracey Bishop">
<P>Itraconazole 2 mg/kg/d oral (not stated whether it was suspension), ketoconazole 5 mg/kg/d, or amphotericin B 50 mg/kg/d<BR/>Prophylactic</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Infections<BR/>Colonisation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-29 14:16:08 +0100" MODIFIED_BY="Tracey Bishop">
<P>Follow-up period (days): NA<BR/>Days on placebo: NA</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:24:03 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-EORTC-1989">
<CHAR_METHODS MODIFIED="2014-09-03 12:24:03 +0100" MODIFIED_BY="Clare Jess">
<P>Allocation concealment: not described<BR/>Blinding of study: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-29 14:16:13 +0100" MODIFIED_BY="Tracey Bishop">
<P>157 participants total, excluded: 25<BR/>AL</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-29 14:16:16 +0100" MODIFIED_BY="Tracey Bishop">
<P>Amphotericin B 0.6 mg/kg/d iv<BR/>Empiric</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death<BR/>Infections</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-29 14:16:18 +0100" MODIFIED_BY="Tracey Bishop">
<P>Follow-up period (days): 30<BR/>Days on placebo: NA</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:24:03 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Estey-1984">
<CHAR_METHODS MODIFIED="2014-09-03 12:24:03 +0100" MODIFIED_BY="Clare Jess">
<P>Allocation concealment: not described<BR/>Blinding of study: NA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-29 14:16:23 +0100" MODIFIED_BY="Tracey Bishop">
<P>150 participants total, excluded: 3<BR/>AL</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-29 14:16:25 +0100" MODIFIED_BY="Tracey Bishop">
<P>Ketoconazole 400 mg/d oral<BR/>Prophylactic</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death<BR/>Infections<BR/>Colonisation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-29 14:16:27 +0100" MODIFIED_BY="Tracey Bishop">
<P>Follow-up period (days): 56<BR/>Days on placebo: 39</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-29 14:16:36 +0100" MODIFIED_BY="Tracey Bishop" STUDY_ID="STD-Fukuda-1994">
<CHAR_METHODS MODIFIED="2014-07-29 14:16:30 +0100" MODIFIED_BY="Tracey Bishop">
<P>Allocation concealment: envelopes<BR/>Blinding of study: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-29 14:16:32 +0100" MODIFIED_BY="Tracey Bishop">
<P>63 participants total, excluded: none<BR/>AL</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-29 14:16:33 +0100" MODIFIED_BY="Tracey Bishop">
<P>Fluconazole 400 mg/d iv<BR/>Prophylactic</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death<BR/>Infections<BR/>Colonisation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-29 14:16:36 +0100" MODIFIED_BY="Tracey Bishop">
<P>Follow-up period (days): NA<BR/>Days on placebo: 7</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:24:04 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Goldstone-1994">
<CHAR_METHODS MODIFIED="2014-09-03 12:24:04 +0100" MODIFIED_BY="Clare Jess">
<P>Allocation concealment: not described<BR/>Blinding of study: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-29 14:16:40 +0100" MODIFIED_BY="Tracey Bishop">
<P>137 participants total, excluded: 4<BR/>BMT</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-29 14:16:42 +0100" MODIFIED_BY="Tracey Bishop">
<P>AmBisome 2 mg/kg/d iv<BR/>Empiric</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death<BR/>Infections<BR/>Use of escape drug</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-29 14:16:44 +0100" MODIFIED_BY="Tracey Bishop">
<P>Follow-up period (days): NA<BR/>Days on placebo: NA</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:24:35 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Goodman-1992">
<CHAR_METHODS MODIFIED="2014-09-03 12:24:35 +0100" MODIFIED_BY="Clare Jess">
<P>Allocation concealment: sequence list by pharmacy<BR/>Blinding of study: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-29 14:16:49 +0100" MODIFIED_BY="Tracey Bishop">
<P>356 participants total, excluded: 1<BR/>BMT</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-29 14:16:51 +0100" MODIFIED_BY="Tracey Bishop">
<P>Fluconazole 400 mg/d oral<BR/>Prophylactic</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death<BR/>Infections<BR/>Colonisation<BR/>Use of escape drug</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-29 14:16:53 +0100" MODIFIED_BY="Tracey Bishop">
<P>Follow-up period (days): 90<BR/>Days on placebo: 20</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-29 14:17:03 +0100" MODIFIED_BY="Tracey Bishop" STUDY_ID="STD-Hansen-1987">
<CHAR_METHODS MODIFIED="2014-07-29 14:16:58 +0100" MODIFIED_BY="Tracey Bishop">
<P>Allocation concealment: blinded random scheme<BR/>Blinding of study: NA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-29 14:17:00 +0100" MODIFIED_BY="Tracey Bishop">
<P>60 participants total, excluded: 4<BR/>AL</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-29 14:17:01 +0100" MODIFIED_BY="Tracey Bishop">
<P>Ketoconazole 400 mg/d oral<BR/>Prophylactic</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Infections<BR/>Colonisation<BR/>Use of escape drug</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-29 14:17:03 +0100" MODIFIED_BY="Tracey Bishop">
<P>Follow-up period (days): NA<BR/>Days on placebo: NA</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:24:42 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Hughes-1983">
<CHAR_METHODS MODIFIED="2014-09-03 12:24:42 +0100" MODIFIED_BY="Clare Jess">
<P>Allocation concealment: not described<BR/>Blinding of study: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-29 14:17:08 +0100" MODIFIED_BY="Tracey Bishop">
<P>64 participants total, excluded: 8<BR/>AL</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-29 14:17:09 +0100" MODIFIED_BY="Tracey Bishop">
<P>Ketoconazole 400 mg/d oral<BR/>Prophylactic</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Colonisation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-29 14:17:11 +0100" MODIFIED_BY="Tracey Bishop">
<P>Follow-up period (days): NA<BR/>Days on placebo: 14</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:24:44 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Kaptan-2003">
<CHAR_METHODS MODIFIED="2014-09-03 12:24:44 +0100" MODIFIED_BY="Clare Jess">
<P>Allocation concealment: NA ('randomized blindly').<BR/>Blinding of study: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-29 14:48:12 +0100" MODIFIED_BY="Tracey Bishop">
<P>61 participants (113 episodes), excluded: 6 (16 episodes)<BR/>AL</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-29 14:48:06 +0100" MODIFIED_BY="Tracey Bishop">
<P>Itraconazole capsules 400 mg/d<BR/>Prophylactic</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death<BR/>Infections<BR/>Use of escape drug</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-29 14:48:03 +0100" MODIFIED_BY="Tracey Bishop">
<P>Follow-up period (days): NA</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-29 14:17:21 +0100" MODIFIED_BY="Tracey Bishop" STUDY_ID="STD-Kelsey-1999">
<CHAR_METHODS MODIFIED="2014-07-29 14:17:13 +0100" MODIFIED_BY="Tracey Bishop">
<P>Allocation concealment: sealed envelopes<BR/>Blinding of study: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-29 14:17:15 +0100" MODIFIED_BY="Tracey Bishop">
<P>170 participants total, excluded: 9<BR/>BMT</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-29 14:17:17 +0100" MODIFIED_BY="Tracey Bishop">
<P>AmBisome 2 mg/kg 3 times a week iv<BR/>Prophylactic</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death<BR/>Infections<BR/>Colonisation<BR/>Use of escape drug</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-29 14:17:21 +0100" MODIFIED_BY="Tracey Bishop">
<P>Follow-up period (days): NA<BR/>Days on placebo: NA</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-29 14:17:36 +0100" MODIFIED_BY="Tracey Bishop" STUDY_ID="STD-Kern-1998">
<CHAR_METHODS MODIFIED="2014-07-29 14:17:24 +0100" MODIFIED_BY="Tracey Bishop">
<P>Allocation concealment: central computer<BR/>Blinding of study: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-29 14:17:32 +0100" MODIFIED_BY="Tracey Bishop">
<P>84 participants total, excluded: 16<BR/>AL</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-29 14:17:34 +0100" MODIFIED_BY="Tracey Bishop">
<P>Fluconazole 400 mg/d oral<BR/>Prophylactic</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death<BR/>Infections<BR/>Use of escape drug</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-29 14:17:36 +0100" MODIFIED_BY="Tracey Bishop">
<P>Follow-up period (days): 42<BR/>Days on placebo: NA</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-29 14:17:43 +0100" MODIFIED_BY="Tracey Bishop" STUDY_ID="STD-Menichetti-1999">
<CHAR_METHODS MODIFIED="2014-07-29 14:17:38 +0100" MODIFIED_BY="Tracey Bishop">
<P>Allocation concealment: NA<BR/>Blinding of study: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-29 14:17:40 +0100" MODIFIED_BY="Tracey Bishop">
<P>405 participants total, excluded: none<BR/>AL</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-29 14:17:42 +0100" MODIFIED_BY="Tracey Bishop">
<P>Itraconazole 5 mg/kg/d oral solution<BR/>Prophylactic</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death<BR/>Infections<BR/>Colonisation<BR/>Use of escape drug</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-29 14:17:43 +0100" MODIFIED_BY="Tracey Bishop">
<P>Follow-up period (days): NA<BR/>Days on placebo: 19</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-29 14:17:53 +0100" MODIFIED_BY="Tracey Bishop" STUDY_ID="STD-Nucci-2000">
<CHAR_METHODS MODIFIED="2014-07-29 14:17:47 +0100" MODIFIED_BY="Tracey Bishop">
<P>Allocation concealment: sealed envelopes<BR/>Blinding of study: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-29 14:17:49 +0100" MODIFIED_BY="Tracey Bishop">
<P>219 participants total, excluded: none from analysis of deaths<BR/>AL</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-29 14:17:50 +0100" MODIFIED_BY="Tracey Bishop">
<P>Itraconazole capsules 200mg/d oral<BR/>Prophylactic</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death<BR/>Infections<BR/>Colonisation<BR/>Use of escape drug</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-29 14:17:53 +0100" MODIFIED_BY="Tracey Bishop">
<P>Follow-up period (days): 60<BR/>Days on placebo: 17<BR/>Data on colonisation not used as they were given only as percentages, and it is clear from the confidence interval that data were not available for all patients</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-29 14:18:02 +0100" MODIFIED_BY="Tracey Bishop" STUDY_ID="STD-Palmblad-1992">
<CHAR_METHODS MODIFIED="2014-07-29 14:17:56 +0100" MODIFIED_BY="Tracey Bishop">
<P>Allocation concealment: pharmacy<BR/>Blinding of study: NA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-29 14:17:57 +0100" MODIFIED_BY="Tracey Bishop">
<P>116 participants total, excluded: 9<BR/>AL</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-29 14:17:58 +0100" MODIFIED_BY="Tracey Bishop">
<P>Ketoconazole 200 mg/d oral<BR/>Prophylactic</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death<BR/>Infections<BR/>Colonisation<BR/>Use of escape drug</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-29 14:18:02 +0100" MODIFIED_BY="Tracey Bishop">
<P>Follow-up period (days): 59<BR/>Days on placebo: 56</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-29 14:18:10 +0100" MODIFIED_BY="Tracey Bishop" STUDY_ID="STD-Penack-2006">
<CHAR_METHODS MODIFIED="2014-07-29 14:18:05 +0100" MODIFIED_BY="Tracey Bishop">
<P>Allocation concealment: central computer system<BR/>Blinding of study: none</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-29 14:18:07 +0100" MODIFIED_BY="Tracey Bishop">
<P>140 participants total, excluded: 8<BR/>AL</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-29 14:18:08 +0100" MODIFIED_BY="Tracey Bishop">
<P>Lipid amphotericin B 50 mg every other day iv<BR/>Prophylactic</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death<BR/>Infections<BR/>Use of escape drug</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-29 14:18:10 +0100" MODIFIED_BY="Tracey Bishop">
<P>Follow-up period (days): 17<BR/>Days on no treatment: NA</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:25:07 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Perfect-1992">
<CHAR_METHODS MODIFIED="2014-09-03 12:25:07 +0100" MODIFIED_BY="Clare Jess">
<P>Allocation concealment: pharmacy codes<BR/>Blinding of study: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-29 14:18:13 +0100" MODIFIED_BY="Tracey Bishop">
<P>188 participants total, excluded: 6<BR/>BMT</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-29 14:18:14 +0100" MODIFIED_BY="Tracey Bishop">
<P>Amphotericin B 0.1 mg/kg/d iv<BR/>Prophylactic</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death<BR/>Infections<BR/>Colonisation<BR/>Use of escape drug</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-29 14:18:16 +0100" MODIFIED_BY="Tracey Bishop">
<P>Follow-up period (days): 42<BR/>Days on placebo: 10</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-29 14:20:45 +0100" MODIFIED_BY="Tracey Bishop" STUDY_ID="STD-Pizzo-1982">
<CHAR_METHODS MODIFIED="2014-07-29 14:18:20 +0100" MODIFIED_BY="Tracey Bishop">
<P>Allocation concealment: sealed envelopes<BR/>Blinding of study: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-29 14:18:21 +0100" MODIFIED_BY="Tracey Bishop">
<P>34 participants total, excluded: none<BR/>AL</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-29 14:18:24 +0100" MODIFIED_BY="Tracey Bishop">
<P>Amphotericin B 0.5 mg/kg/d iv<BR/>Empiric</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death<BR/>Infections</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-29 14:20:45 +0100" MODIFIED_BY="Tracey Bishop">
<P>Follow-up period (days): 50<BR/>Days on placebo: 10<BR/>Numbers of deaths are inconsistently reported, 2 or 3 on study drug, 3, 4 or 5 on control; we used 3 versus 4 deaths for the analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-29 14:18:35 +0100" MODIFIED_BY="Tracey Bishop" STUDY_ID="STD-Riley-1994">
<CHAR_METHODS MODIFIED="2014-07-29 14:18:29 +0100" MODIFIED_BY="Tracey Bishop">
<P>Allocation concealment: random numbers, handled by pharmacy<BR/>Blinding of study: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-29 14:18:31 +0100" MODIFIED_BY="Tracey Bishop">
<P>35 participants total, excluded: none<BR/>BMT</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-29 14:18:32 +0100" MODIFIED_BY="Tracey Bishop">
<P>Amphotericin B 0.1 mg/kg/d iv<BR/>Prophylactic</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death<BR/>Infections<BR/>Colonisation<BR/>Use of escape drug</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-29 14:18:35 +0100" MODIFIED_BY="Tracey Bishop">
<P>Follow-up period (days): 30<BR/>Days on placebo: 15</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:25:19 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Rotstein-1999">
<CHAR_METHODS MODIFIED="2014-09-03 12:25:19 +0100" MODIFIED_BY="Clare Jess">
<P>Allocation concealment: computer generated, sequentially numbered<BR/>Blinding of study: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-29 14:18:38 +0100" MODIFIED_BY="Tracey Bishop">
<P>304 participants total, excluded: 30<BR/>AL</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-29 14:18:40 +0100" MODIFIED_BY="Tracey Bishop">
<P>Fluconazole 400 mg/d oral<BR/>Prophylactic</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death<BR/>Infections<BR/>Colonisation<BR/>Use of escape drug</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-29 14:18:42 +0100" MODIFIED_BY="Tracey Bishop">
<P>Follow-up period (days): NA<BR/>Days on placebo: NA</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-29 14:18:54 +0100" MODIFIED_BY="Tracey Bishop" STUDY_ID="STD-Schaffner-1995">
<CHAR_METHODS MODIFIED="2014-07-29 14:18:46 +0100" MODIFIED_BY="Tracey Bishop">
<P>Allocation concealment: consecutive numbers, prepared by pharmacy<BR/>Blinding of study: yes, data analysis was also blinded<BR/>Mycosis diagnosed by external observer</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-29 14:18:49 +0100" MODIFIED_BY="Tracey Bishop">
<P>96 participants total, but randomised more than once. Total of 154 episodes, excluded: 3 episodes<BR/>AL</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-29 14:18:53 +0100" MODIFIED_BY="Tracey Bishop">
<P>Fluconazole 400 mg/d oral or iv<BR/>Prophylactic</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death<BR/>Infections<BR/>Colonisation<BR/>Use of escape drug</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-29 14:18:54 +0100" MODIFIED_BY="Tracey Bishop">
<P>Follow-up period (days): NA, but sufficient (till symptom resolution or failure)<BR/>Days on placebo: 20</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-29 14:19:02 +0100" MODIFIED_BY="Tracey Bishop" STUDY_ID="STD-Siegel-1982a">
<CHAR_METHODS MODIFIED="2014-07-29 14:18:58 +0100" MODIFIED_BY="Tracey Bishop">
<P>Allocation concealment: NA<BR/>Blinding of study: NA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-29 14:19:00 +0100" MODIFIED_BY="Tracey Bishop">
<P>25 participants total, excluded: NA<BR/>BMT</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-29 14:19:01 +0100" MODIFIED_BY="Tracey Bishop">
<P>Ketoconazole 200 mg/d oral<BR/>Prophylactic</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Infections<BR/>Colonisation<BR/>Use of escape drug</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-29 14:19:02 +0100" MODIFIED_BY="Tracey Bishop">
<P>Follow-up period (days): NA<BR/>Days on placebo: NA</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-29 14:19:10 +0100" MODIFIED_BY="Tracey Bishop" STUDY_ID="STD-Slavin-1995">
<CHAR_METHODS MODIFIED="2014-07-29 14:19:06 +0100" MODIFIED_BY="Tracey Bishop">
<P>Allocation concealment: stratified<BR/>Blinding of study: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-29 14:19:07 +0100" MODIFIED_BY="Tracey Bishop">
<P>301 participants total, excluded: 1<BR/>BMT</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-29 14:19:08 +0100" MODIFIED_BY="Tracey Bishop">
<P>Fluconazole 400 mg/d oral<BR/>Prophylactic</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death<BR/>Infections<BR/>Colonisation<BR/>Use of escape drug</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-29 14:19:10 +0100" MODIFIED_BY="Tracey Bishop">
<P>Follow-up period (days): 89<BR/>Days on placebo: 55</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-29 14:19:16 +0100" MODIFIED_BY="Tracey Bishop" STUDY_ID="STD-Suda-1980">
<CHAR_METHODS MODIFIED="2014-07-29 14:19:12 +0100" MODIFIED_BY="Tracey Bishop">
<P>Allocation concealment: NA<BR/>Blinding of study: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-29 14:19:14 +0100" MODIFIED_BY="Tracey Bishop">
<P>70 participants total, excluded: none<BR/>AL</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-29 14:19:15 +0100" MODIFIED_BY="Tracey Bishop">
<P>Amphotericin B 600 mg/d oral<BR/>Prophylactic</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death<BR/>Infections<BR/>Use of escape drug</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-29 14:19:16 +0100" MODIFIED_BY="Tracey Bishop">
<P>Follow-up period (days): NA<BR/>Days on placebo: NA</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-29 14:19:24 +0100" MODIFIED_BY="Tracey Bishop" STUDY_ID="STD-Tollemar-1993">
<CHAR_METHODS MODIFIED="2014-07-29 14:19:18 +0100" MODIFIED_BY="Tracey Bishop">
<P>Allocation concealment: pharmacy<BR/>Blinding of study: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-29 14:19:20 +0100" MODIFIED_BY="Tracey Bishop">
<P>84 participants total, excluded: 8<BR/>BMT</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-29 14:19:21 +0100" MODIFIED_BY="Tracey Bishop">
<P>AmBisome 1 mg/kg/d iv<BR/>Prophylactic</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death<BR/>Infections<BR/>Use of escape drug</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-29 14:19:24 +0100" MODIFIED_BY="Tracey Bishop">
<P>Follow-up period (days): NA<BR/>Days on placebo: 19</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-29 14:19:33 +0100" MODIFIED_BY="Tracey Bishop" STUDY_ID="STD-Vreugdenhil-1993">
<CHAR_METHODS MODIFIED="2014-07-29 14:19:31 +0100" MODIFIED_BY="Tracey Bishop">
<P>Allocation concealment: A and B; risk of breaking the code<BR/>Blinding of study: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-29 14:19:30 +0100" MODIFIED_BY="Tracey Bishop">
<P>98 participants total, excluded: 6<BR/>AL</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-29 14:19:28 +0100" MODIFIED_BY="Tracey Bishop">
<P>Itraconazole 400 mg/d oral, capsules<BR/>Prophylactic</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death<BR/>Infections<BR/>Colonisation<BR/>Use of escape drug</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-29 14:19:33 +0100" MODIFIED_BY="Tracey Bishop">
<P>Follow-up period (days): 80<BR/>Days on placebo: 80</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-29 14:19:41 +0100" MODIFIED_BY="Tracey Bishop" STUDY_ID="STD-Wingard-1987">
<CHAR_METHODS MODIFIED="2014-07-29 14:19:36 +0100" MODIFIED_BY="Tracey Bishop">
<P>Allocation concealment: computer generated<BR/>Blinding of study: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-29 14:19:38 +0100" MODIFIED_BY="Tracey Bishop">
<P>208 participants total, excluded: 15<BR/>BMT</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-29 14:19:39 +0100" MODIFIED_BY="Tracey Bishop">
<P>Miconazole 15 mg/kg/d oral<BR/>Prophylactic</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death<BR/>Infections<BR/>Colonisation<BR/>Use of escape drug</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-29 14:19:41 +0100" MODIFIED_BY="Tracey Bishop">
<P>Follow-up period (days): NA<BR/>Days on placebo: 9</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-07-29 14:19:48 +0100" MODIFIED_BY="Tracey Bishop" STUDY_ID="STD-Winston-1993">
<CHAR_METHODS MODIFIED="2014-07-29 14:19:44 +0100" MODIFIED_BY="Tracey Bishop">
<P>Allocation concealment: computer generated<BR/>Blinding of study: yes</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-29 14:19:46 +0100" MODIFIED_BY="Tracey Bishop">
<P>257 participants total, excluded: 2<BR/>AL</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-29 14:19:47 +0100" MODIFIED_BY="Tracey Bishop">
<P>Fluconazole 400 mg/d oral<BR/>Prophylactic</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Death<BR/>Infections<BR/>Colonisation<BR/>Use of escape drug</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-29 14:19:48 +0100" MODIFIED_BY="Tracey Bishop">
<P>Follow-up period (days): 90<BR/>Days on placebo: 14</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-09-03 12:25:21 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Yamac-1995">
<CHAR_METHODS MODIFIED="2014-09-03 12:25:21 +0100" MODIFIED_BY="Clare Jess">
<P>Allocation concealment: not described<BR/>Blinding of study: no</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-07-29 14:19:58 +0100" MODIFIED_BY="Tracey Bishop">
<P>70 participants total, excluded: NA<BR/>AL</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-07-29 14:20:01 +0100" MODIFIED_BY="Tracey Bishop">
<P>Fluconazole 400 mg/d oral<BR/>Prophylactic</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Infections</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-07-29 14:20:02 +0100" MODIFIED_BY="Tracey Bishop">
<P>Follow-up period (days): NA<BR/>Days on placebo: NA</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AL: acute leukemia (main disease)<BR/>BMT: bone marrow transplantation (main disease)<BR/>NA: not available</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-09-03 12:25:53 +0100" MODIFIED_BY="Clare Jess" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2014-07-29 14:20:06 +0100" MODIFIED_BY="Tracey Bishop" STUDY_ID="STD-Benhamou-1991b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-29 14:20:06 +0100" MODIFIED_BY="Tracey Bishop">
<P>An unpublished study mentioned in the reference. No data available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-29 14:20:06 +0100" MODIFIED_BY="Tracey Bishop" STUDY_ID="STD-Bodey-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-29 14:20:06 +0100" MODIFIED_BY="Tracey Bishop">
<P>Only 14 of 146 patients had neutropenia</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-29 14:20:07 +0100" MODIFIED_BY="Tracey Bishop" STUDY_ID="STD-Brincker-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-29 14:20:07 +0100" MODIFIED_BY="Tracey Bishop">
<P>An unpublished study mentioned in personal communication. No data available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-03 12:25:40 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Caselli-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-03 12:25:40 +0100" MODIFIED_BY="Clare Jess">
<P>All patients in the untreated control group were deliberately at low risk for getting an invasive fungal infection, and outcome data were unclear. Small trial, with only 31 patients potentially eligible out of 104 patients that 'provided sufficient data.'</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-29 14:20:13 +0100" MODIFIED_BY="Tracey Bishop" STUDY_ID="STD-Ezdinli-1979">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-29 14:20:13 +0100" MODIFIED_BY="Tracey Bishop">
<P>Autopsy subgroup of RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-03 12:25:42 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Hiddemann-1991">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-03 12:25:42 +0100" MODIFIED_BY="Clare Jess">
<P>Not an RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-29 14:20:11 +0100" MODIFIED_BY="Tracey Bishop" STUDY_ID="STD-Prentice-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-29 14:20:11 +0100" MODIFIED_BY="Tracey Bishop">
<P>An unpublished study mentioned in the reference. No data available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-29 14:20:10 +0100" MODIFIED_BY="Tracey Bishop" STUDY_ID="STD-Reed-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-29 14:20:10 +0100" MODIFIED_BY="Tracey Bishop">
<P>Only published as abstract, 96 patients randomised to fluconazole, amphotericin B or no treatment. No fungal disease was documented in any group, colonisation data insuffient for inclusion in the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-29 14:20:09 +0100" MODIFIED_BY="Tracey Bishop" STUDY_ID="STD-Samonis-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-29 14:20:09 +0100" MODIFIED_BY="Tracey Bishop">
<P>Study of oropharyngeal candidiasis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-29 14:20:14 +0100" MODIFIED_BY="Tracey Bishop" STUDY_ID="STD-Schaison-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-29 14:20:14 +0100" MODIFIED_BY="Tracey Bishop">
<P>Not truly randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-29 14:20:17 +0100" MODIFIED_BY="Tracey Bishop" STUDY_ID="STD-Schiel-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-29 14:20:17 +0100" MODIFIED_BY="Tracey Bishop">
<P>Used a surrogate outcome (resolution of fever) and only one patient developed candidaemia</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-07-29 14:20:17 +0100" MODIFIED_BY="Tracey Bishop" STUDY_ID="STD-Siegel-1982b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-07-29 14:20:17 +0100" MODIFIED_BY="Tracey Bishop">
<P>An unpublished study mentioned in the reference. No data available</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-03 12:25:53 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Vehreschild">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-03 12:25:53 +0100" MODIFIED_BY="Clare Jess">
<P>Trial of 'pulmonary infiltrates', not of verified antifungal infections. Trial stopped after only 25 patients for ethical reasons</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-09-03 12:25:53 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Wang-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-09-03 12:25:53 +0100" MODIFIED_BY="Clare Jess">
<P>Control group was not untreated (ranitidine and an antibiotic were used)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2014-09-03 12:46:32 +0100" MODIFIED_BY="Clare Jess" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2014-09-03 12:46:32 +0100" MODIFIED_BY="Clare Jess" STUDY_ID="STD-Cornely-2006">
<CHAR_METHODS MODIFIED="2014-09-03 12:44:26 +0100" MODIFIED_BY="Clare Jess">
<P>Prospective, randomized, double-blind, placebo-controlled phase III trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-09-03 12:45:16 +0100" MODIFIED_BY="Clare Jess">
<P>Patients with AML undergoing first remission induction chemotherapy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-09-03 12:46:11 +0100" MODIFIED_BY="Clare Jess">
<P>Voriconazole 200 mg bid or placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-09-03 12:46:32 +0100" MODIFIED_BY="Clare Jess">
<P>Detection of a lung infiltrate or end of neutropenia</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-09-03 12:45:51 +0100" MODIFIED_BY="Clare Jess"/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-08-07 13:41:29 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Acuna-1981">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Benhamou-1991a">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Brincker-1978">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Brincker-1983">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Caselli-1990">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-EORTC-1989">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Estey-1984">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Fukuda-1994">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Goldstone-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Goodman-1992">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hansen-1987">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hughes-1983">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kaptan-2003">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Kelsey-1999">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Kern-1998">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Menichetti-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Nucci-2000">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Palmblad-1992">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Penack-2006">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Perfect-1992">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Pizzo-1982">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Riley-1994">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Rotstein-1999">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Schaffner-1995">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Siegel-1982a">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Slavin-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Suda-1980">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Tollemar-1993">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Vreugdenhil-1993">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Wingard-1987">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Winston-1993">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Yamac-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2008-08-07 13:41:29 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 13:36:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Acuna-1981">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 13:36:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Benhamou-1991a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 13:36:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brincker-1978">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 13:37:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brincker-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Caselli-1990">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 13:37:11 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-EORTC-1989">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Estey-1984">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 13:37:22 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fukuda-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 13:37:26 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Goldstone-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 13:37:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Goodman-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Hansen-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 13:37:41 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hughes-1983">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 13:37:48 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kaptan-2003">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 13:37:52 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kelsey-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 13:37:58 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Kern-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 13:38:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Menichetti-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 13:38:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nucci-2000">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Palmblad-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 13:38:12 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Penack-2006">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 13:38:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Perfect-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 13:38:20 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Pizzo-1982">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 13:38:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Riley-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 13:40:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rotstein-1999">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 13:40:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schaffner-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" RESULT="UNKNOWN" STUDY_ID="STD-Siegel-1982a">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 13:40:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Slavin-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 13:40:24 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Suda-1980">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 13:40:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tollemar-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 13:40:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Vreugdenhil-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 13:41:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wingard-1987">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 13:41:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Winston-1993">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2008-08-07 13:41:29 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Yamac-1995">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2014-09-03 12:27:22 +0100" MODIFIED_BY="Clare Jess">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2014-09-03 12:27:22 +0100" MODIFIED_BY="Clare Jess" NO="1">
<TITLE>Harms</TITLE>
<TABLE COLS="4" ROWS="33">
<TR>
<TH>
<P>Trial</P>
</TH>
<TH>
<P>Trial drug</P>
</TH>
<TH>
<P>Number of patients</P>
</TH>
<TH>
<P>Harms</P>
</TH>
</TR>
<TR>
<TD>
<P>EORTC 1989</P>
</TD>
<TD>
<P>amphotericin B</P>
</TD>
<TD>
<P>80 versus 77</P>
</TD>
<TD>
<P>Treatment discontinuations: 6 pts on trial drug (infusion-related toxicity, allergic reactions); Nephrotoxicity: 8 versus 3, none required dialysis and renal function restored later; Hypokalaemia: 33 versus 16</P>
</TD>
</TR>
<TR>
<TD>
<P>Goldstone 1994</P>
</TD>
<TD>
<P>amphotericin B</P>
</TD>
<TD>
<P>64 versus 69</P>
</TD>
<TD>
<P>Treatment discontinuations: 4 on trial drug (chills, rigour, hypotension, rash and bronchospasm); Elevated liver function tests: 26 versus 32; Nephrotoxicity: 1 on trial drug that did not require withdrawal of therapy</P>
</TD>
</TR>
<TR>
<TD>
<P>Kelsey 1999</P>
</TD>
<TD>
<P>amphotericin B</P>
</TD>
<TD>
<P>74 versus 87</P>
</TD>
<TD>
<P>Treatment discontinuations: 5 on trial drug, 1 on placebo because of immediate reactions; Nephrotoxicity: 9 versus 6; Hypokalaemia: 1 versus 0; Clinical adverse events were very similar in the two groups</P>
</TD>
</TR>
<TR>
<TD>
<P>Penack 2006.</P>
</TD>
<TD>
<P>amphotericin B</P>
</TD>
<TD>
<P>75 versus 57</P>
</TD>
<TD>
<P>Treatment discontinuations: 2 (1 skin rash, 1 chills) versus 0; Other harms: "no differences in ... liver function tests, renal function parameters and hypokalaemia"</P>
</TD>
</TR>
<TR>
<TD>
<P>Perfect 1992</P>
</TD>
<TD>
<P>amphotericin B</P>
</TD>
<TD>
<P>91 versus 91</P>
</TD>
<TD>
<P>More infusion-related harms on active drug, but no data provided; No significant differences in renal function, hepatic enzymes or electrolytes (no data provided)</P>
</TD>
</TR>
<TR>
<TD>
<P>Pizzo 1982</P>
</TD>
<TD>
<P>amphotericin B</P>
</TD>
<TD>
<P>18 versus 16</P>
</TD>
<TD>
<P>Treatment discontinuations: none; Rash: 2 versus 1; Azotaemia: 1 versus 0; liver enzyme elevations: 2 versus 3; Electrolyte abnormalities: 18 versus 16</P>
</TD>
</TR>
<TR>
<TD>
<P>Riley 1994</P>
</TD>
<TD>
<P>amphotericin B</P>
</TD>
<TD>
<P>17 versus 18</P>
</TD>
<TD>
<P>Treatment discontinuations: none; Renal function: no difference (P value 0.82 for blood urea, P value 0.63 for creatinine); Potassium supplements: no difference; Infusion reactions: none</P>
</TD>
</TR>
<TR>
<TD>
<P>Suda 1980</P>
</TD>
<TD>
<P>amphotericin B</P>
</TD>
<TD>
<P>39 versus 31</P>
</TD>
<TD>
<P>Article is in Japanese</P>
</TD>
</TR>
<TR>
<TD>
<P>Tollemar 1993</P>
</TD>
<TD>
<P>amphotericin B</P>
</TD>
<TD>
<P>42 versus 42</P>
</TD>
<TD>
<P>Treatment discontinuations: 4 versus 0 for infusion reactions; Potassium supplementation: no difference; Renal function: no useful data, but only small changes reported, compared to normal ranges</P>
</TD>
</TR>
<TR>
<TD>
<P>Fukuda 1994</P>
</TD>
<TD>
<P>fluconazole</P>
</TD>
<TD>
<P>37 versus 26</P>
</TD>
<TD>
<P>Article is in Japanese</P>
</TD>
</TR>
<TR>
<TD>
<P>Goodman 1992</P>
</TD>
<TD>
<P>fluconazole</P>
</TD>
<TD>
<P>179 versus 177</P>
</TD>
<TD>
<P>Treatment discontinuations: 1 on trial drug, 2 on placebo for clinical side effects, and 17 versus 11 for elevated liver function tests; in 7 versus 3, hepatic dysfunction contributed to death; Graft-versus-host disease or organ failure: 44 versus 24 deaths; Nausea: 13 versus 9; Skin rash: 9 versus 9; Eosinophilia in 6 versus 0</P>
</TD>
</TR>
<TR>
<TD>
<P>Kern 1998</P>
</TD>
<TD>
<P>fluconazole</P>
</TD>
<TD>
<P>36 versus 32</P>
</TD>
<TD>
<P>Bacteriaemia: 15 versus 7; Other harms similar: 5 versus 6 elevations in transaminases, 19 versus 17 nausea or vomiting, 3 versus 0 allergy</P>
</TD>
</TR>
<TR>
<TD>
<P>Rotstein 1999</P>
</TD>
<TD>
<P>fluconazole</P>
</TD>
<TD>
<P>141 versus 133</P>
</TD>
<TD>
<P>Treatment discontinuations: none reported; Elevated liver enzymes: 17 versus 19; Rash: 51 versus 59; Nausea: 106 versus 95; Vomiting: 68 versus 85</P>
</TD>
</TR>
<TR>
<TD>
<P>Schaffner 1995</P>
</TD>
<TD>
<P>fluconazole</P>
</TD>
<TD>
<P>76 versus 76 episodes</P>
</TD>
<TD>
<P>Treatment discontinuations: none reported; No data on harms ("no significant differences were found")</P>
</TD>
</TR>
<TR>
<TD>
<P>Slavin 1995</P>
</TD>
<TD>
<P>fluconazole</P>
</TD>
<TD>
<P>152 versus 148</P>
</TD>
<TD>
<P>Treatment discontinuations: 32 versus 31 for abnormal liver function; Graft-versus-host disease: 102 versus 85; Nausea: 33 versus 22; Seizures: 8 versus 9; Liver enzymes: no differences</P>
</TD>
</TR>
<TR>
<TD>
<P>Winston 1993</P>
</TD>
<TD>
<P>fluconazole</P>
</TD>
<TD>
<P>124 versus 133</P>
</TD>
<TD>
<P>Treatment discontinuations: none reported; Elevated liver enzymes: 25 versus 14; Nausea and vomiting: 9 versus 5; Rash: 13 versus 7; Other harms were similarly distributed</P>
</TD>
</TR>
<TR>
<TD>
<P>Yamac 1995</P>
</TD>
<TD>
<P>fluconazole</P>
</TD>
<TD>
<P>41 versus 29</P>
</TD>
<TD>
<P>Treatment discontinuations: none reported; Other harms: no data</P>
</TD>
</TR>
<TR>
<TD>
<P>Acuna 1981</P>
</TD>
<TD>
<P>ketoconazole</P>
</TD>
<TD>
<P>28 versus 24</P>
</TD>
<TD>
<P>No data</P>
</TD>
</TR>
<TR>
<TD>
<P>Benhamou 1991</P>
</TD>
<TD>
<P>ketoconazole</P>
</TD>
<TD>
<P>63 versus 62</P>
</TD>
<TD>
<P>Treatment discontinuations: 38 versus 14 (among them 2 patients with veno-occlusive disease, 1 hepatitis, 3 skin rash in active group; none in placebo group); Severe gastrointestinal intolerance: 4 versus 7; Three-fold greater values than normal for transaminases: 13 versus 8</P>
</TD>
</TR>
<TR>
<TD>
<P>Brincker 1983</P>
</TD>
<TD>
<P>ketoconazole</P>
</TD>
<TD>
<P>19 versus 19</P>
</TD>
<TD>
<P>One patient on trial drug stopped treatment because of universal exanthema</P>
</TD>
</TR>
<TR>
<TD>
<P>Estey 1984</P>
</TD>
<TD>
<P>ketoconazole</P>
</TD>
<TD>
<P>77 versus 73</P>
</TD>
<TD>
<P>Bacterial infections: 33 versus 24</P>
</TD>
</TR>
<TR>
<TD>
<P>Hansen 1987</P>
</TD>
<TD>
<P>ketoconazole</P>
</TD>
<TD>
<P>27 versus 29</P>
</TD>
<TD>
<P>Treatment discontinuations: 2 on trial drug (1 skin rash and 1 elevated liver function tests); Bacterial infections: 20% versus 15% of neutropenic episodes</P>
</TD>
</TR>
<TR>
<TD>
<P>Hughes 1983</P>
</TD>
<TD>
<P>ketoconazole</P>
</TD>
<TD>
<P>42 versus 22</P>
</TD>
<TD>
<P>Treatment discontinuations:1 on trial drug (nausea and anorexia); Other harms: 2 nausea and anorexia, 1 abdominal pain, 1 transient rash, all on trial drug</P>
</TD>
</TR>
<TR>
<TD>
<P>Palmblad 1992</P>
</TD>
<TD>
<P>ketoconazole</P>
</TD>
<TD>
<P>55 versus 61</P>
</TD>
<TD>
<P>Treatment discontinuations: 2 (elevated transaminases) versus 6 (1 elevated transaminases, 5 exanthema); Bacteriaemias: 37 versus 21</P>
</TD>
</TR>
<TR>
<TD>
<P>Siegel 1982a</P>
</TD>
<TD>
<P>ketoconazole</P>
</TD>
<TD>
<P>12 versus 13</P>
</TD>
<TD>
<P>No data</P>
</TD>
</TR>
<TR>
<TD>
<P>Brincker 1978</P>
</TD>
<TD>
<P>miconazole</P>
</TD>
<TD>
<P>15 versus 15</P>
</TD>
<TD>
<P>None ascribable to trial drug</P>
</TD>
</TR>
<TR>
<TD>
<P>Wingard 1987</P>
</TD>
<TD>
<P>miconazole</P>
</TD>
<TD>
<P>97 versus 111</P>
</TD>
<TD>
<P>Treatment discontinuations: 1 (pruritis and flushing) versus 2 (1 rash, 1 nausea); Severe hypotension: 2 on trial drug</P>
</TD>
</TR>
<TR>
<TD>
<P>Caselli 1990</P>
</TD>
<TD>
<P>itraconazole, amphotericin B, ketoconazole</P>
</TD>
<TD>
<P>30 versus 10</P>
</TD>
<TD>
<P>No data</P>
</TD>
</TR>
<TR>
<TD>
<P>Kaptan 2003</P>
</TD>
<TD>
<P>itraconazole</P>
</TD>
<TD>
<P>31 versus 24</P>
</TD>
<TD>
<P>Treatment discontinuations: 2 on trial drug (cardiac arrhytmia and gastric irritation); "there was a clinical impression that hypokalaemia occurred at a greater rate in patients with itraconazole"</P>
</TD>
</TR>
<TR>
<TD>
<P>Menichetti 1999</P>
</TD>
<TD>
<P>itraconazole</P>
</TD>
<TD>
<P>201 versus 204</P>
</TD>
<TD>
<P>Treatment discontinuations: 37 versus 27; Bacteriaemia: 47 versus 31; Elevated transaminases: 5 versus 3</P>
</TD>
</TR>
<TR>
<TD>
<P>Nucci 2000</P>
</TD>
<TD>
<P>itraconazole</P>
</TD>
<TD>
<P>104 versus 106</P>
</TD>
<TD>
<P>Treatment discontinuations: 3 versus 4; Skin rash: 3 versus 1; Elevated liver enzymes: 3 versus 4; Nausea: 2 on placebo</P>
</TD>
</TR>
<TR>
<TD>
<P>Vreugdenhil 1993</P>
</TD>
<TD>
<P>itraconazole</P>
</TD>
<TD>
<P>49 versus 49</P>
</TD>
<TD>
<P>Treatment discontinuations: 1 (nausea) versus 1 (liver function deterioration); Liver function deterioration: 28 versus 22 episodes; Renal function deterioration: 4 versus 2 episodes</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-09-03 12:25:53 +0100" MODIFIED_BY="Clare Jess">
<COMPARISON ID="CMP-001" MODIFIED="2014-09-03 12:25:53 +0100" MODIFIED_BY="Clare Jess" NO="1">
<NAME>Antifungals versus placebo or no treatment</NAME>
<DICH_OUTCOME CHI2="15.945539342460343" CI_END="1.0913911393336435" CI_START="0.8140515491910674" CI_STUDY="95" CI_TOTAL="95" DF="25" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9425755395446863" ESTIMABLE="YES" EVENTS_1="281" EVENTS_2="296" I2="0.0" I2_Q="20.31498402287492" ID="CMP-001.01" LOG_CI_END="0.03798042355916176" LOG_CI_START="-0.0893480928744651" LOG_EFFECT_SIZE="-0.02568383465765169" METHOD="MH" NO="1" P_CHI2="0.9164410327762044" P_Q="0.28527563072862516" P_Z="0.4291185151699445" Q="5.019764319490464" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="26" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1961" TOTAL_2="1941" WEIGHT="100.00000000000001" Z="0.7907009729453587">
<NAME>Death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.96589959695616" CI_END="0.9565583533730317" CI_START="0.49832133602158063" DF="8" EFFECT_SIZE="0.6904154087471197" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="70" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="-0.01928853136078277" LOG_CI_START="-0.3024905177696066" LOG_EFFECT_SIZE="-0.1608895245651947" NO="1" P_CHI2="0.4368084764805279" P_Z="0.02595092632023286" STUDIES="9" TAU2="0.0" TOTAL_1="500" TOTAL_2="488" WEIGHT="24.355368809751287" Z="2.2269453518757443">
<NAME>Amphotericin</NAME>
<DICH_DATA CI_END="1.561540263782474" CI_START="0.3662499621461371" EFFECT_SIZE="0.75625" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" LOG_CI_END="0.1935531868455049" LOG_CI_START="-0.4362224115244543" LOG_EFFECT_SIZE="-0.1213346123394747" ORDER="76" O_E="0.0" SE="0.3699333039220034" STUDY_ID="STD-EORTC-1989" TOTAL_1="80" TOTAL_2="77" VAR="0.13685064935064933" WEIGHT="4.796197423655764"/>
<DICH_DATA CI_END="16.879194139594812" CI_START="0.06886309298963386" EFFECT_SIZE="1.078125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2273517083393068" LOG_CI_START="-1.1620134748325706" LOG_EFFECT_SIZE="0.032669116753368144" ORDER="77" O_E="0.0" SE="1.4035249361435698" STUDY_ID="STD-Goldstone-1994" TOTAL_1="64" TOTAL_2="69" VAR="1.9698822463768115" WEIGHT="0.3235243804571235"/>
<DICH_DATA CI_END="2.297871849634296" CI_START="0.5054429452180079" EFFECT_SIZE="1.0777027027027026" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.3613258047924029" LOG_CI_START="-0.2963278607959178" LOG_EFFECT_SIZE="0.03249897199824252" ORDER="78" O_E="0.0" SE="0.3863090186047273" STUDY_ID="STD-Kelsey-1999" TOTAL_1="74" TOTAL_2="87" VAR="0.1492346578553475" WEIGHT="3.7082223825221385"/>
<DICH_DATA CI_END="1.199817765525184" CI_START="0.12035161017706159" EFFECT_SIZE="0.38" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.07911528818356184" LOG_CI_START="-0.9195480949499414" LOG_EFFECT_SIZE="-0.42021640338318983" ORDER="79" O_E="0.0" SE="0.5866198147160935" STUDY_ID="STD-Penack-2006" TOTAL_1="75" TOTAL_2="57" VAR="0.3441228070175439" WEIGHT="3.0560186506248175"/>
<DICH_DATA CI_END="0.9453602492744151" CI_START="0.07867917584470535" EFFECT_SIZE="0.2727272727272727" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="11" LOG_CI_END="-0.024402662963629914" LOG_CI_START="-1.1041401979134953" LOG_EFFECT_SIZE="-0.5642714304385626" ORDER="80" O_E="0.0" SE="0.6342431728165485" STUDY_ID="STD-Perfect-1992" TOTAL_1="91" TOTAL_2="91" VAR="0.4022644022644022" WEIGHT="3.697782567256029"/>
<DICH_DATA CI_END="2.538190125490536" CI_START="0.1751028971316915" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.40452415020897103" LOG_CI_START="-0.7567066683203335" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="81" O_E="0.0" SE="0.6821127309893708" STUDY_ID="STD-Pizzo-1982" TOTAL_1="18" TOTAL_2="16" VAR="0.4652777777777777" WEIGHT="1.423745159585209"/>
<DICH_DATA CI_END="2.027038260727862" CI_START="0.006786021427863038" EFFECT_SIZE="0.11728395061728394" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.30686194616028256" LOG_CI_START="-2.1683847733398864" LOG_EFFECT_SIZE="-0.930761413589802" ORDER="82" O_E="0.0" SE="1.4539721757032693" STUDY_ID="STD-Riley-1994" TOTAL_1="17" TOTAL_2="18" VAR="2.1140350877192984" WEIGHT="1.4718446582198443"/>
<DICH_DATA CI_END="1.458678273923431" CI_START="0.43314635007436486" EFFECT_SIZE="0.7948717948717948" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="13" LOG_CI_END="0.1639595144655197" LOG_CI_START="-0.3633653408499728" LOG_EFFECT_SIZE="-0.09970291319222656" ORDER="83" O_E="0.0" SE="0.30975323031245244" STUDY_ID="STD-Suda-1980" TOTAL_1="39" TOTAL_2="31" VAR="0.09594706368899919" WEIGHT="4.869547432724174"/>
<DICH_DATA CI_END="6.532484503633595" CI_START="0.4252253145388529" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.815078388166772" LOG_CI_START="-0.37138088893405935" LOG_EFFECT_SIZE="0.2218487496163564" ORDER="84" O_E="0.0" SE="0.6969320524371696" STUDY_ID="STD-Tollemar-1993" TOTAL_1="42" TOTAL_2="42" VAR="0.48571428571428565" WEIGHT="1.0084861547061896"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.766961928107656" CI_END="1.2960548610576472" CI_START="0.8380674796597682" DF="6" EFFECT_SIZE="1.0422002834903537" ESTIMABLE="YES" EVENTS_1="132" EVENTS_2="125" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.112623385292549" LOG_CI_START="-0.07672101136493605" LOG_EFFECT_SIZE="0.017951186963806477" NO="2" P_CHI2="0.83747555692663" P_Z="0.7101632309790988" STUDIES="7" TAU2="0.0" TOTAL_1="745" TOTAL_2="725" WEIGHT="42.27466184588158" Z="0.3716368749211123">
<NAME>Fluconazole</NAME>
<DICH_DATA CI_END="14.699243973431315" CI_START="0.13437183280397386" EFFECT_SIZE="1.4054054054054055" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.167294998244059" LOG_CI_START="-0.8716917591084505" LOG_EFFECT_SIZE="0.1478016195678042" ORDER="85" O_E="0.0" SE="1.1977109144160933" STUDY_ID="STD-Fukuda-1994" TOTAL_1="37" TOTAL_2="26" VAR="1.4345114345114345" WEIGHT="0.39485701295374626"/>
<DICH_DATA CI_END="1.6477418930044114" CI_START="0.8483225330326636" EFFECT_SIZE="1.1822929317464173" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="46" LOG_CI_END="0.21688918356081588" LOG_CI_START="-0.07143899717164945" LOG_EFFECT_SIZE="0.07272509319458322" ORDER="86" O_E="0.0" SE="0.1693654006097631" STUDY_ID="STD-Goodman-1992" TOTAL_1="179" TOTAL_2="177" VAR="0.028684638923705544" WEIGHT="15.550327711331024"/>
<DICH_DATA CI_END="3.0503052857877124" CI_START="0.4604994554896496" EFFECT_SIZE="1.1851851851851851" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.4843433073133568" LOG_CI_START="-0.33677087899151953" LOG_EFFECT_SIZE="0.07378621416091864" ORDER="87" O_E="0.0" SE="0.4823265376162593" STUDY_ID="STD-Kern-1998" TOTAL_1="36" TOTAL_2="32" VAR="0.23263888888888884" WEIGHT="2.1356177393778135"/>
<DICH_DATA CI_END="1.8532049486015387" CI_START="0.4801109436560432" EFFECT_SIZE="0.9432624113475178" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="15" LOG_CI_END="0.26792345122649425" LOG_CI_START="-0.31865839460308243" LOG_EFFECT_SIZE="-0.025367471688294094" ORDER="88" O_E="0.0" SE="0.3445610798672593" STUDY_ID="STD-Rotstein-1999" TOTAL_1="141" TOTAL_2="133" VAR="0.11872233775929183" WEIGHT="5.189655029692436"/>
<DICH_DATA CI_END="3.3138823111729323" CI_START="0.30176086719448253" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5203370808739781" LOG_CI_START="-0.5203370808739781" LOG_EFFECT_SIZE="0.0" ORDER="89" O_E="0.0" SE="0.6112971540309311" STUDY_ID="STD-Schaffner-1995" TOTAL_1="76" TOTAL_2="76" VAR="0.37368421052631584" WEIGHT="1.6808102578436497"/>
<DICH_DATA CI_END="1.2265417538055479" CI_START="0.43478689422825684" EFFECT_SIZE="0.7302631578947368" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="28" LOG_CI_END="0.08868233700118637" LOG_CI_START="-0.36172355531741657" LOG_EFFECT_SIZE="-0.13652060915811512" ORDER="90" O_E="0.0" SE="0.264570650693072" STUDY_ID="STD-Slavin-1995" TOTAL_1="152" TOTAL_2="148" VAR="0.06999762920815551" WEIGHT="9.538037943176764"/>
<DICH_DATA CI_END="1.9118140982140586" CI_START="0.7062174822918297" EFFECT_SIZE="1.1619623655913978" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="24" LOG_CI_END="0.2814456598830679" LOG_CI_START="-0.1510615357549426" LOG_EFFECT_SIZE="0.06519206206406263" ORDER="91" O_E="0.0" SE="0.2540568676629145" STUDY_ID="STD-Winston-1993" TOTAL_1="124" TOTAL_2="133" VAR="0.06454489200669167" WEIGHT="7.785356151506149"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.13466107348245288" CI_END="1.492942875858628" CI_START="0.6275928382825229" DF="3" EFFECT_SIZE="0.9679670742612005" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="34" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="0.1740431907297139" LOG_CI_START="-0.20232202096803212" LOG_EFFECT_SIZE="-0.014139415119159138" NO="3" P_CHI2="0.9873757745437344" P_Z="0.8829227190481663" STUDIES="4" TAU2="0.0" TOTAL_1="214" TOTAL_2="215" WEIGHT="11.269635718328681" Z="0.1472651750729224">
<NAME>Ketoconazole</NAME>
<DICH_DATA CI_END="3.7615021524511913" CI_START="0.25747849705622106" EFFECT_SIZE="0.9841269841269841" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5753613146723957" LOG_CI_START="-0.5892590345830514" LOG_EFFECT_SIZE="-0.006948859955327855" ORDER="92" O_E="0.0" SE="0.6841037581163545" STUDY_ID="STD-Benhamou-1991a" TOTAL_1="63" TOTAL_2="62" VAR="0.4679979518689196" WEIGHT="1.355405391925119"/>
<DICH_DATA CI_END="6.3849287248835696" CI_START="0.15661881958098683" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8051560535865078" LOG_CI_START="-0.8051560535865078" LOG_EFFECT_SIZE="0.0" ORDER="93" O_E="0.0" SE="0.9459053029269173" STUDY_ID="STD-Brincker-1983" TOTAL_1="19" TOTAL_2="19" VAR="0.8947368421052633" WEIGHT="0.6723241031374598"/>
<DICH_DATA CI_END="1.8450861414283168" CI_START="0.4093271025209082" EFFECT_SIZE="0.8690476190476191" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.2660166468493724" LOG_CI_START="-0.38792949873222393" LOG_EFFECT_SIZE="-0.060956425941425744" ORDER="94" O_E="0.0" SE="0.3841312030002574" STUDY_ID="STD-Estey-1984" TOTAL_1="77" TOTAL_2="73" VAR="0.14755678111842496" WEIGHT="4.141516475326752"/>
<DICH_DATA CI_END="1.8999035315681008" CI_START="0.5690432732065339" EFFECT_SIZE="1.0397727272727273" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="16" LOG_CI_END="0.27873155002058153" LOG_CI_START="-0.2448547061880222" LOG_EFFECT_SIZE="0.01693842191627966" ORDER="95" O_E="0.0" SE="0.307557158690702" STUDY_ID="STD-Palmblad-1992" TOTAL_1="55" TOTAL_2="61" VAR="0.09459140586189764" WEIGHT="5.10038974793935"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.007250875685067492" CI_END="1.8721578627564515" CI_START="0.7139149946072825" DF="1" EFFECT_SIZE="1.1560975609756097" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="25" I2="0.0" ID="CMP-001.01.04" LOG_CI_END="0.27234246621482966" LOG_CI_START="-0.14635349630613062" LOG_EFFECT_SIZE="0.06299448495434953" NO="4" P_CHI2="0.9321404918828534" P_Z="0.5553456206879783" STUDIES="2" TAU2="0.0" TOTAL_1="112" TOTAL_2="126" WEIGHT="7.951525450568035" Z="0.589768867088106">
<NAME>Miconazole</NAME>
<DICH_DATA CI_END="3.0927915802339063" CI_START="0.4655987843484408" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.49035065436976916" LOG_CI_START="-0.3319881622745195" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="96" O_E="0.0" SE="0.483045891539648" STUDY_ID="STD-Brincker-1978" TOTAL_1="15" TOTAL_2="15" VAR="0.2333333333333334" WEIGHT="1.6808102578436497"/>
<DICH_DATA CI_END="1.9967836527485165" CI_START="0.6558000968974296" EFFECT_SIZE="1.1443298969072164" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="20" LOG_CI_END="0.30033101253850053" LOG_CI_START="-0.18322852349767543" LOG_EFFECT_SIZE="0.058551244520412556" ORDER="97" O_E="0.0" SE="0.28404526512595757" STUDY_ID="STD-Wingard-1987" TOTAL_1="97" TOTAL_2="111" VAR="0.08068171264047552" WEIGHT="6.270715192724385"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.337154403566543" CI_END="1.403903005768488" CI_START="0.627715258911242" DF="3" EFFECT_SIZE="0.93874988082675" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="42" I2="0.0" ID="CMP-001.01.05" LOG_CI_END="0.1473371038659782" LOG_CI_START="-0.20223731410792145" LOG_EFFECT_SIZE="-0.02745010512097161" NO="5" P_CHI2="0.7203300199063654" P_Z="0.7582270577144026" STUDIES="4" TAU2="0.0" TOTAL_1="390" TOTAL_2="387" WEIGHT="14.148808175470418" Z="0.3078098089715469">
<NAME>Itraconazole</NAME>
<DICH_DATA CI_END="9.126454264720179" CI_START="0.41046585082417353" EFFECT_SIZE="1.935483870967742" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="0.9603020817663969" LOG_CI_START="-0.38672296866765493" LOG_EFFECT_SIZE="0.28678955654937094" ORDER="98" O_E="0.0" SE="0.7912491825064999" STUDY_ID="STD-Kaptan-2003" TOTAL_1="31" TOTAL_2="24" VAR="0.6260752688172043" WEIGHT="0.7578926253549547"/>
<DICH_DATA CI_END="1.631390647525887" CI_START="0.43847795105310194" EFFECT_SIZE="0.845771144278607" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="18" LOG_CI_END="0.21255796824480933" LOG_CI_START="-0.3580522403292392" LOG_EFFECT_SIZE="-0.07274713604221493" ORDER="99" O_E="0.0" SE="0.3351792610824826" STUDY_ID="STD-Menichetti-1999" TOTAL_1="201" TOTAL_2="204" VAR="0.11234513705979904" WEIGHT="6.0060953213613075"/>
<DICH_DATA CI_END="3.070516299848342" CI_START="0.43321637220465486" EFFECT_SIZE="1.1533420707732633" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.4872114071783405" LOG_CI_START="-0.36329513878776426" LOG_EFFECT_SIZE="0.061958134195288124" ORDER="100" O_E="0.0" SE="0.49959175517579174" STUDY_ID="STD-Nucci-2000" TOTAL_1="109" TOTAL_2="110" VAR="0.24959192183962825" WEIGHT="2.3423894552232047"/>
<DICH_DATA CI_END="1.528805061129439" CI_START="0.4186276041807356" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="15" LOG_CI_END="0.18435211178698083" LOG_CI_START="-0.3781721378030936" LOG_EFFECT_SIZE="-0.09691001300805639" ORDER="101" O_E="0.0" SE="0.33042952874915366" STUDY_ID="STD-Vreugdenhil-1993" TOTAL_1="49" TOTAL_2="49" VAR="0.10918367346938776" WEIGHT="5.042430773530949"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="18.3580175480374" CI_END="0.7149285098512618" CI_START="0.37868530193189215" CI_STUDY="95" CI_TOTAL="95" DF="19" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5203200155795881" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="93" I2="0.0" I2_Q="38.7624868149624" ID="CMP-001.02" LOG_CI_END="-0.14573738383442414" LOG_CI_START="-0.42172155100209663" LOG_EFFECT_SIZE="-0.2837294674182604" METHOD="MH" NO="2" P_CHI2="0.49865493497388" P_Q="0.1627888264620202" P_Z="5.579157310337842E-5" Q="6.531943888566225" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="23" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1759" TOTAL_2="1731" WEIGHT="99.99999999999999" Z="4.029937972163934">
<NAME>Death related to fungal infection</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.799950906355489" CI_END="0.7572327262498215" CI_START="0.2643482514867501" DF="7" EFFECT_SIZE="0.44740713802160686" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="32" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="-0.12077062486859498" LOG_CI_START="-0.5778235578602215" LOG_EFFECT_SIZE="-0.34929709136440834" NO="1" P_CHI2="0.6843610219127241" P_Z="0.0027376466719631555" STUDIES="9" TAU2="0.0" TOTAL_1="500" TOTAL_2="488" WEIGHT="36.47772015948049" Z="2.995756813101468">
<NAME>Amphotericin</NAME>
<DICH_DATA CI_END="1.9546003328743273" CI_START="0.005857012897191058" EFFECT_SIZE="0.10699588477366255" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.29105796839594134" LOG_CI_START="-2.23232381965093" LOG_EFFECT_SIZE="-0.9706329256274943" ORDER="102" O_E="0.0" SE="1.4822469532400342" STUDY_ID="STD-EORTC-1989" TOTAL_1="80" TOTAL_2="77" VAR="2.197056030389364" WEIGHT="4.632573866350681"/>
<DICH_DATA CI_END="77.90363862395063" CI_START="0.1339843684692309" EFFECT_SIZE="3.230769230769231" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8915577426199215" LOG_CI_START="-0.8729458664377941" LOG_EFFECT_SIZE="0.5093059380910637" ORDER="103" O_E="0.0" SE="1.623883104474068" STUDY_ID="STD-Goldstone-1994" TOTAL_1="64" TOTAL_2="69" VAR="2.636996336996337" WEIGHT="0.4864873333204724"/>
<DICH_DATA CI_END="18.472201543740212" CI_START="0.07482666812088003" EFFECT_SIZE="1.1756756756756757" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2665186583703982" LOG_CI_START="-1.1259435925951136" LOG_EFFECT_SIZE="0.07028753288764232" ORDER="104" O_E="0.0" SE="1.4053441690962833" STUDY_ID="STD-Kelsey-1999" TOTAL_1="74" TOTAL_2="87" VAR="1.974992233612923" WEIGHT="0.9288119369080782"/>
<DICH_DATA CI_END="1.0060817187411422" CI_START="0.04686599461041881" EFFECT_SIZE="0.21714285714285714" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.002633257615508875" LOG_CI_START="-1.3291421617544774" LOG_EFFECT_SIZE="-0.6632544520694843" ORDER="105" O_E="0.0" SE="0.7822914737325767" STUDY_ID="STD-Penack-2006" TOTAL_1="75" TOTAL_2="57" VAR="0.6119799498746867" WEIGHT="8.037247027759552"/>
<DICH_DATA CI_END="8.0762111281345" CI_START="0.013757826454541471" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9072076637368413" LOG_CI_START="-1.8614501731761663" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="106" O_E="0.0" SE="1.626323318480026" STUDY_ID="STD-Perfect-1992" TOTAL_1="91" TOTAL_2="91" VAR="2.6449275362318843" WEIGHT="1.5155951538060872"/>
<DICH_DATA CI_END="2.570915025008434" CI_START="0.034147956795504975" EFFECT_SIZE="0.2962962962962963" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.41008772239166785" LOG_CI_START="-1.4666352767257553" LOG_EFFECT_SIZE="-0.5282737771670437" ORDER="107" O_E="0.0" SE="1.102396379610246" STUDY_ID="STD-Pizzo-1982" TOTAL_1="18" TOTAL_2="16" VAR="1.2152777777777777" WEIGHT="3.2094956198246547"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="108" O_E="0.0" SE="0.0" STUDY_ID="STD-Riley-1994" TOTAL_1="17" TOTAL_2="18" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.2023115438549483" CI_START="0.31094992188294246" EFFECT_SIZE="0.611439842209073" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="0.08001701695608214" LOG_CI_START="-0.5073095479542087" LOG_EFFECT_SIZE="-0.2136462654990633" ORDER="109" O_E="0.0" SE="0.3449985315416897" STUDY_ID="STD-Suda-1980" TOTAL_1="39" TOTAL_2="31" VAR="0.11902398676592227" WEIGHT="14.636318913898783"/>
<DICH_DATA CI_END="3.076455045694317" CI_START="0.03611660481326315" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.48805057339786945" LOG_CI_START="-1.4422930828371945" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="110" O_E="0.0" SE="1.1338934190276817" STUDY_ID="STD-Tollemar-1993" TOTAL_1="42" TOTAL_2="42" VAR="1.2857142857142858" WEIGHT="3.0311903076121745"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.78067298248248" CI_END="0.7331159705573501" CI_START="0.24258493095971" DF="4" EFFECT_SIZE="0.4217142244495858" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="39" I2="16.32977167321528" ID="CMP-001.02.02" LOG_CI_END="-0.13482731950717017" LOG_CI_START="-0.6151361804039301" LOG_EFFECT_SIZE="-0.37498174995555006" NO="2" P_CHI2="0.31055119362529215" P_Z="0.0022109656623796525" STUDIES="6" TAU2="0.0" TOTAL_1="621" TOTAL_2="592" WEIGHT="40.014079065653235" Z="3.060325488896847">
<NAME>Fluconazole</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="111" O_E="0.0" SE="0.0" STUDY_ID="STD-Fukuda-1994" TOTAL_1="37" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.7643576384426325" CI_START="0.012792159352601137" EFFECT_SIZE="0.09888268156424582" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="10" LOG_CI_END="-0.11670339003722638" LOG_CI_START="-1.8930561391989467" LOG_EFFECT_SIZE="-1.0048797646180865" ORDER="112" O_E="0.0" SE="1.043438397945516" STUDY_ID="STD-Goodman-1992" TOTAL_1="179" TOTAL_2="177" VAR="1.0887636903071047" WEIGHT="10.16073155547901"/>
<DICH_DATA CI_END="5.95037946638978" CI_START="0.13278538978111726" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7745446623511103" LOG_CI_START="-0.8768497072458729" LOG_EFFECT_SIZE="-0.05115252244738131" ORDER="113" O_E="0.0" SE="0.9700372272352347" STUDY_ID="STD-Kern-1998" TOTAL_1="36" TOTAL_2="32" VAR="0.9409722222222222" WEIGHT="2.13966374654977"/>
<DICH_DATA CI_END="1.2885720864395604" CI_START="0.019180231143373066" EFFECT_SIZE="0.15721040189125296" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.11010871925262791" LOG_CI_START="-1.7171461633965035" LOG_EFFECT_SIZE="-0.8035187220719378" ORDER="114" O_E="0.0" SE="1.0733385631256456" STUDY_ID="STD-Rotstein-1999" TOTAL_1="141" TOTAL_2="133" VAR="1.1520556710926253" WEIGHT="6.239384428807541"/>
<DICH_DATA CI_END="6.917144572467917" CI_START="0.14456832433143973" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8399268527885413" LOG_CI_START="-0.8399268527885414" LOG_EFFECT_SIZE="0.0" ORDER="115" O_E="0.0" SE="0.9867543820659301" STUDY_ID="STD-Schaffner-1995" TOTAL_1="76" TOTAL_2="76" VAR="0.9736842105263157" WEIGHT="2.020793538408116"/>
<DICH_DATA CI_END="1.143415670047008" CI_START="0.2779139094648599" EFFECT_SIZE="0.5637119113573407" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="19" LOG_CI_END="0.05820413974839" LOG_CI_START="-0.5560897164372283" LOG_EFFECT_SIZE="-0.24894278834441913" ORDER="116" O_E="0.0" SE="0.36083925192706173" STUDY_ID="STD-Slavin-1995" TOTAL_1="152" TOTAL_2="148" VAR="0.13020496573128154" WEIGHT="19.4535057964088"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.674551909753184" CI_END="4.039735143596198" CI_START="0.5492252993694077" DF="2" EFFECT_SIZE="1.489538433077421" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" I2="45.5715948741533" ID="CMP-001.02.03" LOG_CI_END="0.6063528924756325" LOG_CI_START="-0.2602494657479815" LOG_EFFECT_SIZE="0.17305171336382544" NO="3" P_CHI2="0.15925072162050613" P_Z="0.43376224621753456" STUDIES="3" TAU2="0.0" TOTAL_1="151" TOTAL_2="153" WEIGHT="6.171412130997216" Z="0.782769911568894">
<NAME>Ketoconazole</NAME>
<DICH_DATA CI_END="97.69696229084639" CI_START="0.2558933196466676" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9898810603325618" LOG_CI_START="-0.5919410516605246" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="117" O_E="0.0" SE="1.5165750888103102" STUDY_ID="STD-Brincker-1983" TOTAL_1="19" TOTAL_2="19" VAR="2.3000000000000003" WEIGHT="0.505198384602029"/>
<DICH_DATA CI_END="2.2954177618990146" CI_START="0.14096296717950937" EFFECT_SIZE="0.5688311688311688" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="5" LOG_CI_END="0.36086173788041276" LOG_CI_START="-0.8508949672171775" LOG_EFFECT_SIZE="-0.24501661466838237" ORDER="118" O_E="0.0" SE="0.711791886866754" STUDY_ID="STD-Estey-1984" TOTAL_1="77" TOTAL_2="73" VAR="0.506647690209334" WEIGHT="5.186703415247498"/>
<DICH_DATA CI_END="146.75545278511154" CI_START="0.4092692902385523" EFFECT_SIZE="7.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.166594246686194" LOG_CI_START="-0.38799084167357384" LOG_EFFECT_SIZE="0.8893017025063102" ORDER="119" O_E="0.0" SE="1.5005759263026575" STUDY_ID="STD-Palmblad-1992" TOTAL_1="55" TOTAL_2="61" VAR="2.2517281105990783" WEIGHT="0.4795103311476886"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.3290111453415707" CI_START="0.006923525693800835" DF="0" EFFECT_SIZE="0.12698412698412698" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" I2="0.0" ID="CMP-001.02.04" LOG_CI_END="0.36717156682955465" LOG_CI_START="-2.159672691752831" LOG_EFFECT_SIZE="-0.8962505624616381" NO="4" P_CHI2="1.0" P_Z="0.16441784924100192" STUDIES="1" TAU2="0.0" TOTAL_1="97" TOTAL_2="111" WEIGHT="4.243666430657044" Z="1.3903657240308736">
<NAME>Miconazole</NAME>
<DICH_DATA CI_END="2.3290111453415707" CI_START="0.006923525693800835" EFFECT_SIZE="0.12698412698412698" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.36717156682955465" LOG_CI_START="-2.159672691752831" LOG_EFFECT_SIZE="-0.8962505624616381" ORDER="120" O_E="0.0" SE="1.484280825572101" STUDY_ID="STD-Wingard-1987" TOTAL_1="97" TOTAL_2="111" VAR="2.2030895691609977" WEIGHT="4.243666430657044"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.8827474819395453" CI_END="1.5628881233805696" CI_START="0.3094634670403483" DF="2" EFFECT_SIZE="0.6954543674875691" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" I2="0.0" ID="CMP-001.02.05" LOG_CI_END="0.1939278909190889" LOG_CI_START="-0.5093906132004458" LOG_EFFECT_SIZE="-0.15773136114067837" NO="5" P_CHI2="0.39009164652313055" P_Z="0.3793406866923127" STUDIES="4" TAU2="0.0" TOTAL_1="390" TOTAL_2="387" WEIGHT="13.093122213211998" Z="0.8791117687290882">
<NAME>Itraconazole</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="121" O_E="0.0" SE="0.0" STUDY_ID="STD-Kaptan-2003" TOTAL_1="31" TOTAL_2="24" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.7221196332784336" CI_START="0.023925713246085792" EFFECT_SIZE="0.20298507462686566" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.23606331800496205" LOG_CI_START="-1.6211351066661799" LOG_EFFECT_SIZE="-0.6925358943306089" ORDER="122" O_E="0.0" SE="1.0909275479322982" STUDY_ID="STD-Menichetti-1999" TOTAL_1="201" TOTAL_2="204" VAR="1.1901229148375767" WEIGHT="5.014561743457177"/>
<DICH_DATA CI_END="15.930797445760787" CI_START="0.06392855067801674" EFFECT_SIZE="1.0091743119266054" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2022375157650598" LOG_CI_START="-1.1943051413298569" LOG_EFFECT_SIZE="0.003966187217601382" ORDER="123" O_E="0.0" SE="1.407741019855032" STUDY_ID="STD-Nucci-2000" TOTAL_1="109" TOTAL_2="110" VAR="1.9817347789824855" WEIGHT="1.005783085326414"/>
<DICH_DATA CI_END="2.6377614694052958" CI_START="0.379109336306083" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.42123552009404736" LOG_CI_START="-0.42123552009404736" LOG_EFFECT_SIZE="0.0" ORDER="124" O_E="0.0" SE="0.49487165930539345" STUDY_ID="STD-Vreugdenhil-1993" TOTAL_1="49" TOTAL_2="49" VAR="0.24489795918367344" WEIGHT="7.072777384428407"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="22.815649492109028" CI_END="0.6408509390833149" CI_START="0.393957296045533" CI_STUDY="95" CI_TOTAL="95" DF="27" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5024618424611995" ESTIMABLE="YES" EVENTS_1="90" EVENTS_2="173" I2="0.0" I2_Q="61.28711590105607" ID="CMP-001.03" LOG_CI_END="-0.19324297494574513" LOG_CI_START="-0.4045508520244726" LOG_EFFECT_SIZE="-0.2988969134851089" METHOD="MH" NO="3" P_CHI2="0.6948757722051927" P_Q="0.03518453109380815" P_Z="2.9433450021578195E-8" Q="10.332477398936852" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="30" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2052" TOTAL_2="1992" WEIGHT="100.0" Z="5.544773754957889">
<NAME>Invasive infections</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.8657675279256285" CI_END="0.725239606815721" CI_START="0.2358469516293307" DF="7" EFFECT_SIZE="0.41357653520036913" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="35" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="-0.1395184862204708" LOG_CI_START="-0.6273697327280788" LOG_EFFECT_SIZE="-0.3834441094742748" NO="1" P_CHI2="0.7951021836615065" P_Z="0.0020630153761369923" STUDIES="8" TAU2="0.0" TOTAL_1="436" TOTAL_2="419" WEIGHT="21.075144239573824" Z="3.081007376874222">
<NAME>Amphotericin</NAME>
<DICH_DATA CI_END="2.105042768493122" CI_START="0.02750556496600187" EFFECT_SIZE="0.240625" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.32326092389229244" LOG_CI_START="-1.5605794301871407" LOG_EFFECT_SIZE="-0.6186592531474241" ORDER="125" O_E="0.0" SE="1.106577149146406" STUDY_ID="STD-EORTC-1989" TOTAL_1="80" TOTAL_2="77" VAR="1.2245129870129872" WEIGHT="2.276468029425205"/>
<DICH_DATA CI_END="4.811990558849658" CI_START="0.011444005089155655" EFFECT_SIZE="0.23466666666666666" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6823247665806254" LOG_CI_START="-1.9414219577357257" LOG_EFFECT_SIZE="-0.6295485955775503" ORDER="126" O_E="0.0" SE="1.5412018136191739" STUDY_ID="STD-Kelsey-1999" TOTAL_1="74" TOTAL_2="87" VAR="2.3753030303030305" WEIGHT="1.2847685509241653"/>
<DICH_DATA CI_END="1.3750753920951455" CI_START="0.1640819123788002" EFFECT_SIZE="0.475" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.13832651014685707" LOG_CI_START="-0.7849392908971239" LOG_EFFECT_SIZE="-0.3233063903751334" ORDER="127" O_E="0.0" SE="0.5423309017726575" STUDY_ID="STD-Penack-2006" TOTAL_1="75" TOTAL_2="57" VAR="0.2941228070175439" WEIGHT="5.0767823951670055"/>
<DICH_DATA CI_END="2.008894509725816" CI_START="0.07964579485153636" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.3029571318468899" LOG_CI_START="-1.098837149190965" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="128" O_E="0.0" SE="0.8234208996752378" STUDY_ID="STD-Perfect-1992" TOTAL_1="91" TOTAL_2="91" VAR="0.6780219780219781" WEIGHT="2.792230317341853"/>
<DICH_DATA CI_END="1.3654255477994075" CI_START="0.0231465848303052" EFFECT_SIZE="0.17777777777777778" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.13526802446007616" LOG_CI_START="-1.6355130780268763" LOG_EFFECT_SIZE="-0.7501225267834001" ORDER="129" O_E="0.0" SE="1.0401655851086615" STUDY_ID="STD-Pizzo-1982" TOTAL_1="18" TOTAL_2="16" VAR="1.0819444444444444" WEIGHT="2.956479159538432"/>
<DICH_DATA CI_END="2.7192808507398247" CI_START="0.008362036276426198" EFFECT_SIZE="0.15079365079365079" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.4344540643832414" LOG_CI_START="-2.0776879527127092" LOG_EFFECT_SIZE="-0.821616944164734" ORDER="130" O_E="0.0" SE="1.4756446561457002" STUDY_ID="STD-Riley-1994" TOTAL_1="17" TOTAL_2="18" VAR="2.1775271512113616" WEIGHT="1.9017352431625592"/>
<DICH_DATA CI_END="2.834420563055818" CI_START="0.3209906451660129" EFFECT_SIZE="0.9538461538461539" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.4524642900410673" LOG_CI_START="-0.49350762433027073" LOG_EFFECT_SIZE="-0.020521667144601675" ORDER="131" O_E="0.0" SE="0.5556685851382207" STUDY_ID="STD-Suda-1980" TOTAL_1="39" TOTAL_2="31" VAR="0.30876757650951203" WEIGHT="3.111342353609493"/>
<DICH_DATA CI_END="3.076455045694317" CI_START="0.03611660481326315" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.48805057339786945" LOG_CI_START="-1.4422930828371945" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="132" O_E="0.0" SE="1.1338934190276817" STUDY_ID="STD-Tollemar-1993" TOTAL_1="42" TOTAL_2="42" VAR="1.2857142857142858" WEIGHT="1.6753381904051117"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.780529417451074" CI_END="0.5739817258994939" CI_START="0.26798173307607986" DF="7" EFFECT_SIZE="0.3921946170723737" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="84" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="-0.24110193420019116" LOG_CI_START="-0.5718948085631406" LOG_EFFECT_SIZE="-0.40649837138166584" NO="2" P_CHI2="0.45208340524828483" P_Z="1.4569945504003507E-6" STUDIES="8" TAU2="0.0" TOTAL_1="785" TOTAL_2="754" WEIGHT="48.18467044378957" Z="4.817045525642615">
<NAME>Fluconazole</NAME>
<DICH_DATA CI_END="4.673360418948142" CI_START="0.10566081879403245" EFFECT_SIZE="0.7027027027027027" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.6696292759792289" LOG_CI_START="-0.9760860281715829" LOG_EFFECT_SIZE="-0.153228376096177" ORDER="133" O_E="0.0" SE="0.9667013160803262" STUDY_ID="STD-Fukuda-1994" TOTAL_1="37" TOTAL_2="26" VAR="0.9345114345114346" WEIGHT="1.3119050379891881"/>
<DICH_DATA CI_END="0.46473419608745" CI_START="0.07215199124033393" EFFECT_SIZE="0.18311607697082558" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="27" LOG_CI_END="-0.33279537007400634" LOG_CI_START="-1.1417516788081037" LOG_EFFECT_SIZE="-0.7372735244410551" ORDER="134" O_E="0.0" SE="0.47518494014871915" STUDY_ID="STD-Goodman-1992" TOTAL_1="179" TOTAL_2="177" VAR="0.2258007273441418" WEIGHT="15.162751824396825"/>
<DICH_DATA CI_END="5.95037946638978" CI_START="0.13278538978111726" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.7745446623511103" LOG_CI_START="-0.8768497072458729" LOG_EFFECT_SIZE="-0.05115252244738131" ORDER="135" O_E="0.0" SE="0.9700372272352347" STUDY_ID="STD-Kern-1998" TOTAL_1="36" TOTAL_2="32" VAR="0.9409722222222222" WEIGHT="1.182591663815373"/>
<DICH_DATA CI_END="1.005902136915007" CI_START="0.07960710586130118" EFFECT_SIZE="0.28297872340425534" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="0.0025557307545169394" LOG_CI_START="-1.0990481646917802" LOG_EFFECT_SIZE="-0.5482462169686316" ORDER="136" O_E="0.0" SE="0.6470875812123826" STUDY_ID="STD-Rotstein-1999" TOTAL_1="141" TOTAL_2="133" VAR="0.41872233775929185" WEIGHT="5.747510580221916"/>
<DICH_DATA CI_END="2.464061966824633" CI_START="0.3061677574216233" EFFECT_SIZE="0.8685714285714285" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="7" LOG_CI_END="0.391651625372097" LOG_CI_START="-0.5140405468551409" LOG_EFFECT_SIZE="-0.061194460741521906" ORDER="137" O_E="0.0" SE="0.5320080652148369" STUDY_ID="STD-Schaffner-1995" TOTAL_1="75" TOTAL_2="76" VAR="0.28303258145363414" WEIGHT="3.8832342161707887"/>
<DICH_DATA CI_END="1.0292521173155564" CI_START="0.20398424108055743" EFFECT_SIZE="0.4582043343653251" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="17" LOG_CI_END="0.012521769074932255" LOG_CI_START="-0.6904033829472233" LOG_EFFECT_SIZE="-0.3389408069361455" ORDER="138" O_E="0.0" SE="0.4129017138334339" STUDY_ID="STD-Slavin-1995" TOTAL_1="152" TOTAL_2="148" VAR="0.1704878252865869" WEIGHT="9.620164186681796"/>
<DICH_DATA CI_END="1.5252883929481056" CI_START="0.1885592989649385" EFFECT_SIZE="0.5362903225806451" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="10" LOG_CI_END="0.18335196540391457" LOG_CI_START="-0.7245520451221755" LOG_EFFECT_SIZE="-0.2706000398591305" ORDER="139" O_E="0.0" SE="0.5333073099803589" STUDY_ID="STD-Winston-1993" TOTAL_1="124" TOTAL_2="133" VAR="0.2844166868784866" WEIGHT="5.388895865375716"/>
<DICH_DATA CI_END="0.9233997895807123" CI_START="0.10702210157391534" EFFECT_SIZE="0.3143631436314363" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" LOG_CI_END="-0.03461022874951479" LOG_CI_START="-0.970526525114769" LOG_EFFECT_SIZE="-0.502568376932142" ORDER="140" O_E="0.0" SE="0.5497618653453351" STUDY_ID="STD-Yamac-1995" TOTAL_1="41" TOTAL_2="29" VAR="0.3022381085879824" WEIGHT="5.8876170691379635"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.249705287680248" CI_END="2.541878309071549" CI_START="0.681277043840952" DF="5" EFFECT_SIZE="1.315949596378107" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="13" I2="19.99622750441903" ID="CMP-001.03.03" LOG_CI_END="0.4051547551228761" LOG_CI_START="-0.16667624470388331" LOG_EFFECT_SIZE="0.1192392552094964" NO="3" P_CHI2="0.28267429391886" P_Z="0.41370524603444647" STUDIES="7" TAU2="0.0" TOTAL_1="281" TOTAL_2="281" WEIGHT="8.210481727349414" Z="0.8173906130475459">
<NAME>Ketoconazole</NAME>
<DICH_DATA CI_END="111.27424123723816" CI_START="0.32725437405098223" EFFECT_SIZE="6.0344827586206895" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.04639464157416" LOG_CI_START="-0.48511453999948323" LOG_EFFECT_SIZE="0.7806400507873383" ORDER="141" O_E="0.0" SE="1.487021024428907" STUDY_ID="STD-Acuna-1981" TOTAL_1="28" TOTAL_2="24" VAR="2.211231527093596" WEIGHT="0.2999062192700509"/>
<DICH_DATA CI_END="1.8807510762255955" CI_START="0.12873924852811053" EFFECT_SIZE="0.49206349206349204" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.27433131900841445" LOG_CI_START="-0.8902890302470325" LOG_EFFECT_SIZE="-0.30797885561930904" ORDER="142" O_E="0.0" SE="0.6841037581163545" STUDY_ID="STD-Benhamou-1991a" TOTAL_1="63" TOTAL_2="62" VAR="0.4679979518689196" WEIGHT="3.377481791856705"/>
<DICH_DATA CI_END="20.24371955945401" CI_START="0.19759214645571213" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3062903123047387" LOG_CI_START="-0.7042303209767762" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="143" O_E="0.0" SE="1.180989772227204" STUDY_ID="STD-Brincker-1983" TOTAL_1="19" TOTAL_2="19" VAR="1.3947368421052633" WEIGHT="0.5584460634683706"/>
<DICH_DATA CI_END="2.477242732166488" CI_START="0.25196093706834927" EFFECT_SIZE="0.79004329004329" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.39396856293451404" LOG_CI_START="-0.5986667851338157" LOG_EFFECT_SIZE="-0.10234911109965082" ORDER="144" O_E="0.0" SE="0.5830789170795557" STUDY_ID="STD-Estey-1984" TOTAL_1="77" TOTAL_2="73" VAR="0.3399810235426674" WEIGHT="3.4400277509651627"/>
<DICH_DATA CI_END="106.78285035218646" CI_START="0.26876019414337615" EFFECT_SIZE="5.357142857142857" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0285015092893035" LOG_CI_START="-0.5706350538623797" LOG_EFFECT_SIZE="0.728933227713462" ORDER="145" O_E="0.0" SE="1.5267456831287853" STUDY_ID="STD-Hansen-1987" TOTAL_1="27" TOTAL_2="29" VAR="2.330952380952381" WEIGHT="0.26959465132955823"/>
<DICH_DATA CI_END="146.75545278511154" CI_START="0.4092692902385523" EFFECT_SIZE="7.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.166594246686194" LOG_CI_START="-0.38799084167357384" LOG_EFFECT_SIZE="0.8893017025063102" ORDER="146" O_E="0.0" SE="1.5005759263026575" STUDY_ID="STD-Palmblad-1992" TOTAL_1="55" TOTAL_2="61" VAR="2.2517281105990783" WEIGHT="0.2650252504595657"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="147" O_E="0.0" SE="0.0" STUDY_ID="STD-Siegel-1982a" TOTAL_1="12" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.530147079554784E-4" CI_END="1.313921499469486" CI_START="0.20332043990310303" DF="1" EFFECT_SIZE="0.5168627450980392" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="13" I2="0.0" ID="CMP-001.03.04" LOG_CI_END="0.11856941897898587" LOG_CI_START="-0.6918189593309141" LOG_EFFECT_SIZE="-0.2866247701759641" NO="4" P_CHI2="0.9753724698361127" P_Z="0.16561500328644332" STUDIES="2" TAU2="0.0" TOTAL_1="112" TOTAL_2="126" WEIGHT="6.846333951174736" Z="1.3864320902369416">
<NAME>Miconazole</NAME>
<DICH_DATA CI_END="4.943824870337866" CI_START="0.05056813430021737" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6940630779397805" LOG_CI_START="-1.296123069267743" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="148" O_E="0.0" SE="1.1690451944500122" STUDY_ID="STD-Brincker-1978" TOTAL_1="15" TOTAL_2="15" VAR="1.3666666666666667" WEIGHT="1.1168921269367411"/>
<DICH_DATA CI_END="1.4445311923083994" CI_START="0.18729673349511966" EFFECT_SIZE="0.5201499531396439" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="0.15972692416647793" LOG_CI_START="-0.7274697967700652" LOG_EFFECT_SIZE="-0.2838714363017937" ORDER="149" O_E="0.0" SE="0.5211437455727224" STUDY_ID="STD-Wingard-1987" TOTAL_1="97" TOTAL_2="111" VAR="0.2715908035495664" WEIGHT="5.729441824237995"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7564779986371839" CI_END="0.9693173327445737" CI_START="0.28817963111251677" DF="3" EFFECT_SIZE="0.5285238985904989" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="28" I2="0.0" ID="CMP-001.03.05" LOG_CI_END="-0.013534021402770973" LOG_CI_START="-0.5403367189004317" LOG_EFFECT_SIZE="-0.2769353701516013" NO="5" P_CHI2="0.8598460645978271" P_Z="0.03933449942828233" STUDIES="4" TAU2="0.0" TOTAL_1="408" TOTAL_2="402" WEIGHT="15.683369638112456" Z="2.0606703576904812">
<NAME>Itraconazole</NAME>
<DICH_DATA CI_END="5.423846496382679" CI_START="0.11690739992698734" EFFECT_SIZE="0.7962962962962963" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.734307389797554" LOG_CI_START="-0.932157998284318" LOG_EFFECT_SIZE="-0.09892530424338199" ORDER="150" O_E="0.0" SE="0.978890018096003" STUDY_ID="STD-Kaptan-2003" TOTAL_1="54" TOTAL_2="43" VAR="0.9582256675279931" WEIGHT="1.2435499970017325"/>
<DICH_DATA CI_END="1.2315146447364833" CI_START="0.09293646084378104" EFFECT_SIZE="0.3383084577114428" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="9" LOG_CI_END="0.09043958068216812" LOG_CI_START="-1.0318138701106732" LOG_EFFECT_SIZE="-0.47068714471425255" ORDER="151" O_E="0.0" SE="0.6592172322398901" STUDY_ID="STD-Menichetti-1999" TOTAL_1="201" TOTAL_2="204" VAR="0.4345673592820213" WEIGHT="4.988784833650777"/>
<DICH_DATA CI_END="1.8835450127913336" CI_START="0.21544136063329528" EFFECT_SIZE="0.6370192307692307" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.27497600339423817" LOG_CI_START="-0.666670916774108" LOG_EFFECT_SIZE="-0.19584745668993492" ORDER="152" O_E="0.0" SE="0.5531280621343166" STUDY_ID="STD-Nucci-2000" TOTAL_1="104" TOTAL_2="106" VAR="0.30595065312046443" WEIGHT="4.425020236244612"/>
<DICH_DATA CI_END="1.5390976464218644" CI_START="0.20053436897014373" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.18726617405949797" LOG_CI_START="-0.6978111842661101" LOG_EFFECT_SIZE="-0.25527250510330607" ORDER="153" O_E="0.0" SE="0.519898821484045" STUDY_ID="STD-Vreugdenhil-1993" TOTAL_1="49" TOTAL_2="49" VAR="0.2702947845804988" WEIGHT="5.026014571215335"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.03.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="6" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Itraconazole/ketoconazole/amphotericin</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="154" O_E="0.0" SE="0.0" STUDY_ID="STD-Caselli-1990" TOTAL_1="30" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="106.88497440396019" CI_END="0.7703267498247707" CI_START="0.543890704703485" CI_STUDY="95" CI_TOTAL="95" DF="21" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6472816688383348" ESTIMABLE="YES" EVENTS_1="492" EVENTS_2="742" I2="80.35271083039906" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-0.11332502087230317" LOG_CI_START="-0.2644883633772907" LOG_EFFECT_SIZE="-0.1889066921247969" METHOD="MH" NO="4" P_CHI2="1.723066134218243E-13" P_Q="0.4711663320354992" P_Z="9.64833312561714E-7" Q="4.5655121304089334" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="22" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.14725529615039704" TOTALS="SUB" TOTAL_1="1599" TOTAL_2="1579" WEIGHT="600.0" Z="4.898678566742889">
<NAME>Colonisation</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.7139372657540245" CI_END="0.7726931673340558" CI_START="0.33300826475564543" DF="2" EFFECT_SIZE="0.5072604960397148" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="55" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="-0.11199292805811094" LOG_CI_START="-0.47754498783533245" LOG_EFFECT_SIZE="-0.2947689579467217" NO="1" P_CHI2="0.6997945552465762" P_Z="0.0015728311058571763" STUDIES="3" TAU2="0.0" TOTAL_1="182" TOTAL_2="196" WEIGHT="100.00000000000001" Z="3.160898842633066">
<NAME>Amphotericin</NAME>
<DICH_DATA CI_END="0.8470083948744151" CI_START="0.29973246162390205" EFFECT_SIZE="0.5038610038610039" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="35" LOG_CI_END="-0.07211228526602587" LOG_CI_START="-0.5232662195478783" LOG_EFFECT_SIZE="-0.29768925240695204" ORDER="155" O_E="0.0" SE="0.26501005424515217" STUDY_ID="STD-Kelsey-1999" TOTAL_1="74" TOTAL_2="87" VAR="0.0702303288510185" WEIGHT="65.65215297617326"/>
<DICH_DATA CI_END="1.4132719596710763" CI_START="0.2679584932401892" EFFECT_SIZE="0.6153846153846154" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.15022574232948796" LOG_CI_START="-0.5719324729592742" LOG_EFFECT_SIZE="-0.21085336531489315" ORDER="156" O_E="0.0" SE="0.4241993104014373" STUDY_ID="STD-Perfect-1992" TOTAL_1="91" TOTAL_2="91" VAR="0.17994505494505497" WEIGHT="25.623223126091958"/>
<DICH_DATA CI_END="1.257619428529112" CI_START="0.07277158610091249" EFFECT_SIZE="0.3025210084033613" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="7" LOG_CI_END="0.09954923801292884" LOG_CI_START="-1.138038159263416" LOG_EFFECT_SIZE="-0.5192444606252435" ORDER="157" O_E="0.0" SE="0.7269649633165428" STUDY_ID="STD-Riley-1994" TOTAL_1="17" TOTAL_2="18" VAR="0.5284780578898225" WEIGHT="8.7246238977348"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="75.73698089391151" CI_END="0.8951016865835375" CI_START="0.3334755379483293" DF="5" EFFECT_SIZE="0.5463465168296601" ESTIMABLE="YES" EVENTS_1="260" EVENTS_2="441" I2="93.39820528758105" ID="CMP-001.04.02" LOG_CI_END="-0.04812762455721991" LOG_CI_START="-0.47693601819030584" LOG_EFFECT_SIZE="-0.26253182137376285" NO="2" P_CHI2="6.994405055138486E-15" P_Z="0.016398656432409047" STUDIES="6" TAU2="0.2736229293467606" TOTAL_1="702" TOTAL_2="691" WEIGHT="99.99999999999999" Z="2.399919975113921">
<NAME>Fluconazole</NAME>
<DICH_DATA CI_END="9.63557745988069" CI_START="0.4612198712505783" EFFECT_SIZE="2.108108108108108" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="0.9838777470272482" LOG_CI_START="-0.3360919897802775" LOG_EFFECT_SIZE="0.32389287862348537" ORDER="158" O_E="0.0" SE="0.775356757356316" STUDY_ID="STD-Fukuda-1994" TOTAL_1="37" TOTAL_2="26" VAR="0.6011781011781011" WEIGHT="7.252579091952683"/>
<DICH_DATA CI_END="0.5644639202000493" CI_START="0.3436070766073115" EFFECT_SIZE="0.4404018590676494" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="119" LOG_CI_END="-0.24836381239055522" LOG_CI_START="-0.4639379004291014" LOG_EFFECT_SIZE="-0.35615085640982824" ORDER="159" O_E="0.0" SE="0.1266292864227879" STUDY_ID="STD-Goodman-1992" TOTAL_1="179" TOTAL_2="177" VAR="0.016034976179944458" WEIGHT="21.903644066149383"/>
<DICH_DATA CI_END="0.6407969512233505" CI_START="0.39093051083186475" EFFECT_SIZE="0.5005068226120858" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="95" LOG_CI_END="-0.19327956320038753" LOG_CI_START="-0.4079004329987644" LOG_EFFECT_SIZE="-0.30058999809957593" ORDER="160" O_E="0.0" SE="0.12606936131000607" STUDY_ID="STD-Rotstein-1999" TOTAL_1="135" TOTAL_2="131" VAR="0.015893483861112858" WEIGHT="21.914348804286483"/>
<DICH_DATA CI_END="0.5367116716325387" CI_START="0.009761297442326903" EFFECT_SIZE="0.07238095238095238" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="14" LOG_CI_END="-0.27025896019928813" LOG_CI_START="-2.010492453379005" LOG_EFFECT_SIZE="-1.1403757067891467" ORDER="161" O_E="0.0" SE="1.0222217681884866" STUDY_ID="STD-Schaffner-1995" TOTAL_1="75" TOTAL_2="76" VAR="1.044937343358396" WEIGHT="4.811735796185315"/>
<DICH_DATA CI_END="0.991290289417419" CI_START="0.7990743445000851" EFFECT_SIZE="0.8900082236842105" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="128" LOG_CI_END="-0.0037991481070450426" LOG_CI_START="-0.09741281279599871" LOG_EFFECT_SIZE="-0.05060598045152189" ORDER="162" O_E="0.0" SE="0.05498913003340514" STUDY_ID="STD-Slavin-1995" TOTAL_1="152" TOTAL_2="148" VAR="0.0030238044218307385" WEIGHT="22.933810123745594"/>
<DICH_DATA CI_END="0.6022224277698872" CI_START="0.32055653543708673" EFFECT_SIZE="0.4393703847648659" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="83" LOG_CI_END="-0.22024307466960716" LOG_CI_START="-0.49409536438832913" LOG_EFFECT_SIZE="-0.3571692195289681" ORDER="163" O_E="0.0" SE="0.16086219057147405" STUDY_ID="STD-Winston-1993" TOTAL_1="124" TOTAL_2="133" VAR="0.025876644355453234" WEIGHT="21.18388211768054"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="15.132679996381135" CI_END="0.8658166615382388" CI_START="0.5131431013381023" DF="7" EFFECT_SIZE="0.6665492081549073" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="152" I2="53.742496361027946" ID="CMP-001.04.03" LOG_CI_END="-0.06257406099861552" LOG_CI_START="-0.2897615053462853" LOG_EFFECT_SIZE="-0.17616778317245038" NO="3" P_CHI2="0.034335822864853593" P_Z="0.002368715504917666" STUDIES="8" TAU2="0.07014912898738226" TOTAL_1="323" TOTAL_2="303" WEIGHT="99.99999999999999" Z="3.0396266945621444">
<NAME>Ketoconazole</NAME>
<DICH_DATA CI_END="1.6038588113495025" CI_START="0.7891124773851451" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="16" LOG_CI_END="0.2051661344277923" LOG_CI_START="-0.10286108953302973" LOG_EFFECT_SIZE="0.05115252244738129" ORDER="164" O_E="0.0" SE="0.18093671611393647" STUDY_ID="STD-Acuna-1981" TOTAL_1="28" TOTAL_2="24" VAR="0.03273809523809524" WEIGHT="17.3094156087261"/>
<DICH_DATA CI_END="0.7752174953326832" CI_START="0.32944465696903236" EFFECT_SIZE="0.5053625053625054" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="37" LOG_CI_END="-0.11057643456319358" LOG_CI_START="-0.4822175315757941" LOG_EFFECT_SIZE="-0.29639698306949386" ORDER="165" O_E="0.0" SE="0.21830382003830134" STUDY_ID="STD-Benhamou-1991a" TOTAL_1="63" TOTAL_2="62" VAR="0.04765655784331506" WEIGHT="15.117417272957303"/>
<DICH_DATA CI_END="1.4409646389553143" CI_START="0.48193024705166265" EFFECT_SIZE="0.8333333333333334" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.1586533234267511" LOG_CI_START="-0.3170158155220007" LOG_EFFECT_SIZE="-0.0791812460476248" ORDER="166" O_E="0.0" SE="0.2794104068187091" STUDY_ID="STD-Brincker-1983" TOTAL_1="19" TOTAL_2="19" VAR="0.07807017543859651" WEIGHT="12.015423576868685"/>
<DICH_DATA CI_END="0.9089586133605667" CI_START="0.1953237817527153" EFFECT_SIZE="0.4213564213564214" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="18" LOG_CI_END="-0.04145589059356543" LOG_CI_START="-0.7092448757332115" LOG_EFFECT_SIZE="-0.3753503831633884" ORDER="167" O_E="0.0" SE="0.3922625554798167" STUDY_ID="STD-Estey-1984" TOTAL_1="77" TOTAL_2="73" VAR="0.15386991243155626" WEIGHT="7.9498497702098625"/>
<DICH_DATA CI_END="1.3629020526347322" CI_START="0.11903271989207558" EFFECT_SIZE="0.4027777777777778" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.1344646456154876" LOG_CI_START="-0.9243336426801124" LOG_EFFECT_SIZE="-0.3949344985323124" ORDER="168" O_E="0.0" SE="0.6219433556808904" STUDY_ID="STD-Hansen-1987" TOTAL_1="27" TOTAL_2="29" VAR="0.3868135376756066" WEIGHT="3.8972937066222384"/>
<DICH_DATA CI_END="0.9022144419845141" CI_START="0.48523518848509894" EFFECT_SIZE="0.6616541353383458" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="19" LOG_CI_END="-0.04469022531635914" LOG_CI_START="-0.31404771231747525" LOG_EFFECT_SIZE="-0.1793689688169172" ORDER="169" O_E="0.0" SE="0.1582219212055201" STUDY_ID="STD-Hughes-1983" TOTAL_1="42" TOTAL_2="22" VAR="0.02503417634996581" WEIGHT="18.710400092065147"/>
<DICH_DATA CI_END="0.8514054683618405" CI_START="0.31745371757487195" EFFECT_SIZE="0.5198863636363636" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="32" LOG_CI_END="-0.06986356478638325" LOG_CI_START="-0.4983195827090199" LOG_EFFECT_SIZE="-0.28409157374770155" ORDER="170" O_E="0.0" SE="0.25167718581925075" STUDY_ID="STD-Palmblad-1992" TOTAL_1="55" TOTAL_2="61" VAR="0.06334140586189767" WEIGHT="13.34115356536523"/>
<DICH_DATA CI_END="1.3319821072906477" CI_START="0.4317396166936349" EFFECT_SIZE="0.7583333333333333" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.1244983909325328" LOG_CI_START="-0.36477809838559533" LOG_EFFECT_SIZE="-0.12013985372653124" ORDER="171" O_E="0.0" SE="0.2874034317831514" STUDY_ID="STD-Siegel-1982a" TOTAL_1="12" TOTAL_2="13" VAR="0.08260073260073258" WEIGHT="11.65904640718543"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.797820354904436" CI_END="2.2379578423883033" CI_START="0.3748883365639565" DF="1" EFFECT_SIZE="0.9159608576971028" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="58" I2="89.79364834445616" ID="CMP-001.04.04" LOG_CI_END="0.3498519012313949" LOG_CI_START="-0.42609807103406183" LOG_EFFECT_SIZE="-0.03812308490133346" NO="4" P_CHI2="0.0017471942661562156" P_Z="0.8472805399441395" STUDIES="2" TAU2="0.37400740501733565" TOTAL_1="112" TOTAL_2="126" WEIGHT="100.0" Z="0.19258940925798296">
<NAME>Miconazole</NAME>
<DICH_DATA CI_END="0.9349174610911195" CI_START="0.3492614330507978" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="14" LOG_CI_END="-0.02922672899374721" LOG_CI_START="-0.4568493683788417" LOG_EFFECT_SIZE="-0.24303804868629447" ORDER="172" O_E="0.0" SE="0.2511876551410082" STUDY_ID="STD-Brincker-1978" TOTAL_1="15" TOTAL_2="15" VAR="0.06309523809523808" WEIGHT="47.52905891761217"/>
<DICH_DATA CI_END="1.8773174966549273" CI_START="1.050623057719574" EFFECT_SIZE="1.4044048734770385" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="44" LOG_CI_END="0.2735377278076534" LOG_CI_START="0.02144692790673385" LOG_EFFECT_SIZE="0.14749232785719366" ORDER="173" O_E="0.0" SE="0.14807938373138502" STUDY_ID="STD-Wingard-1987" TOTAL_1="97" TOTAL_2="111" VAR="0.021927503886266776" WEIGHT="52.47094108238783"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.03203049142922459" CI_END="1.4485104234062618" CI_START="0.5697660073916821" DF="1" EFFECT_SIZE="0.9084668406768741" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="29" I2="0.0" ID="CMP-001.04.05" LOG_CI_END="0.1609216247117065" LOG_CI_START="-0.244303464613194" LOG_EFFECT_SIZE="-0.04169091995074369" NO="5" P_CHI2="0.857960796304053" P_Z="0.6867309468789072" STUDIES="2" TAU2="0.0" TOTAL_1="250" TOTAL_2="253" WEIGHT="100.0" Z="0.4032953720705317">
<NAME>Itraconazole</NAME>
<DICH_DATA CI_END="1.8714630950044802" CI_START="0.3940811105820202" EFFECT_SIZE="0.8587830080367393" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="13" LOG_CI_END="0.2721812673072725" LOG_CI_START="-0.4044143815936762" LOG_EFFECT_SIZE="-0.06611655714320186" ORDER="174" O_E="0.0" SE="0.3974356333668946" STUDY_ID="STD-Menichetti-1999" TOTAL_1="201" TOTAL_2="204" VAR="0.15795508266974465" WEIGHT="35.87023750009546"/>
<DICH_DATA CI_END="1.678729004066402" CI_START="0.5235545748426438" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="16" LOG_CI_END="0.22498059397155898" LOG_CI_START="-0.28103804117204606" LOG_EFFECT_SIZE="-0.028028723600243537" ORDER="175" O_E="0.0" SE="0.297237851115995" STUDY_ID="STD-Vreugdenhil-1993" TOTAL_1="49" TOTAL_2="49" VAR="0.08835034013605442" WEIGHT="64.12976249990454"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0383507628481332" CI_START="0.31447043131094177" DF="0" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" I2="0.0" ID="CMP-001.04.06" LOG_CI_END="0.016344086303040458" LOG_CI_START="-0.5024201836756295" LOG_EFFECT_SIZE="-0.24303804868629447" NO="6" P_CHI2="1.0" P_Z="0.06628913622937883" STUDIES="1" TAU2="0.0" TOTAL_1="30" TOTAL_2="10" WEIGHT="100.0" Z="1.836463495520289">
<NAME>Itraconazole/ketoconazole/amphotericin</NAME>
<DICH_DATA CI_END="1.0383507628481332" CI_START="0.31447043131094177" EFFECT_SIZE="0.5714285714285714" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.016344086303040458" LOG_CI_START="-0.5024201836756295" LOG_EFFECT_SIZE="-0.24303804868629447" ORDER="176" O_E="0.0" SE="0.304724700110022" STUDY_ID="STD-Caselli-1990" TOTAL_1="30" TOTAL_2="10" VAR="0.09285714285714283" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="53.79364754614449" CI_END="0.9983473728798677" CI_START="0.810831064418556" CI_STUDY="95" CI_TOTAL="95" DF="21" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8997172128016959" ESTIMABLE="YES" EVENTS_1="713" EVENTS_2="844" I2="60.96193331752401" I2_Q="61.495066119314224" ID="CMP-001.05" LOG_CI_END="-7.183205605603471E-4" LOG_CI_START="-0.0910696210457227" LOG_EFFECT_SIZE="-0.04589397080314153" METHOD="MH" NO="5" P_CHI2="1.0575588648242817E-4" P_Q="0.03437124652500345" P_Z="0.0464667493302704" Q="10.388279103126614" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="24" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.03608857248084536" TOTALS="SUB" TOTAL_1="1747" TOTAL_2="1720" WEIGHT="500.0" Z="1.99112861461163">
<NAME>Use of escape drug</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="23.792535481250255" CI_END="1.0316000503376828" CI_START="0.34986572438762287" DF="4" EFFECT_SIZE="0.6007674249571973" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="157" I2="83.18800447664685" ID="CMP-001.05.01" LOG_CI_END="0.013511354657618891" LOG_CI_START="-0.456098602354065" LOG_EFFECT_SIZE="-0.22129362384822304" NO="1" P_CHI2="8.789873983905405E-5" P_Z="0.06472076542119487" STUDIES="6" TAU2="0.2567683733752607" TOTAL_1="328" TOTAL_2="308" WEIGHT="100.0" Z="1.8471820125401646">
<NAME>Amphotericin</NAME>
<DICH_DATA CI_END="1.0764760826476911" CI_START="0.39802983681334175" EFFECT_SIZE="0.6545758928571429" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="28" LOG_CI_END="0.0320043850285067" LOG_CI_START="-0.40008437144966086" LOG_EFFECT_SIZE="-0.18403999321057712" ORDER="177" O_E="0.0" SE="0.2538110744291155" STUDY_ID="STD-Goldstone-1994" TOTAL_1="64" TOTAL_2="69" VAR="0.06442006150286202" WEIGHT="23.69135487040294"/>
<DICH_DATA CI_END="0.6499967047131491" CI_START="0.28625374092434686" EFFECT_SIZE="0.43135135135135133" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="37" LOG_CI_END="-0.18708884509333415" LOG_CI_START="-0.5432488290112346" LOG_EFFECT_SIZE="-0.3651688370522844" ORDER="178" O_E="0.0" SE="0.20921013757372872" STUDY_ID="STD-Penack-2006" TOTAL_1="75" TOTAL_2="57" VAR="0.0437688816636185" WEIGHT="25.319287587099694"/>
<DICH_DATA CI_END="1.0725387395762027" CI_START="0.8152119830501188" EFFECT_SIZE="0.935064935064935" ESTIMABLE="YES" EVENTS_1="72" EVENTS_2="77" LOG_CI_END="0.030412987644946637" LOG_CI_START="-0.08872944512737352" LOG_EFFECT_SIZE="-0.029158228741213422" ORDER="179" O_E="0.0" SE="0.0699848547750147" STUDY_ID="STD-Perfect-1992" TOTAL_1="91" TOTAL_2="91" VAR="0.004897879897879898" WEIGHT="29.08051418852182"/>
<DICH_DATA CI_END="1.62685704583187" CI_START="0.26918931019389386" EFFECT_SIZE="0.6617647058823529" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" LOG_CI_END="0.21134939255946705" LOG_CI_START="-0.5699421904212524" LOG_EFFECT_SIZE="-0.17929639893089266" ORDER="180" O_E="0.0" SE="0.45893454329858385" STUDY_ID="STD-Riley-1994" TOTAL_1="17" TOTAL_2="18" VAR="0.21062091503267974" WEIGHT="16.280623839041397"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="181" O_E="0.0" SE="0.0" STUDY_ID="STD-Suda-1980" TOTAL_1="39" TOTAL_2="31" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.1110029699454145" CI_START="0.018369134752455978" EFFECT_SIZE="0.14285714285714285" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="7" LOG_CI_END="0.04571521990322681" LOG_CI_START="-1.7359112999317405" LOG_EFFECT_SIZE="-0.8450980400142568" ORDER="182" O_E="0.0" SE="1.0465362369445672" STUDY_ID="STD-Tollemar-1993" TOTAL_1="42" TOTAL_2="42" VAR="1.0952380952380953" WEIGHT="5.628219514934161"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="11.057305669443625" CI_END="1.0172939120681725" CI_START="0.7599495160520632" DF="5" EFFECT_SIZE="0.8792565132877423" ESTIMABLE="YES" EVENTS_1="366" EVENTS_2="416" I2="54.78102758959374" ID="CMP-001.05.02" LOG_CI_END="0.007446445497345572" LOG_CI_START="-0.11921525723005116" LOG_EFFECT_SIZE="-0.0558844058663528" NO="2" P_CHI2="0.050255594359517985" P_Z="0.08371762663080329" STUDIES="7" TAU2="0.016936419461306557" TOTAL_1="744" TOTAL_2="725" WEIGHT="100.0" Z="1.7295112956314138">
<NAME>Fluconazole</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="183" O_E="0.0" SE="0.0" STUDY_ID="STD-Fukuda-1994" TOTAL_1="37" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.0177413017016967" CI_START="0.728332753061866" EFFECT_SIZE="0.8609612791369678" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="116" LOG_CI_END="0.007637399295998105" LOG_CI_START="-0.13767015942072294" LOG_EFFECT_SIZE="-0.06501638006236243" ORDER="184" O_E="0.0" SE="0.08535437927421807" STUDY_ID="STD-Goodman-1992" TOTAL_1="179" TOTAL_2="177" VAR="0.0072853700612870685" WEIGHT="22.85386312809558"/>
<DICH_DATA CI_END="1.6233245095198463" CI_START="0.7270929952542105" EFFECT_SIZE="1.0864197530864197" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="18" LOG_CI_END="0.21040534583136503" LOG_CI_START="-0.13841003928832735" LOG_EFFECT_SIZE="0.035997653271518854" ORDER="185" O_E="0.0" SE="0.20489588388331093" STUDY_ID="STD-Kern-1998" TOTAL_1="36" TOTAL_2="32" VAR="0.04198232323232323" WEIGHT="9.395337326618558"/>
<DICH_DATA CI_END="1.421730622470034" CI_START="0.9146778689266825" EFFECT_SIZE="1.14036201968879" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="67" LOG_CI_END="0.15281731773188093" LOG_CI_START="-0.03873182875282256" LOG_EFFECT_SIZE="0.05704274448952918" ORDER="186" O_E="0.0" SE="0.11251691682868203" STUDY_ID="STD-Rotstein-1999" TOTAL_1="141" TOTAL_2="133" VAR="0.012660056572632552" WEIGHT="18.70362748024832"/>
<DICH_DATA CI_END="1.0479637515447273" CI_START="0.4725343809615297" EFFECT_SIZE="0.7037037037037037" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="36" LOG_CI_END="0.020346260914538644" LOG_CI_START="-0.3255665873268553" LOG_EFFECT_SIZE="-0.15261016320615833" ORDER="187" O_E="0.0" SE="0.20319091935320913" STUDY_ID="STD-Schaffner-1995" TOTAL_1="75" TOTAL_2="76" VAR="0.04128654970760233" WEIGHT="9.507613066949128"/>
<DICH_DATA CI_END="0.8951028816017793" CI_START="0.543061792808009" EFFECT_SIZE="0.6972059779077323" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="81" LOG_CI_END="-0.048127044746579924" LOG_CI_START="-0.2651507509844753" LOG_EFFECT_SIZE="-0.15663889786552762" ORDER="188" O_E="0.0" SE="0.12748079932881146" STUDY_ID="STD-Slavin-1995" TOTAL_1="152" TOTAL_2="148" VAR="0.016251354197512696" WEIGHT="16.67968054011939"/>
<DICH_DATA CI_END="1.0220048640451573" CI_START="0.7314909881499159" EFFECT_SIZE="0.8646313364055299" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="98" LOG_CI_END="0.00945296274873766" LOG_CI_START="-0.13579101994314316" LOG_EFFECT_SIZE="-0.06316902859720272" ORDER="189" O_E="0.0" SE="0.08531703440252049" STUDY_ID="STD-Winston-1993" TOTAL_1="124" TOTAL_2="133" VAR="0.007278996359240866" WEIGHT="22.859878457969025"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="12.7683852801555" CI_END="1.4439368579256633" CI_START="0.580664056198068" DF="5" EFFECT_SIZE="0.9156649129550662" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="101" I2="60.84078064458979" ID="CMP-001.05.03" LOG_CI_END="0.1595482023374797" LOG_CI_START="-0.23607505648427973" LOG_EFFECT_SIZE="-0.038263427073400025" NO="3" P_CHI2="0.025648713045829497" P_Z="0.7045965259937399" STUDIES="6" TAU2="0.16268623112286917" TOTAL_1="204" TOTAL_2="208" WEIGHT="99.99999999999999" Z="0.3791230030928311">
<NAME>Ketoconazole</NAME>
<DICH_DATA CI_END="4.664536610764438" CI_START="0.7623304658260973" EFFECT_SIZE="1.8857142857142857" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="5" LOG_CI_END="0.6688085060923986" LOG_CI_START="-0.1178567237092125" LOG_EFFECT_SIZE="0.27547589119159305" ORDER="190" O_E="0.0" SE="0.4620910500411564" STUDY_ID="STD-Acuna-1981" TOTAL_1="28" TOTAL_2="24" VAR="0.21352813852813854" WEIGHT="14.355008580944912"/>
<DICH_DATA CI_END="1.1799528298200128" CI_START="0.8533043684900542" EFFECT_SIZE="1.0034235916588858" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="51" LOG_CI_END="0.07186464615498483" LOG_CI_START="-0.06889603099191487" LOG_EFFECT_SIZE="0.0014843075815349901" ORDER="191" O_E="0.0" SE="0.08268351853267823" STUDY_ID="STD-Benhamou-1991a" TOTAL_1="63" TOTAL_2="62" VAR="0.006836564236943746" WEIGHT="31.85742951649825"/>
<DICH_DATA CI_END="6.3849287248835696" CI_START="0.15661881958098683" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8051560535865078" LOG_CI_START="-0.8051560535865078" LOG_EFFECT_SIZE="0.0" ORDER="192" O_E="0.0" SE="0.9459053029269173" STUDY_ID="STD-Brincker-1983" TOTAL_1="19" TOTAL_2="19" VAR="0.8947368421052633" WEIGHT="5.107284530994775"/>
<DICH_DATA CI_END="3.7381035584283673" CI_START="0.4444057105254937" EFFECT_SIZE="1.288888888888889" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="5" LOG_CI_END="0.5726513286722966" LOG_CI_START="-0.35222036909710935" LOG_EFFECT_SIZE="0.11021547978759363" ORDER="193" O_E="0.0" SE="0.5432742134584891" STUDY_ID="STD-Hansen-1987" TOTAL_1="27" TOTAL_2="29" VAR="0.29514687100894" WEIGHT="11.795915322567016"/>
<DICH_DATA CI_END="0.7240469246342017" CI_START="0.23890768127800344" EFFECT_SIZE="0.4159090909090909" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="32" LOG_CI_END="-0.14023328677341698" LOG_CI_START="-0.621769886738099" LOG_EFFECT_SIZE="-0.38100158675575796" ORDER="194" O_E="0.0" SE="0.2828569824638669" STUDY_ID="STD-Palmblad-1992" TOTAL_1="55" TOTAL_2="61" VAR="0.08000807252856433" WEIGHT="22.252522714218625"/>
<DICH_DATA CI_END="2.199389321490883" CI_START="0.3705609134707082" EFFECT_SIZE="0.9027777777777778" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.3423021121300315" LOG_CI_START="-0.4311403917068573" LOG_EFFECT_SIZE="-0.04441913978841288" ORDER="195" O_E="0.0" SE="0.45432395535592934" STUDY_ID="STD-Siegel-1982a" TOTAL_1="12" TOTAL_2="13" VAR="0.20641025641025645" WEIGHT="14.631839334776407"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.5470730059120725" CI_END="1.4570220539696939" CI_START="0.9429298443018713" DF="1" EFFECT_SIZE="1.1721218274966285" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="64" I2="0.0" ID="CMP-001.05.04" LOG_CI_END="0.1634661254452506" LOG_CI_START="-0.025520618361281645" LOG_EFFECT_SIZE="0.06897275354198447" NO="4" P_CHI2="0.459516227172011" P_Z="0.1525391366909554" STUDIES="2" TAU2="0.0" TOTAL_1="112" TOTAL_2="126" WEIGHT="99.99999999999999" Z="1.4306200544439929">
<NAME>Miconazole</NAME>
<DICH_DATA CI_END="4.943824870337866" CI_START="0.05056813430021737" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6940630779397805" LOG_CI_START="-1.296123069267743" LOG_EFFECT_SIZE="-0.3010299956639812" ORDER="196" O_E="0.0" SE="1.1690451944500122" STUDY_ID="STD-Brincker-1978" TOTAL_1="15" TOTAL_2="15" VAR="1.3666666666666667" WEIGHT="0.9017274420125294"/>
<DICH_DATA CI_END="1.4698121744892445" CI_START="0.9493300269959173" EFFECT_SIZE="1.1812437645493847" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="62" LOG_CI_END="0.16726184033006286" LOG_CI_START="-0.02258278231797109" LOG_EFFECT_SIZE="0.07233952900604587" ORDER="197" O_E="0.0" SE="0.11151567108949327" STUDY_ID="STD-Wingard-1987" TOTAL_1="97" TOTAL_2="111" VAR="0.012435744898540045" WEIGHT="99.09827255798746"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8725036333876277" CI_END="0.9454851401255399" CI_START="0.5737162202275033" DF="2" EFFECT_SIZE="0.7365053705670421" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="106" I2="0.0" ID="CMP-001.05.05" LOG_CI_END="-0.024345292426761457" LOG_CI_START="-0.241302871477644" LOG_EFFECT_SIZE="-0.13282408195220274" NO="5" P_CHI2="0.6464549393969247" P_Z="0.016402785254609666" STUDIES="3" TAU2="0.0" TOTAL_1="359" TOTAL_2="353" WEIGHT="100.0" Z="2.399827819288667">
<NAME>Itraconazole</NAME>
<DICH_DATA CI_END="8.287873105608377" CI_START="0.3060316119300204" EFFECT_SIZE="1.5925925925925926" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9184430930338857" LOG_CI_START="-0.5142337101926873" LOG_EFFECT_SIZE="0.2021046914205992" ORDER="198" O_E="0.0" SE="0.841561446079841" STUDY_ID="STD-Kaptan-2003" TOTAL_1="54" TOTAL_2="43" VAR="0.7082256675279931" WEIGHT="2.2932594603953658"/>
<DICH_DATA CI_END="0.9806721656588494" CI_START="0.5233702356235574" EFFECT_SIZE="0.7164179104477612" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="68" LOG_CI_END="-0.008476151071252488" LOG_CI_START="-0.28119097957922595" LOG_EFFECT_SIZE="-0.14483356532523925" ORDER="199" O_E="0.0" SE="0.16019404022575662" STUDY_ID="STD-Menichetti-1999" TOTAL_1="201" TOTAL_2="204" VAR="0.025662130523851332" WEIGHT="63.28957023439082"/>
<DICH_DATA CI_END="1.126813476911701" CI_START="0.4808777841265522" EFFECT_SIZE="0.7361111111111112" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="36" LOG_CI_END="0.05185203259256387" LOG_CI_START="-0.3179652862535226" LOG_EFFECT_SIZE="-0.1330566268304794" ORDER="200" O_E="0.0" SE="0.2172325237154434" STUDY_ID="STD-Nucci-2000" TOTAL_1="104" TOTAL_2="106" VAR="0.04718996935978068" WEIGHT="34.41717030521381"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2011-09-29 11:17:35 +0100" MODIFIED_BY="Clare Jess">
<APPENDIX ID="APP-01" MODIFIED="2011-09-29 11:17:35 +0100" MODIFIED_BY="Clare Jess" NO="1">
<TITLE MODIFIED="2011-09-29 11:17:35 +0100" MODIFIED_BY="Clare Jess">PubMed search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-09-29 11:17:35 +0100" MODIFIED_BY="Clare Jess">
<P>#1: random* OR control* OR blind*<BR/>#2: nystatin OR amphotericin OR fluconazol* OR itraconazol* OR ketoconazol* OR miconazol* OR voriconazol*<BR/>#3: bone-marrow OR cancer* OR fungemia OR hematologic* OR malignan* OR neoplas* OR neutropeni* OR granulocytopeni* OR leukemi* OR lymphom*<BR/>#4: #1 AND #2 AND #3.</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>